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4Abstract
Background and Aims: Inflammation is implicated in common disorders of ageing including
atherosclerosis and age-related macular degeneration (AMD), although the link between
inflammation and cardiovascular disease (CVD) is the more studied. The recent finding that
susceptibility to AMD is increased substantially by common single nucleotide polymorphisms
(SNPs) in the gene that encodes complement factor H (CFH; a circulating inhibitor of
complement activation) provides evidence that inflammation in general, and complement in
particular, maybe causally involved in AMD. Since AMD and atherosclerosis share similar
pathological features and risk factors, including a link with inflammation, an important question
arises: is complement factor H (fH) a shared risk factor for both AMD and CHD? One SNP in
particular, which has the most replicated association in AMD, rs1061170, which encodes a
putative functional tyrosine to histidine change (Y402H), and has been studied in both AMD
and coronary heart disease (CHD). I hypothesised that genetic variants in CFH, in particular
rs1061170 is associated with risk of both AMD and CHD and that this association may be
mediated through changes in circulating fH concentration. I addressed this hypothesis by: (i)
precisely defining the effect of the association of the rs1061170 SNP encoding Y402H in CFH
on AMD risk; (ii) precisely defining the association of rs1061170 on risk of CHD events; and
(iii) developing and validating a high throughput assay of circulating fH, to enable further
evaluation of the nature of the association between CFH genotype and fH concentration, and
fH concentration and disease; (iv) measuring fH in a population based sample to determine its
non-genetic correlates and genetic determinants (v) measuring fH in case control studies of
AMD and genotyping of SNPs in the CFH and related genes to determine the concordance of
the genetic associations of fH and AMD.
Methods: To address aims (i) and (ii), I conducted a systematic review of published studies
investigating the effect of variants in CFH on AMD and CHD risk respectively, supplementing
data with results from newly genotyped studies in both AMD and CHD. To address aim (iii) I
developed and validated a high-throughput assay measuring circulating fH, which I used to
undertake studies in aim (iv) in which I measured fH in a population based sample with an
existing range of blood and lifestyle measures as well as anthropometric, cardiovascular,
5glycaemic, lipid, liver, renal, and inflammation markers. In addition to this genome wide
information was also available on ~500,000 SNPs across the genome with additional
imputation of un-typed SNPs, giving coverage of ~ 2 million markers across the genome. In
order to achieve aim (v) I measured fH in case control studies of AMD, with additional
genotyping of SNPs in the CFH and CFH related gene in order to attain a more high resolution
signal of association in this genomic region for both fH concentration and AMD risk.
Results: Data synthesis from published literature and newly genotyped studies, confirmed the
strong association of the rs1061170 SNP with risk of AMD (per-allele odds ratio (OR) of 2.30,
99% CI 1.93, 2.73; p<0.001), in individuals of European descent, although the association was
less clear in individuals of Chinese or Japanese descent. However, there was no association
of rs1061170 with CHD (per-allele OR 1.01 95% CI 0.98, 1.04), or established risk factors for
CHD. Adaptation of an existing commercial, low through-put assay allowed the development
and validation of a high throughput assay to measure circulating fH concentrations. With an
operating range of 7-1000 mg/L, this assay was reliable, repeatable and robust, enabling
assay of fH in stored samples. In a large population study, novel associations of fH with lipids,
apo-lipoproteins and indices of adiposity were identified and genetic determinants localised to
the CFH/CFHR gene cluster on Chromosome 1. In case-control analysis, there was no
association of fH concentration with AMD risk.
Conclusions: Genetic variation in CFH, and in particular the effect of the most replicated
rs1061170 SNP is robustly associated with AMD with little attenuation in the effect size as
data has accrued. However the effect of the same SNP is not associated with CHD.
Circulating fH is associated with a range of cardio-metabolic biomarkers and regulated by
common genetic variants in the vicinity of the encoding gene on chromosome 1. However fH
itself is not associated with risk of AMD, suggesting the genetic association of CFH with AMD
is mediated through altered fH function or perhaps through an fH-related protein encoded by
an adjacent gene.
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1 Introduction
Diseases of aging are of mounting public health importance worldwide. Associated with
significant mortality and morbidity, they impact not only on current but projected health care
resources. One way to reduce this burden is early identification and treatment of those at risk
of disease. Cardiovascular disease (CVD) and age-related macular degeneration (AMD) are
two such common, age-related, complex diseases which will be the focus of discussion herein.
There are a number of parallels between these two conditions, not only because they are both
age-related, but because they share common pathological features, risk factors and evolution.
Moreover inflammation is thought to contribute to both CVD and AMD. In this introductory
chapter I aim to discuss, both these diseases, highlighting the parallels that exist between
them, before moving on to examine the evidence implicating inflammatory pathways in both
conditions and in particular the complement pathway. I finally propose an approach to address
the limitations of the evidence, in the context of emerging data from genome wide association
scans (GWAS), thus setting out the aims of this thesis.
1.1 Atherosclerosis and age-related macular degeneration: parallels and
differences
Comparisons have been drawn between AMD and CVD that support the view of a shared
common pathological basis. Recent findings in the field of AMD have found compelling links
with inflammation, and in particular with the complement cascade, a key part of the innate
immune system. Atherosclerosis, the pathological lesion that underlies CVD, is also believed
to represent a chronic inflammatory process, in which both innate and adaptive immune
responses have been implicated, including the complement cascade.
1.1.1 Coronary heart disease
1.1.1.1 Disease burden
Cardiovascular disease, the most common forms of which are coronary heart disease (CHD)
and stroke remain a major cause of mortality and morbidity worldwide. It is the most common
21
cause of premature death in industrialised nations, accounting for 4.35 million deaths per year
in Europe and 35% of deaths in the United Kingdom [1, 2]. CVD is also associated with
considerable morbidity, accounting for 20% of disability-adjusted life years [3]. CHD alone is
the most common cause of death in Europe with 1.95 million deaths per annum, of these an
estimated 94 000 deaths per annum are in the UK [1, 2].
1.1.1.2 Risk factors and risk prediction
Epidemiological evidence has been central in establishing that certain exposures increase risk
of CVD [4]. Those “risk factors” that can be modified include smoking, blood pressure, high
cholesterol and diabetes. Non-modifiable risk factors include age, family history and male sex.
Although measurement of these risk factors has formed the cornerstone of targeting those at
increased absolute risk of CVD, it is well known that most events occur in individuals with
average levels of most of the modifiable risk factors [5], including blood pressure and
cholesterol even though they are causal [6, 7]. This has been the motivation to search for
other biomarkers that may influence CVD, in order to improve risk prediction, provide new
therapeutic intervention and or preventative strategies and enable identification of novel drug
targets, with the aim of lowering the burden of CVD.
1.1.1.3 Patho-physiology of CHD
A key element of the search for biomarkers has been on better understanding the pathological
processes of atherosclerosis that underlie CVD. Atherosclerosis is thought to arise from
damage to the single cell layer of vascular endothelium that lines all arteries [8]. Damage can
occur through one of a number of proposed pathways including high levels of (oxidised) low
density lipoprotein cholesterol (LDL-C), local free radical generation, elevated plasma
homocysteine, infectious micro-organisms such as Chlamydia pnuemoniae, shear stress in
areas of turbulent flow, and local release of cytokines (all of which are reviewed in [9]).
Endothelial function itself is thought to become altered as a consequence. Under normal
physiological conditions the endothelial surface is anti-adhesive, anti-coagulant and
impermeable, but in response to injury becomes pro-adhesive, attracting in the early stages
blood derived monocytes, which gain entry to the underlying medial layer, as endothelial cells
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become permeable, and induction of pro-coagulant pathways as a response to damage. Injury
to the endothelium thus triggers an inflammatory response and like injury in other any other
tissue, the immune system is mobilised. One of the first features in the development of
atherosclerosis is the entry of lipids and monocytes into the media, where monocytes
differentiate into macrophages, and take up oxidised LDL-C forming characteristic lipid laden
macrophages commonly referred to as foam cells. A collection of foam cells appear as small
raised yellow lesions on the intimal surface of the arterial wall. Known as ‘fatty streaks’, these
are hallmarks of very early atherosclerosis and can be found in otherwise healthy adolescents.
Not all fatty streaks will progress to mature atherosclerotic plaques. However with continued
damage, the immune process continues unabated, becoming chronic, promoting the formation
of a lipid laden necrotic core, mediated by elements of the innate immune system migrating
into the lesion (T cells and macrophages), activation of which amplifies inflammation further
with the release of cytokines, chemokines, hydrolytic enzymes and growth factors. The
response to necrosis by any tissue is an attempt at healing by fibrosis, and atherosclerosis is
no exception, with the formation of a fibrous cap eventually protruding into the arterial lumen
causing flow limiting or clinically catastrophic occlusive symptoms. The interface between the
vascular endothelial cell lining of the artery and the outer bounds of the arterial media has
been the focus of much investigation and this is where the pathological changes that define
atherosclerosis occur.
Clinically, atherosclerosis in the context of CHD can present either as symptoms of angina,
form blood flow limitations, or as an acute occlusive event (myocardial infarction), due to the
rupture of a plaque leading to thrombosis in an affected coronary vessel. Medical therapies
are targeted at dissolving acutely formed thrombus, and reducing further platelet aggregation.
Mechanical interventional procedures may be used to re-establish and maintain patency of
coronary vessels. In the longer term, therapy is targeted at reducing platelet activation, which
plays a crucial role in formation of thrombosis, and control of afore mentioned modifiable risk
factors.
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1.1.1.4 The complement system
Complement is one component of the immune process implicated in atherosclerosis. Findings
from recent GWAS indicate that variants in genes encoding complement components are
associated with a number of diseases of aging, including AMD [10] and Alzheimer’s disease
[11], discussed in further detail in section 1.1.2, as well as susceptibility to infections [12]. This
provides evidence of a common mechanism that may be advantageous for protection from
early-life infection but which underlies these diseases of aging. A brief overview of the
complement system and its function is presented here, in order to be able to place subsequent
descriptions of the role of specific complement proteins in atherosclerosis and AMD into
context.
An essential part of the immune system, complement is composed of over 30 proteins
distributed in plasma and on cell membranes. It provides a generalised non-specific response
which identifies targets (via C3b) and destroys them (via direct lysis) while dispatching
messengers to seek help (via anaphylotoxins C3a and C5a) thus mediating a more specific
antibody-mediated response (reviewed in [13, 14]). The importance of individual constituent
proteins has been demonstrated by the diseases that arise from mutations leading to complete
deficiency of a component of the complement system, or those that severely affect function of
the whole system. In general, individuals with mutations affecting complement components
have predisposition to recurrent bacterial infections or immune related disorders. However,
complement has also been shown to play a role in a number of diseases which, at first glance,
may not be thought of in either of these categories (Figure 1.1).
Down-regulation of the complement system is as important as its activation. Although
complement is essential for clearance of pathogenic or altered host cells, its activity must also
be regulated in order to avoid damage to host cells, which become tagged with C3b at the
same time as pathogenic material. Protection and control is achieved through a number of
complement regulators, all which have a similar structure and are collectively known as
regulators of complement activity (RCA), most being encoded by genes that form the RCA
cluster on chromosome 1. Regulatory proteins can either be membrane bound, soluble or
both, and protect against complement activation by down-regulating the central proteolytic
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activity of the amplification and opsonisation steps (centred on C3b). In theory, deficiencies
and mutations in these regulators may lead to excessive complement activation and tissue
injury.
Figure 1.1 The role of complement in health and disease. The functions of the complement
cascade in recognition of pathogens, mediating adaptive immunity and effector functions through the
disposal of pathogens, immune complexes and apoptotic cells. Dysfunction or uncontrolled regulation of
any of these functions has been implicated in a number of organ specific and systemic diseases.
Adapted from Ricklin D and Lambris JD, Nature Biotechnology 2007 [15].
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Complement is activated by one of three pathways, classical, alternate or lectin (Figure 1.2).
Of the three only the alternate pathway can be continuously activated in the absence of
foreign material, through the action of the continuous, although slow, spontaneous hydrolysis
of C3, commonly referred to as the ‘tick over’ pathway [16]. Importantly, all pathways converge
on C3 and the formation of C3 convertase, a proteolytic enzyme complex, without which full
activation of complement cannot be achieved. This is also the focal point of the amplification of
the activated complement cascade. The C3 convertase formed by the classical and lectin
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pathway, although assembled using different components of complement (Figure 1.2), is
functionally homologous to that which is formed through the alternate pathway.
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Figure 1.2 Activation of the complement cascade. Activation occurs via three distinct pathways.
The alternate pathway is the only one that does not require exposure to foreign material, C3b being
generated through continuous hydrolysis of circulating C3. This action exposes an internal thioester bond
which is required for the subsequent attachment of C3b to target surfaces, and can also bind Factor B
(homologous to C2 of classical/lectin pathway). Bound factor B can be activated by factor D, the resulting
Bb combines with C3b to form C3 convertase. The classical pathway is initiated via recognition of
immune complexes on target surfaces by C1q , binding which induces a conformational change in C1q
which in turn activates serine proteases C1r and C1s, which goes on to proteolytically activate C4,
homologous to the alternate pathways C3. The lectin pathway is initiated through recognition of sugars
(e.g. mannose) on the microbial cell surface, recognised through mannose binding lectins (MBL) or
ficolins which form a complex with mannose associated serine proteases (MASPs). It is MASPs that are
activated as a result of recognition, and go on to activate C4 like the classical pathway, and
subsequently C3 convertase.
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The focus of this project is on the alternative complement pathway, in particular one of its
regulatory proteins, and therefore further descriptions are limited to this pathway. The
alternative pathway constitutes six major serum proteins: C3, factor B, factor D, properdin,
factor I and factor H, the latter three which act to regulate the pathway. Initiation of the
pathway can either be by foreign materials (such as bacterial or viral cells walls) or through the
aforementioned tick over pathway by slow, continuous hydrolysis of circulating inactive C3
yielding C3a and C3b. The C3b component binds to cells, both foreign and host. In the
presence of polyanions (sialic acid and heparin), commonly found on mammalian cell
membranes but not on bacterial cell walls, C3b preferentially binds factor H (fH), a regulatory
protein described in more detail below, inhibiting further assembly of C3 convertase. In the
absence of polyanions, C3b preferentially binds factor B, and this complex serves as the
substrate for enzymatically active serum protease factor D, which cleaves C3b releasing Ba,
and in the process generating C3bBb, or C3 convertase (Figure 1.3).
Under normal physiological conditions, this C3 convertase has a short half life although this is
extended by the binding of an additional protein properdin, which acts to stabilise alternative
pathway C3 convertase. The presence of properdin is thus a marker of complement activation
via the alternative pathway. C3 convertase can cleave C3, thus seeding an amplification loop
of complement activation, a key strength and feature of this cascade. Full activation of the
complement cascade then proceeds as C3 convertase binds C5 to generate C5b (and in the
process releasing the potent anaphylotoxin C5a) which then binds C6 and initiates the
formation of the membrane attack complex (MAC). Formed by the sequentially binding
components C5a, C6, C7, C8 and C9, the MAC displaces membrane phospholipids forming a
large pore in cellular membranes enabling free diffusion of ions and small molecules, which
disrupt the function of the target cell, often leading to lysis. Steps subsequent to the formation
of C3 convertase are often referred to as the final common pathway, as these steps are
common to the complement pathway regardless of how it has been activated.
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Figure 1.3 Activation and regulation of the alternate complement pathway Circulating
(inactive) C3 is hydrolysed to C3a (an anaphylotoxin which mediates downstream adaptive responses)
and C3b. C3b possesses an active thioester bond, which enables C3b to bind covalently to hydroxyl
groups on nearby host cell surfaces. Under such conditions fH preferentially binds C3b. This complex is
recognised by factor I, which cleaves C3b into inactive products. Alternatively binding of C3b to bacterial
cell walls, in the absence of surface heparin and sialic acid leads to C3b preferentially binding to factor B
(FB), forming a complex which is recognised and cleaved by the protease factor D, leading to the
formation of C3 convertase (C3bBb). C3 convertase of the alternate pathway is stabilised by properidin,
increasing its half life. C3 convertase additionally seeds the amplification loop by cleavage of more C3
leading to the deposition of more C3b on host and foreign cell surfaces. In addition to the regulation
mediated by fH and factor I, the alternative pathway can also be regulated through action of DAF, which
accelerates decay of C3b, and CR1 which is also a cofactor for factor I mediated neutralisation of C3b
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Regulation of the alternative pathway is key, given that C3 convertase can be produced under
normal physiological conditions without exposure to any foreign material. Prevention of the
assembly of C3 convertase is mediated by a number of the RCA proteins, including
complement receptor 1 (CR1), membrane cofactor protein (MCP), decay accelerating factor
(DAF) and fH, (the focus of this thesis, and the only one of these regulators specific for the
alternate pathway). CR1, DAF and MCP also regulate the classical and lectin pathways. In
general, regulatory proteins act either by promoting irreversible dissociation (decay
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acceleration) of the convertase enzymes, or by acting as co-factors for enzymatic cleavage.
CR1, DAF and fH, all act to dissociate C3b from Bb, as well as acting as co-factors for factor I
in the processing of C3b (Figure 1.3). Regulation of the terminal pathway (subsequent to the
formation of C5b) occurs through regulators clusterin and vitronectin and CD59. Lack of any of
these regulatory proteins may therefore lead to the unchecked activation of the complement
cascade, mediating injury to host cells. Specific lack of fH or loss of its function could be
particularly problematic given the continuous, albeit slow, production of C3b.
1.1.1.5 Complement and atherosclerosis
Complement components and their regulators have both been implicated in atherosclerosis.
Normal arterial intima lacks signs of complement activation, therefore findings from a number
of studies demonstrating complement is associated with atherosclerotic lesions suggests that
complement activators may be generated or deposited during atherogenesis. Complement is
known to be activated by a number of factors that are present in the atherosclerotic plaque
over its life course including modified LDL-C deposits, apoptotic cells and C-reactive protein
(CRP).
The location of complement components in post mortem human atherosclerotic plaques,
detected by immunohisochemistry, is such that the MAC (indicating full activation of
complement), and regulatory proteins associated with MAC (clusterin and vitronectin), are
found in the deeper musculo-elastic layer of the intima, whereas regulatory proteins which
operate at the C3 convertase level, including fH and C4bp are limited to superficial
proteoglycan-rich areas, consistent with the localisation of LDL-C in deeper layers [17].
Moreover, in these experiments MAC was found to co-localise with properedin suggesting
complement activation via the alternate pathway. Evidence of full activation of complement,
has been linked with severity of atherosclerosis [18, 19], leading to the suggestion that
complement activation could be the key initiating event in atherosclerosis, a notion that is
supported by findings in animals that suggest complement activation occurs temporally with
deposition of lipids in arteries, and more importantly, that this precedes the accumulation of
components of cell mediated immunity [20].
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A number of other lines of investigation in humans have linked complement to atherosclerosis.
These include the expression of membrane bound complement regulators on cells resident in
the atherosclerotic plaque (DAF on vascular smooth muscle cells and macrophages, CD59 on
T cells and macrophages, CR1 on macrophages) which implicate local activation of
complement [21-23] Complement has been shown to be activated in plaques prone to rupture,
moreover high circulating levels of anaphylotoxins and terminal complex regulators (CD59)
have been reported in individuals presenting with acute coronary syndromes [24-26]. Elevated
levels of C5a have been shown in one study to independently predict future major
cardiovascular events in patients with documented atherosclerosis [27], and circulating C3
concentration in men has been shown to be associated with established markers of
complement activation [28]. C4 concentrations have also been shown to be higher in
individuals with acute coronary syndrome and stable angina [29].
Animal studies have supported a role of complement in both acute MI, where complement
depletion in a model of myocardial injury in non-human primates [30] and in the mouse [31]
limits infarct size; as well as in more long term development of atherosclerosis, for example
where the expression of DAF decreased the burden of atherosclerosis, possibly through
regulation of C3 convertase in apolipoprotein E (ApoE) and low-density lipoprotein receptor
(LDL-R) double knockout mice [32, 33].
More recently, high-density lipoprotein cholesterol (HDL-C), which exhibits an inverse
association with CHD in prospective observational studies [34], has been shown to be bound
by a number of components of the complement system using proteomic analysis of human
plasma [35]. These include C3, C1 inhibitor, fH, C4a, C4b, C9, clusterin and vitronectin,
indicating that HDL-C may modify complement activation in some way. Moreover genes that
play a role in HDL-C regulation including hepatic lipase (LIPC), cholesteryl-ester transfer
protein (CETP), lipoprotein lipase (LPL), and ATP-binding cassette transporter (ABCA1), have
recently been implicated in AMD [36, 37], supporting shared mechanisms contributing to both
atherosclerosis and AMD.
Taken together these data suggest that complement activation might promote development of
the atherosclerotic plaque, while the regulatory components might inhibit atherogenesis.
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1.1.1.6 Limitations of observational evidence linking inflammation to CHD
Inflammation and atherosclerosis have been studied in vitro, in animal models, and in man.
Numerous components of the inflammatory response have emerged as potential candidates
for use as biomarkers of cardiovascular risk with potential clinical application as predictors or
as therapeutic targets. These include for example CRP, fibrinogen, interleukins and leucocyte
cell count, [38, 39]. Links between inflammation and CHD have also been made, for example
individuals with an acute infection are at a transiently increased risk of MI or stroke [40], and
individuals with chronic inflammatory disorders such as rheumatoid arthritis and systemic
lupus erythematosus are at increased risk of cardiovascular events later in life [41, 42].
However, most of the evidence linking inflammation and markers of inflammation with CHD
comes from observational epidemiology, and such associations are prone to confounding
(where associations between an inflammation marker and CHD are not causal but explained
by a common association of the two with a causal factor (e.g. smoking)). They may also be
affected by reverse causation bias, where atheroma provides a stimulus for inflammation
rather than being the target of it. Thus the causal relevance of inflammation in general and
inflammatory mediators specifically in atherosclerosis remains uncertain [39, 43].
One way in which the causal relevance of the associations could be confirmed of refuted is by
studying the effect of genes associated with activation or deficiency in inflammatory pathways
[44-46]. However, genetic studies of this type have previously however been inconsistent in
their findings, largely due to the limited number of genetic variants tested and by the low
power of individual studies.
1.1.1.7 Overcoming limitations of observational evidence
Another way in which to establish whether or not an inflammatory molecule is causally related
to disease would be to carry out a randomised controlled trial (RCT) using a therapeutic
intervention that modifies the concentration or fraction of each implicated mediator selectively.
Randomised intervention studies are free from many of the biases of observational
associations. The randomised treatment allocation balances any confounders between
treatment groups, and reverse causation is mitigated because the outcome is assessed
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following the intervention. Through the use of RCTs, the apparently protective role of anti-
oxidants in CHD was shown to be unfounded [47], drugs targeting tumour necrosis factor
(TNF), which reduce the inflammatory burden in rheumatoid arthritis, were shown not to confer
protection on CHD, and treatment with antibiotics against Chalmydia spp. was not found to
protect against CHD [48, 49]. More specifically, to the address the causal role of the
complement cascade, monoclonal antibodies that target specific components of the
complement cascade e.g. pexelizumab, that targets complement component C5, was shown
not to be beneficial as an adjunctive therapy to primary-percutaneous coronary intervention in
acute MI [50, 51]. These are important negative findings in the CHD arena and perhaps more
importantly, highlight the value of defining the precise causal pathways that are of patho-
physiological significance in CHD, to allow these to be targeted by appropriate therapies.
RCTs however cannot be used to test every one of the very large number of biomarkers or
proposed mechanisms implicated in CHD by observational epidemiology. The life-cycle of any
drug from discovery to phase III studies is 15-20 years, with estimated costs of its
development running into billions of pounds [52]. One way of exploiting the benefits of
randomisation but without resorting to the expensive and lengthy development of a new drug
by conducting a RCT, is to harness the random assortment of genotype during gamete
formation and fertilisation (Mendel’s second law). Natural variation in a gene that alters the
concentration or function of its encoded protein is transmitted at random from parent to
offspring. This randomisation should balance the distribution of known and unknown
confounders between genotype groups, just as confounders are balanced in treatment and
placebo arms of a RCT. Genotype is fixed throughout life and non-modifiable and therefore
genetic associations are not affected by reverse causality. In essence a genetic study is
therefore akin to ‘natural’ randomised controlled trial (Figure 1.4) [45, 53]. Allocation in this
case is not to placebo or drug but to a genotype that influences an encoded protein or
downstream biomarker. If a biomarker is causally involved in CHD (or any other outcome
being investigated) individuals with genotypes that associate with higher levels of the marker,
should have a higher risk of CHD, commensurate with the effect of the change in the
biomarker [54, 55]. This use of genetic studies as tools to dissect causal association is
commonly known as Mendelian randomisation analysis and has already been applied to a
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number of putative markers in the cardiovascular arena. For example it is overturning the
firmly held views that the inflammatory markers CRP and fibrinogen are likely causally linked
to CHD [56-58], whereas the evidence using the same approach indicates that lipoprotein (a)
is causally related to MI [59]. If genetic variants were identified that influence the level or
function of complement components, the approach could be applied to test the causal nature
of complement proteins and their regulators in CHD.
Figure 1.4 Parallels between randomised controlled trials and Mendelian randomisation
Comparison of randomised evidence from clinical trials and Nature’s randomised trials. A
hypothetical drug that lowers a deleterious biomarker would be hypothesised to be protective
from CVD according to current observational evidence, although this is unknown. As an
alternative or adjunct to inform drug development, study of randomly allocated single
nucleotide polymorphisms (SNP) in the gene encoding the deleterious marker may inform its
causal nature. Figure taken from Hingorani AD, Humphries SE, Lancet 2005 [45].
1.1.2 Age-related macular degeneration
1.1.2.1 Disease burden
Age-related macular degeneration ranks as the third cause of visual impairment worldwide
[60]. It is estimated that approximately 35% of individuals over the age of 75 in the United
States of America have some degree of AMD [61]. This will increase with the demographic
trend towards an aging population in middle and high income countries. AMD will therefore
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become a major economic and public health burden [62], and a greater understanding of its
aetiology together with development of improved therapies and preventative strategies is
therefore of great importance.
1.1.2.2 Risk factors for AMD, and potential overlap with CHD
Despite the burden of AMD, few factors have been reliably identified as altering the course of
disease once early signs are present. The most consistent link is with cigarette smoking [63-
69]. Associations also exist with blood pressure [63, 64, 70], lipid levels [63, 64, 70, 71]
abdominal obesity [63, 64, 72], physical activity [63, 64, 70, 72] and dietary factors including
consumption of fat [73]. There are inverse associations with consumption of caretenoids and
antioxidants [74, 75]. All of these have also been proposed as risk or protective factors for
CHD, suggesting the aetiology of the two disorders may overlap. Compared to the evidence
base in CHD, the epidemiological foundations of these associations in AMD are still maturing.
Early associations were reported from small cross sectional and case control studies, and thus
prone to chance findings and bias. Only more recently have large prospective cohorts been
established whose primary focus is on dissecting the precise epidemiology, disease
progression and molecular epidemiology of AMD [76-79]. However, even in the early phase,
findings from these studies need to be interpreted cautiously. The low incidence of late stage
AMD, which poses the greatest threat to vision, means the power to detect and quantify
associations of exposure and disease outcomes in such studies is low. Only with a large
evidence base can the determinants of AMD be reliably identified. Thus some additional risk
factors, for which the evidence is currently inconclusive, may still, emerge as being common to
both AMD and CHD.
The ability to precisely delineate the risk factors for AMD may have also been somewhat
limited by the more heterogeneous nature of AMD given its distinct subtypes and clinically
identifiable early and late stages. Early AMD may never proceed to the late AMD, which is
associated with greatest visual loss. This division into early and late stages is similar to
descriptions of lesions that define CHD. Fatty streaks could be analogous to early AMD
changes, not all progressing to late stage atherosclerotic plaques. Once plaques have
developed, there may be further stratification into those more likely to rupture or cause flow
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limiting symptoms. However given that coronary arteries are not amenable to non-invasive
visualisation unlike the retina, the focus in CHD has remained on clinical events, which might
be analogous to visual loss in AMD. However, the identification of early atherosclerotic lesions
is now of interest in CHD, with development of techniques enabling measurement of intimal
media thickness in vessels such as the carotid artery (CIMT), coronary artery calcification
(CAC) by use of computed tomography (CT) scanning, and detection of plaque by the more
invasive intravascular ultrasound (IVUS) in the coronary artery. These are techniques currently
reserved for research and thought of as surrogate measures for ‘hard’ cardiovascular events,
and their clinical utility as predictors of disease risk, or as outcome measures in clinical trials is
the subject of much debate [80].
As in CHD, RCTs have also played some role in deciphering the causal nature of some of the
proposed risk factors for AMD. The Age-Related Eye Disease study (AREDS), a randomised
study found support for prior observations that dietary supplementation with high doses of
vitamin C, vitamin E, beta-carotene and zinc are effective at lowering overall risk of late AMD
once it is established, but are not effective in preventing the development of new lesions [79].
However these effects were seen in a post-hoc analysis of small sub-groups defined
according to disease severity in which there were few events. In contrast a role for anti-oxidant
and vitamin C supplementation in reducing the risk of CHD events was not supported by
RCTs, despite high expectations of success based on prior observational studies [81].
Another common pathway of interest in both AMD and CHD is the biology of vascular
endothelial growth factor (VEGF). Blockade of VEGF signalling using monoclonal antibodies
[82] or antisense RNA to VEGF-A receptor [83] has been found be beneficial in RCT’s of late
AMD, probably by inhibiting the formation of new and rupture prone vessels thus reducing the
progression of visual disability. The gene encoding VEGF (VEGF) has been investigated as a
candidate gene for AMD, and in small studies polymorphisms in VEGF have been associated
with an increase in AMD risk [84, 85], although these finding are not always replicated in larger
studies [86]. Similarly VEGF polymorphisms have been associated with CHD (see [87] for a
summary of all studies), although the exact role of therapeutic manipulation of VEGF in
atherosclerosis is controversial given that it can both promote atherosclerosis through pro-
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inflammatory pathways but may also have beneficial effects through re-canalisation of
occlusive lesions (see [88] for a critical appraisal in this field).
In summary, in terms of the understanding of aetiology and identification of risk factors for
disease prediction the proposal that there may be shared risk factors for both AMD and CHD
is plausible but there are several potential sources of error and bias in the epidemiological
studies of AMD so far, though common associations with several risk factors lends support to
the partially shared pathological basis for these two disorders. In the subsequent sections, I
detail the pathological features of AMD, drawing further comparisons with CHD.
1.1.2.3 Patho-physiology of AMD
The pathological lesion of AMD centres on the area of the retina known as the macula, a small
(~6mm diameter), densely packed area of photoreceptor cells (rods and cones) located at the
centre of the fovea. This area of the retina is critically responsible for the integrity of the central
visual field. The retina can be thought of as two functional units, one comprising photoreceptor
cells and their neuronal connections, the other providing support and vascular supply to these
cells. The layer underlying photoreceptor cells comprises epithelial cells, known as the retinal
pigment epithelium (RPE) that nourish the retinal cells and below lies a basement membrane,
called Bruch’s membrane. These structures maintain a barrier between the retinal cells and
the underlying vascular supply from the choroid. This interface between the photoreceptor
cells and vascular supply is where the pathological changes that define AMD are thought to
occur [89].
Clinically, AMD has been sub-divided into early and late forms. Early disease, also known as
age-related maculopathy (ARM), is diagnosed by the presence of pathological lesions known
as drusen, which are amorphous extracellular deposits, and/ or changes in the RPE, including
hyper-pigmentation and detachment (Figure 1.5). These changes can be asymptomatic
(similar to the early lesions of atherosclerosis), although they begin to develop much later in
life than fatty streaks in arteries that can be seen from as early as the second decade of life.
Drusen appear as punctuate yellow lesions, however these lesions are not specific for AMD,
and can be found as a normal feature of ageing. Lipids are a common constituent of both fatty
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streaks and drusen, with drusen being first described on the basis of their appearance as
“Colloidkuglen” or colloid spheres, rich in “fettreichen” or fat [90]. More recent
immunohistochemical and chromatographic techniques have confirmed the presence of lipid,
including cerebrosides, gangliosides, esterified and unesterified cholesterol. There is also
evidence of local transcription of genes for lipoprotein components (e.g. apolipoprotein E).
However there is uncertainty around the exact origin of lipid components within drusen, in
particular whether these are derived from the circulation, or synthesised locally (all these
findings are reviewed in [91]).
Figure 1.5 Clinical and histological features of sub-classes of AMD. Taken from Jager RD
et al NEJM 2008 [92]
Prospective clinical studies have catalogued features of drusen that are more likely to be
associated with progression to late stage AMD. These include size, number, confluence and
appearance (with a distinction being drawn between hard and soft drusen), and the presence
of associated changes in the RPE [93]. These finding contribute to the classification systems
for clinical AMD [94].
Individuals who do progress to late disease can present with one or a combination of three
clinical types: either ‘dry’, ‘wet’ or mixed AMD. Dry AMD or geographic atrophy (GA) is
thought to result from cell death within the RPE, progressing to atrophy of photoreceptor cells.
Wet AMD or choroidal neovascularisation (CNV) is thought to be due to the formation of new
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vessels sprouting from existing choriocapilliaries, which extend into the areas below the RPE
and photoreceptor cells. These new vessels are prone to damage causing local haemorrhage
and exudative changes, which can result in sudden visual loss. Advanced stages of disease
are characterised by a fibrovasular or atrophic macular scars and are associated with
permanent damage to central vision (reviewed in [95]). Although CNV accounts for 10% of
overall AMD cases, it importantly contributes to 90% of visual loss [96]. Strategies to target
late stage disease overall would potentially save the site of many individuals.
1.1.2.4 Inflammation and AMD
Like CHD, many of the pathological changes in AMD have been attributed to inflammation,
with identification of the contents and mechanisms which lead to the formation of drusen being
a focus of current research [91]. The formation of drusen has been thought of as an
inflammatory response to damage to the RPE, analogous to the formation of fatty streaks
following endothelial cell damage in atherosclerotic arteries. Evidence accrued from human
and animal studies has implicated local inflammatory and immune-mediated events in the
development of drusen and, by extension, in the development of AMD. Components of the
inflammatory response identified in drusen include: ubiqutin, intergrins, tissue inhibitor of
metalloproteinaises, fibronectin and components of the complement system including
regulators such as components of the MAC, and its regulator vitronectin; complement
component C3 and fragments associated with its cleavage as well as other regulators
complement including MCP, CR1, fH and clusterin (reviewed in [91]). In addition proteins that
are associated with other chronic diseases of ageing including beta-amyloid (associated with
Alzheimer’s disease), ApoE (associated with both Alzheimer’s disease and CVD), and
generalised inflammation including MHC class II antigens, have all been shown to be present
in drusen [97]. Given that access to circulating complement components may be limited in the
brain and neural retina it has been hypothesised that local synthesis may occur [97].
Quantitative methods to assess gene expression of elements of the complement cascade
have been carried out with the finding that components that comprise alternate and classical
pathway are expressed by the human RPE-choroid complex, but with little evidence to support
local generation of lectin and terminal complement pathways [98].
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Like atherosclerosis higher concentrations of circulating markers of sub-clinical inflammation
including CRP and IL-6 [99, 100] have been found to be associated with a higher risk of AMD,
and other circulating biomarkers are also associated with both diseases including
homocysteine. Candidate gene studies have also implicated certain inflammatory genes in
AMD, as well as other genes which are also implicated in atherosclerosis (e.g. VEGF, LRP6,
APOE, VLDLR, reviewed in [101])
1.1.2.5 Genetic association studies in AMD
The unique attributes of genetic studies for causal inference as well as the limitations of
genetic association studies have been discussed previously in the context of CVD.
Sequencing of the human genome and subsequent cataloguing of common variation in the
genome through the HapMap project [102] (hapmap.ncbi.nlm.nih.gov), has lead to
development of technologies that allow the efficient typing of hundreds of thousands of SNPs
allowing the conduct of GWAS. These studies overcome the some of the biases inherent in
candidate gene studies. In GWAS, several hundreds of thousands of variants (up to 1 million
at the time of writing) can be typed in several thousand cases and controls to identify genetic
variants that differ between cases and controls providing valuable insights into the genetic loci
that may underlie susceptibility to complex diseases [103].
One of the first of this new generation of genetic studies has provided the most compelling
evidence of a link between inflammation and AMD and, in particular, a link between
complement and risk of AMD [10, 104-106] . In 2005 a GWAS of ~90 late AMD cases and 90
controls found a highly significant association of a SNP in the complement factor H (CFH)
gene with AMD [10]. The gene product is essential in regulation of the alternate complement
pathway. This association has been independently replicated in numerous studies [107-110].
The particular SNP, encoding a tyrosine to a histidine change at residue 402 (Y402H), has
been thought of as a putatively a causal variant, because it lies within a functional domain of
the protein implicated in the binding of fH with heparin and CRP. Although many SNPs in this
and adjacent genes have been associated with risk of AMD, many are in strong linkage
disequilibrium; it is the association with this lead SNP in particular that has been the most
studied. Other complement related genes have also been found to be strongly associated with
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altered risk of AMD based on candidate gene studies. These include the complement
regulators factor B (CFB) [111], C3 [112] and SERPING1 also known as C1 inhibitor [113]. In
addition, the genes neighbouring CFH, the CFHRs (CFH related genes) which share
homology with CFH, having arisen through gene duplication, have also shown association with
AMD. For example deletions in the CFHR1 and CFHR3 genes confer protection from AMD
[114].
The 2005 AMD GWAS used a 100,000 SNP array, but a more recent GWAS using a denser
500,000 SNP array validated the association of SNPs in the CFH gene cluster with AMD [36,
37]. In addition SNPs in other complement related genes, which previously emerged from
candidate gene studies (including C3 C2/ CFB and CFI) were confirmed to be associated with
AMD. Intriguingly genes involved in the regulation of HDL-C (for example CETP, LIPC, LPL
and ABCA1) some of which are also been associated with CHD risk [115] were also found to
be associated with AMD [36, 37]. The preliminary finding of genes that appear common to
both AMD and CHD provides additional evidence that both disorders may share a common
pathological basis. The rs1061170 CFH SNP encoding Y402H was also subsequently found
to be associated with MI in two candidate gene studies. However, the magnitude of effect on
CHD was much smaller than that for AMD [116, 117]. These findings led me to hypothesise
that complement factor H could therefore be a shared risk factor for both AMD and
atherosclerosis.
1.2 Complement factor H: genetic variation and functional effects
Despite the consistent genetic association of SNPs in CFH with AMD, the biological pathway
linking variation in the CFH gene with the development of the retinal lesions is as yet
uncertain. Regulatory SNPs in the vicinity of the CFH gene could alter CFH gene transcription
or mRNA stability leading to an alteration in the concentration of circulating fH. Alternatively, or
additionally non-synonymous coding SNPs in the gene itself (for example the variant encoding
Y402H) could alter the function of fH. There is substantial precedent for circulating protein
biomarkers to be regulated by common genetic variants located in the vicinity of the encoding
gene (i.e. cis-acting variants). The evidence for this comes from identification of cis-acting
regulatory variants: (i) through candidate gene studies (e.g. for CRP [56], and fibrinogen [118]
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(ii) GWAS of multiple blood proteins [119, 120] and (iii) GWAS of messenger RNA expression
profiles [121]. However at the time this work was initiated there were no studies of the
association between CFH variants and fH level, of the non-genetic determinants of fH in the
population, or the relationship between fH concentration and the risk of AMD or CHD. If the
association between genetic variation in CFH and risk of AMD were mediated through
differences in the amount of fH produced, fH itself would emerge as a potential biomarker and
therapeutic target for treatment of prevention of AMD, that may be relevant not only to
individuals who may carry CFH gene variants, but more generally to all those with AMD.
1.2.1 Structure and function of fH
First identified in 1965, complement factor H (fH) is a ~150 kDa protein. A single polypeptide
chain plasma glycoprotein [122], fH is composed of 1213 amino acid residues, arranged in 20
repetitive units termed short consensus repeats (SCRs), each of ~60 amino acid residues in
length. Functional domains of fH include three C3b binding sites in SCRs 1-4, SCR 12-14 and
SCRs 19-20; and three binding sites for heparin/ sialic acid in SCR7, SCR 13 and SCRs 19-
20. Thus SCRs 19-20 houses overlapping sites for both polyanion and C3b binding (Figure
1.7). A binding site for the acute phase protein CRP has also been identified on SCR7, and it
has been proposed that binding to CRP may arrest the alternative pathway. The N-terminal
SCRs 1-4 appear to be essential for factor I cofactor activity [123] and C-terminal SCRs 19-20
appear to be the most important for preventing alternate pathway activation on host cells
[124]. Recombinant fH lacking SCRs 16-20 cannot function adequately, although removal of
the C3b binding site in SCR 7 or SCRs 12-14 only reduces function modestly [125]. The
Y402H SNP, implicated in AMD lies in SCR 7, and prior to GWAS had already been
highlighted as a potentially important mutation with functional consequences, because of the
substitution of a positively charged histidine for a non-charged tyrosine. This substitution event
could have significant functional implications, as this amino acid change occurs in a cluster of
positively charged amino acids, disruption of which could potentially alter binding properties to
cell surface components which determines the further activity of fH [126].
Factor H is encoded by a single gene on chromosome 1q32 in the RCA gene cluster. The
cluster contains separate genes for the structurally similar complement regulatory proteins
42
including MCP, DAF and CR1. In addition, genes whose proteins show marked homology with
CFH, FHR1-5 are located immediately downstream of CFH (Figure 1.6) CFHRs are thought to
have arisen by genomic rearrangement, and although their precise function is not known,
some studies suggest that like fH they may have anti-inflammatory actions. Naturally occurring
haplotypes incorporating deletions in CFHR1 and CFHR3 have been shown to have a
protective effect in AMD. CFH itself comprises 23 exons spanning over 94 kb genomic DNA.
Each SCR is encoded by a single exon in CFH, apart from SCR2 which is encoded by exons 3
and 4 together. Exon 10 is only transcribed as part of the smaller (43 kDa) and less abundant
alternatively spliced product of CFH, termed factor H like-1 protein (FHL1).
Figure 1.6 The Regulation of Complement activation gene cluster. The RCA cluster
includes more than 60 genes, 15 of which are complement related, arranged in tandem
forming 2 groups separated by a number of genes un-related to complement. Within the group
that houses CFH and CFHRs there are large genomic duplications (indicated as A-D), which
include different exons of the CFH and CFHR 1-5 genes. Schematic taken from Rodriguez de
Cordoba et al., Molecular Immunology 2004 [127]
A key regulator of the alternate complement pathway at the level of C3 convertase, fH
functions in accelerating decay of C3b and acts as a co-factor for factor I accelerating
enzymatic cleavage of activated C3 (Figure 1.3). Soluble fH acts to dissociate circulating C3b
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(decay acceleration function), and membrane bound fH binds C3b, forms a complex with
factor B, that is recognised by factor I, which cleaves C3 into inactive components iC3b (which
remains surface bound) and can longer participate in the formation of C3 convertase. Factor H
preferentially binds C3b on host cell surfaces, recognising C3b in conjunction with anionic
clusters on host cell surfaces (heparin and sialic acid). Conversely C3b binding to microbial
cell surfaces lacking these structures increases the affinity of C3b to bind factor B which leads
to formation of C3 convertase, via the action of factor D (Figure 1.3). Factor H is therefore
considered to protect host cells from complement mediated damage while leaving pathogens
open to complement mediated attack. Micro-organisms have however evolved surface
molecules which bind fH, similar to polyanions on host cells, thus evading complement
mediated destruction. Pathogens that have developed such surface molecules include
Streptococcus pyogenes [128], Neisseria meningitides [129], Borrelia burgdorferi [130].
Null mutations in fH have been identified that play a role in renal diseases including atypical
haemolytic uraemic syndrome (aHUS) where mutations alter the membrane binding capability
of fH, and reduce protection to complement mediated damage, and membranoproliferative
glomerulonephritis type II (MPGN II), characterised by uncontrolled activation of C3. The CFH
knockout mice provide a disease model for human MPGN II [131]. Aged CFH knockout mice
also develop a phenotype akin to AMD, although this is a difficult disease to model in mice
given the absence of a macula in this species [132].
Synthesis of both fH and fHL1 is largely in the liver [133], and one study to date has measured
fH in a moderately sized population, indicating that circulating concentrations are in the range
110-615 mg/L [134]. The alternatively spliced fHL-1 circulates at a much lower concentration
of 10-50 mg/L. Extra-hepatic synthesis has also been shown and, in particular, local synthesis
in the RPE, choroid and neural retina, although expression of the alternatively spliced variant
has not been studied in such depth. fHL-1 is thought to have complement regulatory activity
with an N terminal region homologous to fH (Figure 1.7). Five additional proteins share
homology with fH although these are the products of different but related genes, CFHR 1-5.
Functions of the fHR proteins are as yet un-certain. Although they share homology with fH,
they lack N- terminal regions that define the regulatory activity of fH of decay accelerating and
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co-factor functions (Figure 1.7). However complement modulatory activity has been ascribed
to some of the fHR proteins [135, 136], and these functions may well extend to others in this
family of proteins. It has been suggested that CFHRs have functions which might be co-
operative or competitive with fH, but these are yet to be fully defined. More recent evidence
suggests that novel a mutation in CFHR5 predisposes to renal glomerular disease (termed
CFHR5 nephropathy) in individuals of Cypriot origin, suggesting there is an overlapping role
for factor H and related proteins [137].
1.2.2 Genetic regulation of circulating fH
One study to date has investigated the effects of genetic variation on fH level [134], reporting
substantial inter-individual variation in fH concentration (100-600 mg/L), a heritability of 0.6
and using microsatellite markers to conduct linkage analysis that fH is likely to be regulated by
a quantitative trait locus (QTL) mapping to chromosome 1q within a region that corresponds to
the RCA cluster. Independent mapping of a QTL for fH and a susceptibility locus for AMD to
the RCA cluster provides some evidence that variation in the same region, perhaps in the
vicinity of CFH itself influences fH concentration, and perhaps even that SNPs influencing fH
level and AMD risk might be concordant. If this were to be the case, it would provide strong
evidence that alterations in fH concentration play a pathogenic role in susceptibility to AMD.
However, the exact causal gene was not identified because of the low resolution of linkage
studies. Given the precedent for circulating biomarkers to be regulated by common genetic
polymorphisms in the vicinity of the encoding genes, I hypothesised that genetic variants may
exist in the vicinity of the CFH gene and that this might explain the observed association of
SNPs in this region with AMD.
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Figure 1.7 Homology between factor H, fHL-1, and members of the CFHR protein
family., a) Schematic view of complement factor H protein, delineating regions involved in
regulation (shaded green) and cell surface binding (shaded blue). Regions involved in binding
to C3b and heparin are indicated. The Y402H variant lies in a region that is implicated in C3
binding and in an interaction with CRP. (b) Shared homology with alternative splice variant
FHL1 is shown. Critically, FHL1 lacks key surface binding domains although it is postulated to
have some regulatory functions. (c) CFHR 1-5 are shown with homology to fH protein
indicated by the overlap of SCRs sharing similar activities that are shaded in the same colour.
Although the precise function of CFHRs is yet to be determined, structural homology suggests
that they may have similar, competitive or even independent actions to fH. CFHR4 has two
alternatively spliced forms.
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1.3 Hypothesis
Based on the preceding background, I developed the following specific hypotheses:
 Common variants in CFH in particular the Y402 polymorphism is associated with risk
of both CHD and AMD
 The association of CFH variants with AMD, and perhaps CHD, are mediated through
changes in circulating fH
 fH may be a therapeutic target and/ or a predictive factor for AMD (and perhaps CHD)
1.4 Aims
My initial aim was to carry out a systematic review and meta-analysis of genetic association
studies using both published literature and newly genotyped studies, to more precisely
estimate the association of the CFH rs1061170 SNP encoding Y402H with AMD and CHD, to
ascertain whether this variant was a risk factor for both disorders.
A further aim was to develop and validate an assay for circulating fH in order to (i) study the
genetic and non-genetic determinants of fH using stored blood samples, (ii) to examine the
association between circulating fH and the risk of AMD and CHD.
Completion of these studies would allow assessment of the consistency of the associations of
genetic variation at the CFH locus with fH level, and fH level itself with disease risk (Mendelian
randomisation), to test if fH is causally involved in both CHD and AMD, and thus if it is a
shared risk factor for both disorders.
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2 Genetic variation in complement factor H and age-related macular
disease: Assessment of effect size, modifiers, and relationship to
disease subtype using meta-analysis
Late stage AMD is an important cause of visual loss in the elderly. Early identification of
individuals at greater risk of disease and, in particular, the most sight threatening forms of
AMD might help target current preventative interventions to those at highest risk. Moreover,
better understanding of the causes of AMD could lead to the development of improved
treatments. A susceptibility locus on the gene that encodes complement factor H has been
identified in those with AMD [10, 104-106]. The most replicated association has been with the
SNP: rs1061170 encoding a tyrosine to histidine change at position 402 (Y402H).
rs1061170 is a common variant, the risk allele (C), encoding fH-402H, and has a frequency of
38%. Given that this variant is associated with a large effect on AMD, it has been proposed
that genotyping of this variant may be helpful in predicting future risk of AMD [138]. However a
number of existing uncertainties require resolution before a genetic test of this type could be
recommended for use in clinical practice. First, the precise magnitude of the effect size
requires better delineation as large effect sizes in initial ‘discovery’ studies can become
attenuated as the literature matures [139]. Second, it is unclear if the risk conferred by
carriage of this variant is the same for all grades/ severity of AMD. Third, although it has been
suggested that smoking (a recognised risk factor for late AMD) could modify the effect of the
rs1061170 variant, individual studies have not been large enough to address this question
reliably. Fourth, it is uncertain whether rs1061170 is itself a causal variant or simply marks
another causal site (because of linkage disequilibrium (LD)), either within or outside of CFH.
Since LD patterns vary among populations of differing ancestry, the magnitude of association
and in turn the predictive performance of rs1061170 could be very different in populations of
differing ancestry. Moreover, if rs1061170 marks a causal site in an adjacent gene, of which
several exist in the region of complement activation (RCA) cluster on chromosome 1, targeting
fH or its downstream effects may not provide a useful means of treating or preventing AMD.
To address these uncertainties the association of rs1061170 with AMD was tested in two new
genetic association studies that had not previously contributed to GWAS of AMD, together
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totalling 2,222 cases and 795 controls. These studies were further incorporated into meta-
analysis of 22 prior studies (14,174 cases/ 26,494 individuals) of which 18 reported
information on the late sight-threatening forms of AMD and 9 studies (~6500 cases) provided
either participant or aggregate level information.
The aims of this chapter were to more precisely quantify genetic effects of rs1061170
polymorphism on AMD risk in individuals of European and non-European descent, assess the
effect of genotype on different grades and severity of AMD, and the potential interactive effect
of smoking on AMD. Collectively this substantially updates and extends the prior meta-
analysis [140] in this area.
2.1 Methods
2.1.1 Newly genotyped Studies
2.1.1.1 MRC AMD Case Control Study
A prospective case control study was conducted in 1,469 unrelated individuals of European
ancestry (1234 cases and 194 controls) recruited from Moorfields Eye Hospital. All individuals
were examined by an ophthalmologist and completed a health and lifestyle questionnaire to
gather information on family history, smoking and other medical history. Clinical examination
included colour stereoscopic fundus photography of the macular region and photographs were
graded according to the International Classification System for age-related maculopathy [94]
(ICARMS) classification by 2 ophthalmologists independently at two stages (preliminary and
final), with any discrepancies being resolved by consensus. Cases or controls were excluded if
they had evidence of diabetic retinopathy, inflammatory or retinovascular disease. Blood was
drawn at the time of examination from an ante cubital vein into EDTA, and samples stored at -
20⁰ C for DNA extraction. The rs1061170 polymorphism was typed blind to the clinical status
of the participants using Taqman (ABI),which was carried out commercially.
2.1.1.2 EUREYE Study
rs1061170 was genotyped in a nested case control subset of the EUREYE study, a cross
sectional study investigating the prevalence and risk factors for AMD across Europe. The
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study randomly sampled individuals ≥ 65 years of age who were invited to an eye examination 
at one of 7 participating centres across Europe (Norway, Estonia, United Kingdom, France,
Italy, Greece and Spain). [141]. Fundal images were taken of each eye and were graded
masked to clinical status, according to ICARMS classification at a single reading centre.
Drusen were categorised according to their size, homogeneity of surface features and
outlines, pigmentory irregularities were classified into either hypopigmentation or
hyperpigmentation. Early AMD was defined as the presence of soft indistinct drusen (≥ 125 
μm) or reticular drusen only or soft distinct drusen (≥ 63 μm) with pigmentary abnormalities or 
soft indistinct drusen (≥ 125 μm) or reticular drusen with pigmentary abnormalities. Late AMD 
subtypes were geographic atrophy (GA) or choroidal neovascularisation (CNV). GA was
defined as any sharply demarcated round or oval areal of apparent absence of the RPE, larger
than 175µm, with visible choroidal vessels, and no CNV. CNV was defined as the presence of
a serous or hemorrhagic detachment of the RPE and/or a sub retinal neovascular membrane
and/or sub retinal hemorrhage, and/or peri-retinal fibrous scarring, even with patches of GA.
When geographic atrophy and choroidal neovascularisation co-existed in the same eye this
was categorised as CNV. When in doubt, eyes with other disorders resembling AMD were
excluded. Interviews were also conducted with individuals in order to ascertain lifestyle risk
factors including smoking history. Blood was drawn at the time of interview into EDTA and
DNA was extracted and stored at -80⁰ C. Genotyping was carried out at KBiosciences using
KASPar chemistry, a competitive allele specific polymerase chain reaction (PCR) SNP
genotyping system using FRET quencher cassette oligos.
(http://www.kbioscience.co.uk/genotyping/genotyping-chemistry.htm).
2.1.2 Meta-analysis
2.1.2.1 Search Strategy
MEDLINE, (using Pubmed up to August 2008) and EMBASE (1981-2008) were searched for
studies evaluating the association between rs1061170 polymorphism and AMD. Free text and
MeSH terms used were ‘age related macular degeneration’, ‘macular degeneration’,
‘complement factor H’ and ‘Y402H’. Searches were limited to “human”. Additional studies were
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identified through reference lists of publications and searching through ‘related articles’ link on
Pubmed.
2.1.2.2 Inclusion criteria
To be included, studies had to be cohort or case control (nested/ prospective/ retrospective)
studies studying unrelated individuals. Where studies contained duplicated results; the study
with the smaller population was excluded. If there were clearly two populations (e.g. discovery
and replication populations), both these were included, and notation used for these were as
used in the primary study. Where studies contained data sets from related and un-related
cases, information extracted was limited to unrelated dataset.
2.1.2.3 Data Collection and Management
Data were extracted on AMD outcome from studies which reported any subtype of AMD, these
were categorised either as early AMD or late AMD, and if reported separately data was
collected on the discrete sub-categories of ARM, GA, CNV, or mixed GA and CNV. Study
quality was assessed according to HuGENET guidelines for genetic association studies
(http://www.hugenet.ca). The following information was abstracted from published reports:
grading scales used for AMD diagnosis, clinical categories of AMD (early AMD, GA, CNV, late
AMD), if genotyping was carried out blinded to outcome, genotyping platform used, deviation
from Hardy Weinberg Equilibrium (HWE) and ancestry of population under study.
Corresponding authors from the studies that met inclusion criteria and which included a total of
≥500 individuals were contacted on at least three occasions to request further aggregate or 
participant level data. Information was requested on age, gender, smoking status, rs1061170
genotype, AMD status, and AMD sub-type if affected and grading scale used for diagnosis.
Participant level data was reconstructed from limited tabular data where necessary.
2.1.2.4 Study Quality
The Venice criteria were applied to the studies included in the meta-analysis to assess the
strength of the cumulative evidence on genetic associations. These criteria are a semi-
quantitative index which assigns three levels to the association under study [142]. The levels
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assigned include first the amount of evidence, second the extent of replication, and third the
degree of protection from bias. Within each category, three scores from A to C were assigned,
with A signifying the highest level indicating the strength of data in each category, and C the
lowest in each category, indicating paucity of data or poor data quality in each category. A
composite score of assessment for an association is generated which can then be graded as
strong, moderate or weak.
2.1.3 Statistical analysis
2.1.3.1 Newly genotyped studies
To evaluate differences between cases and controls, unpaired Student’s t or 2 tests were
used as appropriate. Departure from Hardy-Weinberg equilibrium (HWE) was evaluated using
a 2 analysis in controls. The principal a priori hypothesis was that the association between
rs1061170 and late AMD follows an additive model according to the number of C alleles,
however recessive and dominant models and pair-wise comparisons (that is CC homozygotes
vs TT homozygotes and CT heterozygotes vs TT homozygotes) were also evaluated. For the
additive model the OR was compared using logistic regression between cases and controls by
assigning scores (0,1,2) for different genotype groups and calculating the OR’s and 95%
confidence intervals (CI’s). For the EUREYE data set, standard errors were adjusted to
account for data clustered by country. Concomitant subsidiary analyses assessed the
association rs1061170 in the different subtypes of AMD. The joint contribution of rs1061170
genotype and smoking on the risk of AMD was assessed to evaluate any gene- smoking
interaction. Smoking was coded as ever and never or as current, ex-smoker and never
smoked. Interaction was assessed overall on the multiplicative scale and separately by strata
of age and gender. All data were analysed using Stata (Version 11, StataCorp LP College
Station, TX, USA)
2.1.3.2 Meta analysis
2.1.3.2.1 Participant level meta-analysis
Nine studies provided either participant level or limited tabular information and these data
were analysed as follows:
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2.1.3.2.2 Main effect of rs1061170 on late AMD
As for the case control and cross sectional study, the model specified a priori was an additive
(per-allele) model for late AMD. Secondary analyses explored other genetic models of
inheritance. Mixed logistic models treating ‘study’ as the random factor were used. Interaction
by age, gender was assessed on the multiplicative scale using studies able to provide these
data.
2.1.3.2.3 AMD subtype
The effect of rs1061170 genotype on different clinical grades of AMD was assessed in using
mixed models as above with study as the random factor and using 99% confidence intervals.
2.1.3.2.4 Smoking
A number of approaches were used to explore effect modification by smoking on the effect of
rs1061170 genotype on any AMD, late AMD (GA and CNV together) and subtypes of AMD
(GA and CNV separately). The first approach was to use all participant level data merged with
limited tabular data (9 studies 5,804 cases) to assess the effect of smoking on the rs1061170
effect on all AMD; second using only participant level data (5 studies) allowed me to assess
the effect of smoking on rs1061170 genotype effect on all late AMD (CNV and GA together) as
well as individual subtypes of late AMD (GA and CNV separately). Thirdly a case only design
[143] was used in a subset of studies providing genotype and smoking data to further assess
an effect modification with smoking. This analysis is based on the premise that in the absence
of any effect modification, smoking distribution among cases will not be related to genotype,
provided smoking is independent of CFH genotype in the general population. Advantages of
the case-only approach are that it excludes potential biases arising from control selection and
overcomes problems arising from combining different study designs while maintaining
statistical power. Lastly using a further subset of data (3 studies) where pack years of smoking
could be determined, association between intensity of smoking and AMD risk stratified by
rs1061170 genotype was also calculated. Given the exploratory nature of the analyses 99%
confidence intervals were used.
53
2.1.3.2.5 Aggregate level meta-analysis
Aggregate information was available from 16 studies and these were included in the analysis
of the main effect of rs1061170 on AMD and investigation of heterogeneity of effect size based
on pre-specified subgroups.
2.1.3.2.6 Biological and technical variables
Heterogeneity can arise because of errors and biases as well as true biological variation.
Therefore the effect of study design, genotyping platform, and grading scale for the diagnosis
of late AMD (as sources of error and bias) and the effect of smoking and disease subtype (as
potential explanations for true biological variation) were evaluated. Using aggregate level
meta-analysis summary measures for all variables were calculated using a random effects
model with inverse variance weights. Heterogeneity between estimates was assessed using
the Der Simonian and Laird Q test and I2 was used as a measure to describe the percentage
of variability in point estimates.
2.1.3.2.7 Non European Populations
Studies investigating the association of rs1061170 in non European populations (mainly
Chinese and Japanese) were analysed separately by collecting aggregate level data from
published studies. Summary estimates were generated using random effects models as
above. Where there were “zero” cells, that is there were no cases for a given genotype, a
value of 0.5 was added to all cells and meta-analysis carried out [144]. If case/control counts
by genotype were not readily extractable from published studies, but allele frequencies were
given, genotype frequencies were calculated. If no data was given from which genotype data
could be calculated, summary odds ratios were extracted and included in the meta-analysis.
All data analysis was carried out using Stata (Version 11, StataCorp LP College Station, TX,
USA) all studies included reported findings of late AMD cases.
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2.1.3.2.8 Small study bias and cumulative meta-analysis
Small study bias was assessed using funnel plots and the Egger test, and cumulative meta-
analysis was performed to test the cumulative evidence at the time each study was published,
to examine attrition in the effect size after initial studies reporting a large effect size.
2.1.3.2.9 Data extraction and database reconstruction
Submitted databases were cleaned and checked and any uncertainties resolved by contact
with the authors. Aggregate level data from studies investigating European individuals was
converted to “pseudo” participant level data by expanding the aggregate database. A unique
“studyid” variable was created and a unique number was assigned to individuals in the
aggregate database. Similarly the number of cases and their genotypes were also assigned in
the same manner. Details of other covariates: age, gender and smoking were added to the
baseline information of genotype and outcome although in separate databases, as not enough
information was available to merge all covariates into one database. The individual databases
were merged with participant level databases thus creating four databases: one for the main
effect of late AMD, one for age, one for gender and one database of pooled studies where all
fields at participant level were available. The latter was used to explore interaction between
covariates, as this was not possible with databases limited to one covariate
2.2 Results
2.2.1 Newly genotyped studies
Clinical, demographic data and distribution of rs1061170 genotype from the MRC case control
study and EUREYE are shown in Table 2.1. Allele frequencies in cases and controls were
comparable to other published studies, with an increased frequency of the C allele in cases.
There was no deviation from Hardy Weinberg Equilibrium in controls. An additive age
adjusted model (per C allele) demonstrated a significant association between rs1061170 SNP
and late AMD risk in both MRC case control study (OR 2.04 (95% CI 1.63, 2.56 p<0.001)) and
EUREYE studies (OR 2.43 (95% CI 2.04, 2.90 p<0.001)) (Table 2.2). The effect was found to
be similar in analysis for each clinical subtype of AMD and, in ever-smokers compared to
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never smokers (Table 2.2).There was no evidence for a gene-smoking interaction (p=0.42 for
the MRC case control study and p=0.78 for the EUREYE study).
Table 2.1 Demographic characteristics of AMD cases and controls with differing
rs1061170 genotype from the MRC case-control study and the EUREYE study (* indicates
ever smoked, GA=Geographic Atrophy, CNV=Choroidal neovascularisation)
Characteristic MRC Case Control Study EUREYE
AMD Controls AMD Controls
Total number 1,234 235 686 604
Age (mean, sd) 77.36 (8.21) 74.88 (8.11) 75.4 (6.43) 74.6 (6.02)
% males 35.17 41.28 45.9 45.6
% Smokers* 62.80 59.57 50.4 44.4
TT genotype 201 71 206 251
CT genotype 591 105 333 285
CC genotype 397 38 147 68
Deviation from HWE
for controls (p value
for 2 test)
0.94 0.33
AMD Grade
% early 18.56 79.5
% GA 17.34 6.3
% CNV 60.00 14.3
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Table 2.2 Effect of rs1061170 polymorphism on AMD risk in MRC case control and
EUREYE studies
Additive OR (95%
CI), unadjusted
Additive models,
age adjusted
OR (95% CI)
Genetic Models, age
adjusted TC vs TT
OR (95% CI)
Genetic Models, age
adjusted CC vs TT
OR (95% CI)
MRC Case Control Study
Main effect:
Late AMD
1.90 (1.53, 2.36) 2.04 (1.63, 2.56) 2.24(1.56, 3.21) 4.08 (2.61, 6.39)
ARM/ Early AMD 2.07 (1.56, 2.72) 2.07 (1.56, 2.73) 1.96 (1.20, 3.20) 4.26 (2.43, 7.45)
GA 2.12 (1.60, 2.83) 2.23 (1.66, 3.00) 2.27 (1.36, 3.82) 4.99 (2.77, 9.00)
CNV 1.77 (1.41, 2.22) 1.90 (1.51, 2.41) 2.10 (1.44, 3.06) 3.57 (2.24, 5.70)
Ever Smoked 2.06(1.55, 2.74) 2.25 (1.67, 3.03) 1.67 (1.07, 2.61) 4.58 (2.66, 8.51)
Never Smoked 1.71 (1.22, 2.41) 1.81 (1.28, 2.56) 1.59 (0.89, 2.87) 3.31 (1.63, 6.69)
EUREYE*
Main effect:
Late AMD
2.30 (1.93,2.73) 2.43 (2.04,2.90) 2.59 (2.02,3.32) 5.90 (4.13,8.44)
ARM/ Early AMD 1.43 (1.21, 1.70) 1.44 (1.21, 1.71) 1.27 (1.09, 1.48) 2.22 (1.47, 3.37)
GA 2.41 (1.39, 4.19) 2.74 (1.60, 4.69) 1.73 (0.82, 3.65) 7.16 (2.93, 17.51)
CNV 2.26 (1.64, 3.11) 2.34 (1.61, 3.40) 3.12 (1.69, 5.74) 5.47 (2.42, 12.36)
Ever Smoked 1.99 (1.32,2.99) 2.14 (1.42, 3.21) 2.39 (1.26, 4.54) 4.74 (1.95, 11.52)
Never smoked 2.72 (1.81, 4.08) 2.90 (1.90, 4.43) 3.17 (2.14, 4.71) 8.15 (3.65, 18.18)
* Clustering of data by country has been accounted for in analysis
2.2.2 Meta-analysis
The search identified 40 studies from which relevant information could be abstracted, 24 of
which were in European populations [10, 104, 105, 107-110, 145-158], six were in Japanese
populations [159-164], six in Chinese [165-170] (including Hong Kong Chinese and
Taiwanese), one Korean [171], one in Indian/ South Asians [172], one in Latin Americans
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[173] and one in Black South Africans [174] (Figure 2.1, Table 2.3). The main focus of the
analysis was on the relationship of the rs1061170 SNP and late AMD in individuals of
European ancestry, although secondary analyses on association in other ethnic groups were
also performed. Nine studies, comprising 5,185 cases of AMD identified from the search, or by
direct contact, were able to provide more detailed information, either aggregate or individual
level, in addition to the newly genotyped studies [107-109, 154, 158].
Figure 2.1 Flow diagram illustrating identification of studies included in the meta-
analysis of the rs1061170 variant in CFH and AMD.
167 potentially relevant
citations identified and
screened in publically available
databases
100 Citations excluded on the
basis of title, abstract or both
67 Full text articles
retrieved for detailed
evaluation
28 Articles excluded as not
investigating outcome under
study, or other genetic variants,
duplicate date, or insufficient data
Total of 17 studies included
Europeans included in late amd
analysis
40 Included studies, 24 in
Europeans, 6 in Japanese, 6 in
Chinese, 1 Korean, 1 Indian, 1
Latin American, 1 Black South
African
Table 2.3 Studies included in the meta-analysis of the association of CFH rs1061170
variant and AMD risk. The table is divided by the type of data that were gathered and
according to the ancestry of the participants. The first section details characteristics of studies
where information was abstracted from the publication, which studied individuals of European
ancestry. Studies indicated with a *, are those for which the outcome of late AMD alone was
not reported, rather all AMD (including early disease) reported as one- and were therefore
NOT included in the subsequent meta-analysis of late AMD. The second section details the
studies that were contacted, and who were able to provide either limited tabular data or
participant level data. These studies are also of individuals of European ancestry. The final
part of the table includes information of data abstracted from published literature in non-
European ethnicities. HWE is not given as all studies report control population in HWE.
Published studies with participants of European Ancestry
Study Ethnicity
Study
Design
Grading
Scales used
for AMD
Source of
population:
Cases
Source of
population:
controls
Genotyping
platform
Edwards AO et
al., Discovery
Set*
European Case control Wisconsin Clinic Based
Clinic/
Spouse
controls
TaqMan (ABI);
MassARRAY
(Sequenom)-
analysed by
MALDITOF
Edwards AO et
al., Replication
set*
European Case control Wisconsin Clinic Based Population
TaqMan (ABI);
MassARRAY
(Sequenom)-
analysed by
MALDITOF
Hageman G., et
al Columbia
population*
European Case control ICARMS Clinic Based Clinic TaqMan
Hageman G., et
al Iowa
population*
European Case control ICARMS Clinic Based Clinic TaqMan
Souied EH et al European Case control ICARMS Clinic Based Clinic
PCR directed
sequencing
Physicians
Health Study*
European
Nested Case
control
Not specified
Nested in
RCT
Nested in
RCT
TaqMan
Simonelli F et al European Case control ICARMS Clinic Based Clinic Taqman
Seitsonen S et
al*
European Case control Not specified Clinic Based
Clinic and
anonymous
blood
donors
PCR directed
sequencing
Baird et al European Case control Wisconsin Clinic Based Population MassArray
Fisher et al* European Case control ICARMS Clinic Based Spouse
PCR Directed
Sequencing
Nurses Health/
Health
Professionals study
European
Nested case
control
ICARMS Population Population Taqman
dTable 2.3 continue59
Published studies with participants of European Ancestry
Study Ethnicity
Study
Design
Grading
Scales used
for AMD
Source of
population:
Cases
Source of
population:
controls
Genotyping
platform
Weger et al.
European Case control AREDS Clinic Based Clinic
RFLP
Pulido et al. European Case control Not specified Clinic Based
Disease
controls
(cystic
fibrosis)
RFLP
Droz et al. European Case control ICARMS Clinic Based
Clinic and
Spouse
DHPLC
Blue Mountain
Eye Study
European
Prospective
cohort
Wisconsin Population Population TaqMan
Rotterdam European
Prospective
cohort
Rotterdam Population Population TaqMan
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Table 2.3 continued. Limited tabular and participant level data from studies of individuals of
European ancestry.
Limited Tabular data, European Ancestry
Study Ethnicity
Study
Design
Grading
Scales used
for AMD
Source of
population:
Cases
Source of
population:
controls
Genotyping
platform
Rivera et al European
Case
control
ICARMS Clinic Based Clinic MassArray
Conley et al European
Case
control
In House Clinic Based Clinic RFLP
CHS European
Nested
Case
control
In House Population Population RFLP
AREDS European
Nested
Case
control
AREDS Nested in RCT
Nested in
RCT
RFLP
Participant level data, European Ancestry
Study Ethnicity
Study
Design
Grading
Scales used
for AMD
Source of
population:
Cases
Source of
population:
controls
Genotyping
platform
MRC Case Control
Study
European
Case
control
ICARMS Clinic Based Clinic Taqman
Zhang et al. European
Case
control
ICARMS Clinic Based Clinic
Direct DNA
Sequencing
Zareparsi et al. European
Case
control
ICARMS Clinic Based Clinic
Not
specified
Sepp T et al. European
Case
control
ICARMS Clinic Based Clinic SNaPshot
Southampton European
Case
control
AREDS Clinic Based Clinic
GenomeLa
b
SNPstream
EUREYE European
Nested case
control in
cross
sectional
study
ICARMS
Population
based
Population
Based
KASPar
Amsterdam European
Population
based
Rotterdam
Population
based
Population
Based
Taqman
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Table 2.3 continued. Aggregate level data abstracted from publications of non-European
populations.
Study Ethnicity
Study
Design
Grading
Scales used
for AMD
Source of
population:
Cases
Source of
population:
controls
Genotyping
platform
Japanese
Studies
Okomoto et al. Japanese
Case
control
Not
specified
Clinic Based Clinic Based
Direct
sequencing
Gotoh et al. Japanese
Case
control
Not
specified
Clinic Based Clinic Based
Direct
sequencing
Uka et al. Japanese
Case
control
Not
specified
Clinic Based Clinic Based Taqman
Fuse et al. Japanese
Case
control
Not
specified
Clinic Based Clinic Based
PCR
amplification
restriction
digest
Tanimoto et al. Japanese
Case
control
Not
specified
Clinic Based Clinic Based Taqman
Mori et al. Japanese
Case
control
AREDS Clinic Based Clinic Based Taqman
Chinese Studies
Lau et al. Chinese
Case
control
ICARMS Clinic Based Clinic Based
PCR
amplification
restriction
digest
Chen et al. Chinese
Case
control
ICARMS Clinic Based Clinic Based Taqman
Lin et al (wet
AMD)
Chinese
Case
control
ICARMS Clinic Based Clinic Based
Melting curve
mutation
analysis
Ng et al. Chinese
Case
control
ICARMS Clinic Based Clinic Based
Direct
sequencing
Xu et al. Chinese
Case
control
Not
specified
Clinic Based Clinic Based
PCR
amplification
restriction
digest
Lin et al (early
AMD)
Chinese
Case
control
Clinic Based Clinic Based
Melting curve
mutation
analysis
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Table 2.3 continued. Aggregate level data abstracted from publications of non-European
populations.
Study Ethnicity
Study
Design
Grading
Scales used
for AMD
Source of
population:
Cases
Source of
population:
controls
Genotyping
platform
Korean Study
Kim et al Korean
Case
control
Not
specified
Clinic Based Clinic Based
Direct
Sequencing
Indian/ South
Asian study
Kaur et al.
Indian/
South
Asian
Case
control
AREDS Clinic Based Clinic Based
PCR
amplification
restriction
digest
Latin American/ US based
study
Tedeschi-Blok
et al.
Latin
American
case
control
Wisconsin Clinic Based Clinic Based
PCR
amplification
restriction
digest
South African
Study
Ziskind et al.
South
African
case
control
Rotterdam Clinic Based Clinic Based RFLP
2.2.2.1 Main effect of rs1061170 polymorphism on late AMD
Of a total of 26 studies, 18 reported information on late AMD and included 6,322 cases and
10,467 controls. The per-C allele OR for late AMD was 2.27 (95% CI 2.10, 2.45) (Figure 2.2)
and for any AMD the OR was 1.86 (95% CI 1.77, 1.97, for 26,494 individuals including 14, 174
cases). These estimates are more precise than the previously published meta-analysis which
included 4,856 cases from 8 studies [140]. Genotyping platform (2 p =0.06 on 6 degrees of
freedom, I2=49.6%), clinical grading scale (2 p =0.33 on 5 degrees of freedom, I2=13.3%),
and study design (2p =0.0.80 on 2 degrees of freedom, I2=0.0%) contributed to some
heterogeneity in effect size (Figure 2.3)
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Figure 2.2 Overall association of the rs1061170 SNP on the risk of late AMD and the
effects of this polymorphism on clinical subtypes of AMD. For the outcome of “late AMD”
GA, CNV and mixed GA and CNV were combined into a single category.
All late AMD
GA
CNV
Early AMD
Any AMD
18
9
9
13
24
6231
1088
3795
5224
14174
16738
3846
6716
13908
26494
2.27 (2.10, 2.45)
2.50 (2.17, 2.99)
2.28 (2.04, 2.56)
1.47 (1.37, 1.58)
1.86 (1.77, 1.97)
10 2 3
AMD
subtype
Total Number of
studies
Total number of
cases
Total number
of individuals OR (99% CI)
Late AMD
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Figure 2.3 Association of rs1061170 variant on late AMD stratified by diagnostic grading
scale, population type and genotyping method
MassArray
Taqman
RFLP
PCR Directed Sequencing
Not Specified
SNaPshot
KASPar
Overall
Wisconsin
ICARMS
Rotterdam(ICARMS based)
Not Specified
AREDS
In House
Overall
Clinic Based
Population Based
RCT
Overall
Strata
2
5
6
2
1
1
1
18
2
9
2
1
2
2
18
12
5
1
18
Number of
Studies
2054
8283
3277
761
789
704
745
16613
2724
7618
3308
319
1307
1337
16613
7617
8157
839
16613
Total number
of individuals
3.01 (1.88, 4.14)
2.01 (1.62, 2.40)
2.40 (1.63, 3.17)
2.00 (1.56, 2.44)
3.26 (2.47, 4.06)
2.57 (1.98, 3.16)
2.31 (1.75, 3.05)
2.39 (2.06, 2.71)
2.88 (1.18, 4.57)
2.23 (1.87, 2.60)
2.59 (2.03, 3.16)
2.13 (1.38, 2.89)
1.91 (0.71, 3.11)
3.39 (2.30, 4.48)
2.39 (2.08, 2.70)
2.33 (1.95, 2.72)
2.28 (1.63, 2.94)
2.54 (1.97, 3.11)
2.38 (2.09, 2.66)
OR (95% CI)
10 2 3 4
Genotyping Platform
Grading Scale
Population
P value for 2 test of
heterogeneity (degrees
of freedom)
0.06 (6)
0.33 (5)
0.80 (2)
OR
Where studies genotyped multiple variants in the CFH gene, and did not specify genotyping platform used for
rs1061170 encoding Y402H they were coded as “not specified”. For AREDS, limited tabular data was available by
request as appears in Conley et al.[107] , which stated genotyping was carried out using RFLP rather than Affymetrix
100K Chip as per original genome wide scan.
ICARMS: International classification and grading system for age-related macular degeneration [94]; AREDS: Age-
Related Eye Disease Study System for classifying age-related macular degeneration [143], Wisconsin age related
maculopathy grading system[175], Rotterdam age-related macular degeneration scale[176]
2.2.2.2 Effect of rs1061170 on grade of AMD, assessed using participant level data
The OR per-C allele for the association with early AMD was 1.47 (99% CI 1.37, 1.58;
information from 13 studies, 5,224 cases); for GA was 2.50 (99% CI 2.17, 2.99; 9 studies,
1,088 cases), and for CNV was 2.28 (99% CI 2.04, 2.56; 9 studies, 3,795 cases) (Figure 2.2).
2.2.2.3 Effect modification of the rs1061170- AMD association by smoking
First I assessed the effect of smoking on AMD risk without taking genotype into account. Using
participant level data from five studies (2,403 cases of late AMD) the odds ratio for late AMD in
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those who had smoked at any time in their life (ever smoked) compared to those who had
never smoked was 1.12 (99% CI 0.88, 1.43) .
The smoking effect stratified by rs1061170 genotype was such that the odds for late AMD in
smokers versus non-smokers in individuals who were homozygous for the T allele was 1.66
(99% CI 1.00, 2.75), for TC heterozygotes the odds for late AMD was 0.82 (99% CI 0.56, 1.17)
and for CC individuals the odds for late AMD in smokers versus never smoked is 1.67 (99% CI
0.90, 3.08).
Adding genotype and using an additive (per allele model), the odds ratio for late AMD per C
allele in current versus never smoked was 2.50 (99% CI 1.58, 3.96) and ex-smokers versus
never smoker 2.25 (99% CI 1.83, 2.76), with no evidence for interaction using either
categorisation (p value for interaction 0.63 and p=0.75 respectively). The findings were similar
when using merged participant level and tabular data from 11 studies (6,422cases of any
AMD) and are summarised in Figure 2.4.
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Figure 2.4 Association of rs1061170 genotype on AMD stratified by smoking The boxes
in the plot below represent the additive (per-allele) estimate for rs1061170 genotype on AMD
and their 99% confidence intervals. These estimates are stratified by smoking, and the
category of smoking is displayed on the left hand side. For the analyses shown, smoking was
coded as never and ex-smoker and current smoker. Using the additive model the reference
group is that coded ‘0’ in the genotype model, which here are individuals homozygous for the
rs1061170 ‘TT’ genotype.
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Lastly using the case only approach, limited to late AMD cases (n=2,403) from studies
providing participant level data, the odd ratio was 0.81 (99% CI 0.60, 1.10), indicating no
evidence for a gene-environment interaction. To test the assumption of independence
between the genotype and smoking in the general population the control group (n=1556) was
also assessed, and the odds ratio for smoking in this group was 1.04 (99% CI 0.79, 1.35).
Further assessment of the effect of intensity of smoking on AMD risk by genotype also did not
show any evidence of interaction, for both pair-wise and per allele comparisons (Figure 2.5).
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Figure 2.5 Association of rs1061170 and late AMD by stratum of smoking intensity.
Additive, per-allele estimates are given above. Data is taken from three studies in which pack
years of smoking was recorded.
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2.2.2.4 Influence of ethnicity on the association of rs1061170 and late AMD
HapMap (www.hapmap.org) LD patterns for common SNPs in the vicinity of CFH differ among
ancestral groups, and the frequency of the C allele for rs1061170 is lower in Japanese
(MAF=0.06) and Chinese (MAF=0.07), compared to European subjects (MAF=0.36) (Figure
2.6).
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Figure 2.6 Linkage disequilibrium maps of CFH in populations of European ancestry
(CEPH) and Japanese and Han Chinese ancestry. LD plots were constructed using Build 22
Hapmap. The rs1061170 SNP is indicated by a red bar in both LD panels to serve as a marker
for comparison of the surrounding LD patterns. LD metric displayed is r2, darker red indicating
higher degree of LD.
CEPH
Japanese/ Chinese
A systematic review and meta-analysis of published studies on the association of rs1061170
and AMD risk in non-European populations was therefore performed. The search identified 16
studies carried out in non-European populations, with six being in Japanese, six being in
Chinese, one in south Asians, one in Black South Africans, and one in Latin Americans. Data
was reported in a form amenable to meta-analysis from 14 out of 15 studies, with genotype
counts being calculated from allele frequencies in one study [160] and summary odds ratio
being used from the Indian/ South Asian study [172] . In ten studies there were no cases or
controls with the putative risk allele, and an estimate for odds could only be obtained by
adding 0.5 to each cell [144]. Meta-analysis was carried out using data from 2 studies (206
cases) with full data and showed no evidence of an effect of rs1061170 on AMD risk in
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individuals of Japanese ancestry, (OR 1.72 95% CI 0.51, 5.79 for CC compared to TT; and
1.49 95% CI 0.86, 2.58 in CT vs TT). Estimates from analysis using the complete subset of
the data from Japanese and Chinese studies adding a value of 0.5 to cells with zero counts (6
Japanese studies,672 cases ) demonstrated an odds of 1.71 (95%CI 0.65,4.49) for CC
homozygotes compared to TT individuals, and for individuals of Chinese ancestry (6 studies,
839 cases) the odds of disease in CC individuals compared to TT individuals was 5.34 (95%
CI 0.81, 23.12), Risk in heterozygous subjects and data from other ancestries is given in
Table 2.4. The observed differences in disease risk may in part be due to the differences in
allele frequencies in the different populations (Figure 2.7).
Table 2.4 Results of meta-analysis from non-European populations, on the effect of
rs1061170 on AMD. All summary statistics are random effects estimates, 0.5 has been added
to cells with zero counts to allow pooling of the individual studies. For populations represented
by a single study, summary measures were not included.
Ethnicity No of studies Summary OR for CC vs TT (95%
CI)
Summary OR for TC vs TT
(95%CI)
Japanese 6 1.79 (0.69, 4.66) 1.03 (0.71, 1.50)
Chinese 4 5.34 (1.05, 27.07) 1.73 (1.08, 2.77)
Taiwan* Chinese 2 22.26 (2.85, 173.83) 1.83 (1.08, 3.08)
*Two studies combined, one wet AMD , one early AMD
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Figure 2.7 Frequency of rs1061170 genotypes in studies included in the analysis of the
main effect on AMD risk.
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2.2.2.5 Venice Criteria applied to the association of rs1061170 and AMD in European
and non-European populations
Venice criteria were applied to evidence from populations of all ancestries, the largest amount
of information coming from genetic association studies in those of white European ancestry.
The findings are summarised in Table 2.5. The evidence for the association was greatest in
European subjects (graded AAA) and least in Indian, Latin American and Black African
subjects (CCC). The strength of the evidence from Japanese studies (BCB) and Chinese
subjects (BCC) was intermediate.
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Table 2.5 Strength of evidence for the association of rs1061170 genotype with AMD risk
in individuals of differing ancestry assessed using Venice Criteria. A score of A indicates
strong epidemiological credibility, B indicates moderate and C indicates weak, therefore a
score of AAA in all categories indicates a large amount of evidence with extensive replication
and protection from bias. Studies amongst European descent populations present strong
epidemiological credibility although the relative paucity of data amongst other ancestries
makes this association less so, although this may reflect inadequate power to detect an effect
given the MAF particularly in Japanese and Chinese populations.
Population Amount of
Evidence
Replication Protection from
Bias
Venice Score
White European A A A AAA
Japanese B C B BCB
Chinese B C C BCC
Indian (South Asian) C C C CCC
Latin American C C C CCC
Black African C C C CCC
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2.3 Discussion
2.3.1.1 Summary of main findings
By conducting a meta-analysis using a combination of new studies and published data, what I
have been able to present here is a more precise and reliable estimate of late AMD conferred
by carriage of the rs1061170 variant in the CFH gene. This analysis indicates that the
association has remained robust, with the best estimate of the effect size being largely
undiminished despite the continuing accrual of information on this association since the
original GWAS. Of the 813 GWAS of common diseases and disease related risk factors
conducted to date (www.genome.gov/26525384), the association of CFH (in particular the
rs1061170 variant) with AMD, is amongst the largest for a common allele conferring
susceptibility for a complex disease with a per-allele odds ratio of 2.27 (95% CI 2.10, 2.45) in
European populations.
Exploiting the large size of the assembled data set, I also found no evidence for effect
modification in Europeans by smoking habit, which has been reported previously in other,
smaller (and therefore lower power) studies. However, there was evidence of a modest
difference of genetic effect by disease category, with a slightly higher risk of GA compared to
other forms of AMD among individuals carrying risk alleles for rs1061170. However given the
overlap of the confidence intervals for the association with GA and CNV, it remains somewhat
inconclusive whether the variant confers greater risk of GA compared to other disease sub-
types. Importantly, the association of rs1061170 was not replicated in individuals of non-
European (mainly Chinese and Japanese) ancestry, though published information from all
non-European populations is limited and precludes firm conclusions in these groups.
These findings from a meta-analysis of association studies that followed the initial discovery
GWAS are of specific relevance to AMD, but the approach to collation of information are likely
to be informative for other complex disorders where GWAS have provided new leads on
causative genes that are subsequently assessed by an additional studies in independent data
sets.
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2.3.1.2 Implication of main effect estimate for predictive genetic testing
Irrespective of whether it is directly causal or not, the strong association of rs1061170 and
AMD risk, and the high frequency of the variant in the population has led to an interest in its
use as a potential screening or predictive tool. This variant has been included, for example, in
a genetic risk profile offered by DeCode genetics (www.decodeme.com) and 23 and me
(www.23andme.com), two commercial providers of genetic screening tests for complex
diseases. However, initial effect estimates in genetic association studies, whether candidate
based or GWAS, can be prone to the winner’s curse [139] – inflation of the reported effect
estimate over its true value. This can be a particular problem where the initial discovery study
is small (and low in power) and declaration of association is based on its crossing a pre-
specified p-value threshold. The initial GWAS in AMD was based on a collection of only 96
cases and 50 controls [10] which would be considered small for a GWAS of common disease
by current standards, where a minimum of 2000 cases and 2000 controls are considered
necessary. Thus while the reported association of rs1061170 can be considered robust, the
initial effect estimate of a per-allele odds ratio of 7.4 (95% CI 2.9.19: for homozygotes) is likely
to exceed the true effect. In our analysis of 6,231 late AMD cases including the initial
discovery study, there is some attenuation of the effect size as data on this association has
expanded (Figure 2.8), and the summary estimate identified by the meta-analysis presented
here is likely to be closer to the true effect.
A smaller effect estimate in prospective compared to case-control studies was also noted.
Case-control studies which are the preferred design for gene discovery and tend to be based
on highly-selected samples chosen to maximise the differences between cases and controls
by choosing patients with younger onset or more advanced disease, and excluding controls
whose fundoscopic examinations are not entirely normal.
Genetic association studies that follow a GWAS tend to focus on a subset of SNPs and often
only the lead SNP(s) with the most extreme p-value that may not itself be causal. The
literature may also become prone to publication bias as positive replications may be more
likely to be published than negative ones. However, this particular association does not seem
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to be substantially influenced by publication bias as shown by the symmetry of the funnel plot
(Figure 2.9) though a test for small study bias (Egger test p<0.001), was significant.
Figure 2.8 Cumulative Meta-analysis of the rs1061170-AMD association in studies of
European individuals. Effect estimates are per-allele odds rations for the association with
any form of AMD
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Figure 2.9 Begg’s funnel plot with pseudo 95% confidence limits, illustrating the
relationship between an index of study size (the SE of the log odds ratio) and the effect
estimate for studies in Figure 2.8
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2.3.1.3 Heterogeneity of effect estimates
One important attribute of a meta-analysis of genetic association is that it allows exploration of
the existence and reasons for variation of effect size across data sets. In the analysis of the
main effect of CFH genotype on late AMD risk there was no evidence for heterogeneity and
explored reasons for this. Potential modifiers of the effect size were further tested with
particular focus on investigating the effect of modification by smoking, which has aroused
considerable interest. Study design, genotyping and grading scale all contributed to the
observed heterogeneity but the influence was not large suggesting that these sources of
variation do little to alter the summary effect estimate.
The absence of a smoking interaction in this meta-analysis is at odds with the findings and
interpretation from some individual studies. The analysis of effect modification by smoking was
conducted in a subset of the database in which participant level or new tabular information on
effect size by smoking habit was available through direct contact with the study authors.
Despite being limited to part of the dataset, the smoking analysis still incorporated data on
2,392 cases AMD cases of which 1,498 individuals were classified as current or prior smokers.
Quantitative data on smoking exposure (in terms of pack years) was also available from 3,279
individuals. In none of these analyses was there any positive evidence for a gene smoking
interaction. Further case only analyses indicated an absence of gene-environment interaction,
highlighting a consistent lack of evidence of interaction with smoking given the number of
methods used to explore its presence. Even with the large size of the dataset, this may still be
underpowered to detect a modest interaction, but the analysis presented here suggests that
the detection of smoking interaction in individual studies in this field is just as likely to be due
to chance as a real finding.
The patho-physiological relationship between the different subtypes of AMD is poorly
understood and the mechanisms may be different. For this reason a separate analysis of the
association of rs1061170 with the different subtypes of AMD was performed, an analysis that
no individual study to date has been sufficiently powered to do. There was some evidence for
a larger effect of this variant on risk of GA compared to other forms of the disease. However
this finding should be interpreted with caution because it is based on a subgroup analysis
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(though attempts were made to reduce the potential for type 1 error by pre-specifying the
analysis and using 99% rather than 95% confidence intervals). Furthermore, the apparently
more modest effect of rs1061170 on early AMD may simply reflect the fact that prospective
observational studies with a surveillance approach to assessment of AMD contributed the
majority of cases of this end-point. Although the difference is probably insufficiently large for
this information to be useful for disease prediction, it may shed light on mechanistic
differences in the disease subtypes that could be enhanced by meta-analyses of the effect of
other variants in CFH and variants in other risk genes on disease subtype.
2.3.1.4 Rationale for the specific interest in rs1061170
Although, multiple SNPs in and around the CFH gene demonstrated association with AMD in
the initial discovery studies, including a copy number variant and SNPs in downstream genes
[114] apparently independently of rs1061170, it is this SNP that has been most widely studied
based on the significance level of the initial association and the fact that it encodes a
rs1061170 substitution in the encoded protein, which may alter function. However, evidence
on the functionality of the variant is by no means conclusive [177, 178], and this SNP may
simply mark another causal site in the gene or region. The absence of an association of
rs1061170 with AMD risk in patients of non-European ancestry in this meta-analysis provides
some evidence for that, although this interpretation must be treated with caution because of
the much more modest size of the data set in non-European subjects. However, the lack of, or
attenuated association in non-European individuals could occur if rs1061170 is not the causal
SNP but a marker in non-European populations. Because there are some differences in the
LD structure of CFH, rs1061170 may mark the causal variants less well. Nevertheless, this
finding suggests that other variants in this region are worthy of further investigation as
identification of these would have important implications for use of genetic information in risk
prediction of AMD, and importantly the development of therapeutic interventions that target
factor H related pathways. Given that the initial GWAS in AMD was modest in size by current
standards (96 cases and 50 controls) and a SNP array only of ~100,000 variants (compared to
those currently in use by GWAS, i.e. up to 1 million markers), larger GWAS analyses in AMD,
involving more dense next generation whole genome SNP arrays together with imputation of
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un-typed SNPs using standard methods are likely to be fruitful in refining the association
signal in this region.
2.4 Conclusions
The rs1061170 variant of the CFH gene is associated with the risk of AMD, with slightly larger
effect on GA than other forms of the disease. As the evidence base on this association has
matured, the association remains robust and in keeping with findings from the initial discovery
study. There was no evidence for a true interaction of this variant with smoking though both
exposures independently increase risk of AMD. The attenuated association of this variant with
AMD in non-European subjects provides some evidence that rs1061170 could be a marker
rather than a causal variant in these populations, or that sample sizes need to be much
greater in order to detect an adequate signal. Since the signals of association in the region
span more than one gene, further genetic analyses, as well as studies that measure the
complement factor H protein itself are required to assess whether complement factor H itself
or the product of another complement related gene in the near vicinity mediates the
association with AMD risk. This information will be essential to convert the exciting genetic
findings into new therapies for AMD. Further prospective studies in general populations with
records of incident AMD will be required to precisely define the absolute risk of AMD
associated with the carriage of this and other SNPs which have been linked to AMD before a
genotype based predictive test could be adopted in clinical practice.
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3 Genetic variation in complement factor H and risk of coronary heart
disease: systematic review and meta-analysis of published,
unpublished and newly genotyped studies
There is evidence for an epidemiological association between both AMD and CHD [179-181]
and that the complement pathway may contribute to both (as discussed in chapter 1).
Following evidence of the robust association of CFH genetic variants with AMD risk, and the
previous association of circulating complement components with CHD risk, investigations have
evaluated the role of the rs1061170 variant in the CFH gene with the risk of CHD. Due the
nature of randomised allocation of genotypes at conception (which balances the distribution
of potential confounding factors among genotypic classes) and the fact that genotype is
invariant and unaffected by the presence of disease, genetic studies are less affected by
biases that may affect non-genetic observational associations [45]. If the association of CFH
SNPs with CHD were verified, it would provide strong evidence for a partially overlapping
pathological basis and common routes to the prevention of the AMD and CHD.
Individual genetic association studies of the rs1061170 variant in CHD have thus far been
small, and the findings inconsistent. Moreover, few studies have evaluated the effect of CFH
SNPs on blood lipids or inflammation markers that have been linked to CHD, and which might
provide a plausible mechanism for the reported association between CFH SNPs and CHD.
There has been some interest in the association of SNPs in CFH and C-reactive protein
(CRP), as fH is thought to harbour a binding site for CRP and CRP itself been implicated in
CHD. More recent evidence has also suggested that combing both CFH and CRP genetic
profiles could be useful in the prediction of incident MI [182].
In order to address some of the uncertainties, in this chapter I conducted a systematic review
of published genetic association studies and supplemented these data with information from
several studies in which genotyping of the rs1061170 variant had already been completed as
well as a further four studies in which genotyping was conducted de novo for the purposes of
addressing the research question. In addition, where possible, I also evaluated the association
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of the rs1061170 variant with established CHD risk factors as well as biomarkers of
inflammation.
3.1 Methods
3.1.1 Published Studies- Systematic review
I searched two electronic databases (MEDLINE using PubMed and EMBASE up to January
2009). Using free text and MeSH terms “complement factor H”, “rs1061170”, “Y402H”,
“myocardial infarction”, “cardiovascular disease”, “coronary heart disease” with the search
being limited to “human” studies. Further studies were identified through reference lists of the
identified publications and by using the ‘related articles’ link in PubMed. Electronic searches of
published data were supplemented by personal contact with a number of studies known to
have repositories of genetic data and information on cardiovascular outcomes.
3.1.1.1 Inclusion Criteria
To be included, studies had to be cohort or case control studies evaluating unrelated
individuals, and had typed the rs1061170 variant or one in strong linkage disequilibrium (LD;
r2>0.7) with it. Outcomes recorded were fatal and non-fatal myocardial infarction, angiographic
evidence of atherosclerosis, and coronary artery bypass grafting. Both incident and prevalent
CHD outcomes were recorded and analyses were limited to studies investigating individuals of
European ancestry.
3.1.1.2 Data extraction
I extracted data and it was checked for consistency by others. Any disagreements were
resolved by consensus. Following HuGENET Guidelines (http://www.hugenet.ca), I extracted
information on whether genotyping was carried out masked to outcome, deviation from HWE
and the method used for genotyping. Where directly available, information on coronary events
in each genotype group was used. Where this was unavailable the number of cases by
genotype category was estimated using published information on allele frequencies and odds
ratios for coronary events.
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3.1.2 Studies in which genotyping was performed de novo
Genotyping of the rs1061170 variant was performed in six new studies.
The Second Northwick Park Heart Study (NPHSII) is a prospective study of 3,012 healthy
Caucasian men aged 50 to 64, recruited from 9 general practices across the UK in 1986 [183].
At the time of recruitment individuals were healthy with no history of CHD. Baseline
characteristics were ascertained using a questionnaire completed at the beginning of the
study. Individuals were followed up annually at which time events were ascertained and blood
samples taken. End points recorded included fatal and non-fatal CHD, coronary artery by-pass
surgery (CABG) and silent MI (ascertained using ECG). In total 227 CHD events were
recorded, with a median length of follow-up of 10.6 years (9 days to 13.7 years).
University College Diabetes and Cardiovascular Study (UDACS) comprises 1020
consecutive subjects recruited from the diabetes clinic at University College London Hospitals
NHS Trust (UCLH) between the years 2001–2 [184]. All patients had diabetes according to
WHO criteria. No subjects requiring renal dialysis were recruited. Subjects were categorised
by the presence/absence of clinically manifest CVD. CVD was recorded if a patient had one or
more of CHD, peripheral vascular disease (PVD) or cerebrovascular disease (CVD). The
presence of CHD was recorded if any patient had positive coronary angiography or
angioplasty, coronary artery bypass, a positive cardiac thallium scan or exercise tolerance
test, documented evidence of myocardial infarction or symptomatic/treated angina.
Ealing Diabetes Study of Coagulation (EDS) is a cross sectional study of 927 patients
recruited consecutively from the diabetic clinic at Ealing Hospital over a two year period of
time [185]. 927 patients remained in the study. Three ethnic groups were collected, although
for the purpose of the analyses presented here, investigation was limited to those of European
ancestry. Patients were investigated for CHD if they had symptoms (chest pain). If neither the
patient nor the clinic records suggested clinical symptoms of CHD, these patients were
recorded as negative for CHD. If either the patient or clinic records suggested they had had an
event or had angina the full medical records were searched to identify the criteria used to
determine the event. Patients with chest pain but with normal ECG, Holter exercise test,
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thallium scan or angiogram, were classified negative for CHD. Patients positive for CHD
included patients with severe atherosclerosis, shown by angiogram, and/or requiring surgical
intervention (per-cutaneous intervention or CABG), those who had been admitted with an
acute MI determined by ECG/increase in cardiac enzymes, patients who had a silent MI but
showed unequivocal ECG changes suggesting previous MI, and those with a positive exercise
test or thallium scan for ischaemia.
The Hypercoagulability and Impaired Fibrinolytic function MECHanisms predisposing to
MI (HIFMECH) study is a European multicentre case-control study of Caucasian men under
the age of 60 who have suffered a MI [186].The dataset excluded individuals with familial
hypercholesterolaemia and insulin-dependent diabetes mellitus. Age-matched controls from
the same regions as cases were recruited. Recruitment centres included Stockholm, London,
Marseilles and San Giovanni Rotondo. Blood samples from both affected individuals and
controls were taken following an overnight fast. In total 491 individuals with MI and 517
controls were available for genotyping.
Whitehall II (WII) study recruited 10,308 individual (70% men) between 1985 and 1989 from
20 London based Civil service departments. Genetic samples were collected in 2004 from
over 6,000 participants and are included in the analyses presented here [187]. The study is
highly phenotyped for cardiovascular outcomes with 9 phases of follow up. In total 5,039
individuals were available for genotyping and are included here, of which 88 are cases of
CHD. Data were used as a nested case control study rather than prospective.
English Longitudinal Study of Ageing (ELSA) is a national cohort of participants (48% men)
aged over 50 years recruited from the Health Surveys for England in 1998, 1999 and 2001.
Genetic data were collected at wave 2 of the study (2004/5) [188]. A wide range of phenotypic
measures relevant to ageing are available. These measures were made at Wave 0 of the
study (1998, 1999 and 2001) and at follow up (2004/5).
3.1.3 Previously unreported studies
The British Women’s Health and Heart Study (BWHHS) [189], were known to have a genetic
repository and prevalent and incident measures of CHD. Principal investigators of the study
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were contacted to ascertain if rs1061170 or SNPs in the CFH gene had been typed, and
second the Wellcome Case Control Consortium 1 (WTCCC 1) in which a genome wide
association scan for CHD had previously been completed [103]. Information on a SNP in LD
with the rs1061170 variant was extracted as part of a previous data application by Professor
Hingorani’s group.
BWHHS is a prospective population based study which recruited 4286 women between the
ages of 60-79. Women were randomly selected from 23 general practices across the United
Kingdom. Follow up for disease outcomes is by annual medical review (with validation checks)
and obtaining copies of death certificates. More detailed follow-up is collected on coronary
heart disease, stroke and type 2 diabetes and cancer events.
The WTCCC1 CAD collection includes 1988 individuals with either a history of MI or coronary
revascularisation before the age of 66 years, as well as a strong family history of CAD with
controls from two independent control groups the National Blood Service and the 1958 Birth
Cohort- recruited as part of the WTCCC project. These studies provided information on
genotype for the rs1061170 variant, or one in LD with it based on prior genotyping.
3.2 Statistical analysis
3.2.1 Newly genotyped studies
Continuous variables were logarithmically transformed where appropriate and differences
tested by unpaired t-test or ANOVA. Differences in the distribution of categorical variables
were assessed by the 2 test. Allele frequencies between groups were compared using

2tests, and tested for departure from HWE in controls. Hazard ratios (HR) were calculated in
the prospective study (NPHSII), using Cox regression models with corresponding 95%
intervals. Odds ratios (OR) were calculated from case-control and cross sectional studies
using logistic regression models. Genetic associations were tested using a pair wise
comparison, individuals homozygote for the T allele being the reference group. Dominant and
recessive models were also tested. All gene-disease associations were adjusted for age as a
continuous outcome and, in NPHS II, further adjustment was made for recruitment site. To
evaluate the association between genotype and continuous risk markers the mean difference
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in each variable between genotype groups for each quantitative trait within each study was
calculated, and then the overall weighted mean difference using random effect models was
derived.
Thus, three sources of information contributed to the meta-analysis: (i) newly genotyped
studies: NPHSII, HIFMECH, UDACS and EDS. (ii) studies with unpublished data of CFH SNP
and CHD status identified by direct contact with study authors and (iii) published studies
identified by literature search;
3.2.2 Meta-analysis
For studies that typed the CFH SNP rs1061170 directly, pair-wise comparisons using the TT
homozygote group as the reference group were made. Where information on rs1061170 was
unavailable, information on any SNP in linkage disequilibrium (r2>0.7) with rs1061170 was
incorporated. A random effects model meta-analysis was used weighting effect size in
individual studies by the inverse of the variance. Heterogeneity was tested using the Der
Simonian and Laird Q test and quantified using the I2. Evidence for publication bias was
assessed by visual inspection of Begg’s funnel plots.
3.3 Genotyping
Genotyping for NPHSII, UDACS, EDS and HIFMECH was carried out using ABI Taqman
assay by design (primers, probes and PCR conditions described below). Variants in ELSA
were genotyped commercially using SNPLex, and CFH SNPs were included as part of a
custom SNP array designed by the Institute of Translational Medicine and Therapeutics, the
Broad institute and the National Lung and Blood Institute supported Candidate gene
Association Resource Consortium (Human CVD BeadChip; Illumina) [190], and typed at the
Bart’s Genome Centre by Jutta Palmen. Methods for the newly genotyped studies are
described below, and from all studies included in the meta-analysis are summarised in Table
3.1.
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Taqman
Primers and probes designed by Applied Biosystems (ABI TaqMan assays by design,
Warrington, UK. Forward Primers GGTCCTTAGGAAAATGTTATTTTCCTTATTTGG; reverse
primer: GGCAGGCAACGTCTATAGATTTACC; probes- forward labelled with VIC:
TTTCTTCCATGATTTTG, reverse labelled with FAM: TTCTTCCATAATTTTG) were used in
384-well Thermo-fast PCR plates (Fisher Scientific). 2.5 ng DNA was used per reaction.
Samples were left to dry prior to adding PCR reaction mastermix (containing AmpiTaq Gold
DNA polymerase, AMPErase uracil-N-glycosylate (UNG), dNTPs with dUTP and
dichlororhodamine acceptor dye, passive reference to which samples are normalised), the
SNP assay containing primers and VIC and FAM probes. Cycling conditions were 50C for 2
min, 95C for 10 min, followed by 40 cycles of 95C for 15 sec, and 60C for 1 min. Genotypes
were read on a 7900HT sequence detector with laser fluorescence detection (Applied
Biosystems) using Sequence Detection Systems (SDSv2.1) software. Genotypes were
automatically called and grouped into three distinct clusters according to genotype (allele 1
homozygote, allele 1/2 heterozygote, or allele 2 homozygote). Negative controls were present
in each plate to test for DNA contamination. The rs1061170 SNP is common with a minor
allele frequency (MAF) of 0.38, therefore positive controls were not required. Call rates and
Hardy Weinberg frequency were determined following genotyping.
3.4 Results
3.4.1 New Genotyped Studies NPHSII, HIFMECH and UDACS
The distribution of clinical and demographic variables by rs1061170 genotypes in all newly
genotyped studies is shown in Table 3.1. There was no deviation of genotype frequency from
Hardy-Weinberg proportions in controls for all studies. There were no differences in genotype
frequency for rs1061170 by case-control status in any of the studies regardless of study
design and the inclusion of incident or prevalent CHD cases (Table 3.2). When finding from all
studies were pooled using random effects meta-analysis. there was no association between
the rs1061170 SNP and the established risk factors for CHD including cholesterol (total LDL
and HDL cholesterol), smoking, age, or systolic blood pressure either within study or after
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pooled analysis (Table 3.1 for individual study results and Table 3.3 for pooled results). There
was a borderline difference in triglycerides between CC homozygotes and the reference TT
group (p=0.06) although no difference between the heterozygote (TC) and reference (TT)
group. There was also no evidence of association between rs1061170 and other circulating
inflammation markers, including CRP. (Table 3.1, and Figure 3.1).
Table 3.1 Association of established cardiovascular risk factors with rs1061170 in 4 newly genotyped studies *indicates where variables have been log
transformed
rs1061170
TT TC CC
NPHS Total Mean/% SD Total
Mean/
% SD Total
Mean/
% SD
P Value
(Anova/
chi2)
Age 1030 56.22 3.39 1268 55.99 3.46 401 56.21 3.45 0.23
Systolic Blood
Pressure* 1030 136.91 18.43 1267 137.27 18.73 400 138.02 19.53 0.60
Diastolic Blood
Pressure 1030 84.92 11.17 1267 84.69 11.25 400 83.82 11.42 0.24
Total Cholesterol 1022 5.73 1.02 1259 5.72 1.02 397 5.84 0.98 0.11
LDL-Cholesterol 668 3.98 0.97 798 4.00 0.96 229 4.06 0.93 0.57
HDL-Cholesterol 698 0.84 0.26 850 0.83 0.26 245 0.85 0.26 0.45
Triglycerides* 1023 1.77 0.90 1260 1.80 0.97 397 1.88 1.00 0.20
BMI* 1029 26.20 3.30 1268 26.28 3.48 399 26.23 3.19 0.85
Smoking Status
(% Current) 279 27.10 364 28.70 120 29.90 0.50
C-Reactive
Protein* 938 3.07 3.20 1159 3.09 3.21 355 2.97 3.09 0.83
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Table 3.1 continued
rs1061170
TT TC CC
Ealing
Diabetes
Total Mean/% SD Total
Mean/
% SD Total
Mean/
% SD
P Value
(Anova/
chi2)
Age 123 64.11 12.78 158 63.46 14.00 41 61.51 15.69 0.58
Systolic Blood
Pressure* 121 134.97 19.28 155 138.48 23.05 41 4.89 132.49 0.17
Diastolic Blood
Pressure 121 71.65 11.57 155 73.86 11.71 40 71.90 8.27 0.24
Total
Cholesterol 117 4.92 1.13 151 5.02 1.12 40 4.61 1.09 0.13
LDL-Cholesterol 104 2.82 0.83 128 2.90 0.93 34 2.65 0.95 0.34
HDL-
Cholesterol* 111 1.20 0.36 139 1.13 0.35 36 1.17 0.33 0.33
Triglycerides* 111 1.68 1.04 139 1.98 1.15 36 2.03 1.20 0.06
BMI* 113 28.60 5.36 145 29.84 5.79 40 29.12 5.23 0.20
Smoking Status
(% Current) 23 18.70% 32 0.20 5 0.12 0.80
C-Reactive
Protein* 28 2.29 3.13 42 2.63 2.60 12 1.68 1.11 0.46
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Table 3.1 continued
rs1061170
TT TC CC
UCL Diabetics Total Mean/% SD Total
Mean/
% SD Total
Mean/
% SD
P Value
(Anova/
chi2)
Age 47 57.96 10.03 45 60.49 12.00 12 60.17 9.20 0.52
Systolic Blood
Pressure* 47 138.68 17.12 45 138.75 16.94 12 139.03 18.46 1.00
Diastolic Blood
Pressure 47 81.96 11.53 45 78.73 7.84 12 82.25 9.63 0.25
Total
Cholesterol 47 4.95 1.05 45 4.84 0.98 12 4.73 0.89 0.75
LDL-Cholesterol 45 2.82 1.14 40 2.66 0.94 12 2.52 0.88 0.59
HDL-
Cholesterol* 47 1.14 0.29 45 1.13 0.34 12 1.14 0.14 0.99
Triglycerides* 47 1.97 0.96 45 2.16 1.40 12 2.13 0.95 0.72
BMI* 46 27.50 3.65 45 25.72 4.28 11 26.98 3.56 0.10
Smoking Status
(% Current) 11 0.24 8 0.19 3 0.25
C-Reactive
Protein* 46 1.71 1.23 45 1.75 1.49 12 1.63 1.48 0.96
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Table 3.1 continued
rs1061170
TT TC CC
HIFMECH Total Mean/% SD Total
Mean/
% SD Total
Mean/
% SD
P Value
(Anova/
chi2)
Age 396 51.40 5.60 541 51.70 5.28 139 51.70 5.71 0.75
Systolic Blood
Pressure* 395 128.34 15.03 534 127.62 15.62 136 127.06 17.16 0.65
Diastolic Blood
Pressure 394 83.58 9.50 534 82.50 9.36 136 82.93 9.80 0.23
Total Cholesterol 389 5.46 1.10 511 5.48 1.09 129 5.43 0.97 0.88
Triglycerides* 389 1.65 0.73 511 1.62 0.70 129 1.65 0.74 0.71
BMI* 396 26.54 3.32 539 26.53 3.19 138 26.54 3.53 1.00
Smoking Status
(% Current) 285 0.72 386 0.71 102 0.73 0.89
C-Reactive
Protein* 388 1.80 1.98 511 1.59 1.92 134 1.36 1.73 0.04
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Table 3.2 Association of the CFH variant rs1061170 with CHD in four newly genotyped
studies *Hazard ratios are given for NPHS II rather than odds ratios, calculated using Cox
proportional hazards, the remainder of the studies were analysed using logistic regression.
Case Control Status according to genotype group OR (95% CI) for association withCHD
TT TC CC
Study Case Control Case Control Case Control TC vs TT CC vs TT
NPHS* 110 920 120 1,148 38 363 0.87 (0.67, 1.12) 0.90 (0.63, 1.13)
HIFMECH 183 215 271 271 64 75 1.18 (0.91, 1.52) 1.0 (0.68, 1.47)
Ealing
Diabetes 22 95 24 126 5 35 0.93 (0.65, 1.31) 1.0 (0.57, 1.76)
UCL
Diabetics 54 180 76 195 16 57 1.27 (0.88, 1.81) 0.89 (0.50, 1.58)
Table 3.3 Weighted mean difference in the level of CHD risk factors between genotype
groups of rs1061170, data pooled from 4 studies. Pairwise comparisons are shown of
individuals homozygous or heterozygous for the risk ‘C’ allele compared to those homozygous
for the common ‘T’ allele, which is used as the reference group.
Trait No. ofIndividuals
No. of
Studies CC vs TT CT vs TT
Weighted mean
difference (95% CI)
Weighted mean
difference (95% CI)
Age (Years) 2189 4 0.02 (-0.35, 0.39) -0.11 (-0.46, 0.25)
DBP (mmHg) 2180 4 -0.81 (-1.82, 0.20) -0.41 (-1.70, 0.88)
TC (mmol/L) 2153 4 -0.02 (-0.19 ,0.15) 0.00( -0.07, 0.07)
HDL-C (mmol/L) 1149 3 -0.05 (-0.11, 0.02) -0.04 (-0.09, 0.01)
LDL-C (mmol/L) 1092 3 -0.02 (-0.23, 0.19) 0.02 (-0.07, 0.11)
TRG (mmol/L) 2144 4 0.08 (-0.01, 0.17) 0.04 (-0.06, 0.14)
CRP (mg/L) 1913 4 -0.28 (-0.52, -0.04) -0.08 (-0.26, 0.10)
BMI 2172 4 0.03 (-0.29, 0.35) 0.02 (-0.49, 0.54)
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Figure 3.1 CRP concentrations stratified by the CFH rs1061170 variant in CHD cases
and controls
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3.4.2 Meta-analysis
Eleven eligible studies were identified among individuals of European descent [116, 117, 191-
198]. Nine of these (4,510 cases, 18,381 controls) included unrelated individuals [116, 117,
192-196, 198], and had information on genotype frequencies according to case or control
status that could be abstracted from the published report (Figure 3.2). All studied the
association of SNP rs1061170. Two further studies were excluded on the basis that they
examined association within families [191, 197]. The Whitehall II prospective study, ELSA,
BWHHS, together with the WTCCC 1 genome wide association scan of coronary disease with
controls from the National Blood Service and the 1958 Birth Cohort [103] contributed a further
2,417 cases and 16,526 controls. SNPs in LD (r2>0.7) were used as a proxies for rs1061170
in ELSA, Whitehall II and WTCCC1 (Figure 3.3). Thus, in total, 7,909 cases and 38,576
controls contributed to the meta-analysis. Details of all studies, the genotyping platform used,
and outcomes measured are given in (Table 3.1)
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Figure 3.2 Flow diagram indicating identification of studies included in the meta-
analysis of rs1061170 and CHD
11 potentially relevant
citations identif ied and
screened in publically
available databases
2 Citations excluded on the
basis of title, abstract or both
9 Full text articles
retrieved for detailed
evaluation
4 newly genotyped studies
3 additional unpublished studies
added by direct approach
(BWHHS, WII, ELSA)
WTCCC access obtained and
added
17 studies included in meta-
analysis in total
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Table 3.4 Studies contributing to the meta-analysis of the association of the CFH
variant rs1061170 and CHD. The first part of the table indicates the newly genotyped studies,
and previously unreported studies and the second is a summary of the studies identified using
the search strategy.
Study Study Design SampleSize Outcome reported SNP Typed Genotyping Method
Newly genotyped and previously unreported studies
NPHS II ProspectiveCohort study 3012
Fatal and non Fatal
CHD events rs1061170
Taqman (Applied
Biosystems)
HIFMECH Case Control 1074 MI rs1061170 Taqman (AppliedBiosystems)
UDACS Cross Sectional 571
MI/ Positive exercise
tolerance test / CABG
or PTCA for CHD
rs1061170 Taqman (AppliedBiosystems)
Ealing Diabetes Cross Sectional 307
MI/ Positive exercise
tolerance test / CABG
or PTCA for CHD
rs1061170 Taqman (AppliedBiosystems)
BWHHS Nested CaseControl (Cohort) 3437
Fatal and non fatal
CHD events rs1061170
Taqman (Applied
Biosystems)
ELSA Nested CaseControl (Cohort) 5475 MI rs2300430 SNPLex
Whitehall II Nested CaseControl (Cohort) 3445 MI rs7529589
Illumina IBD 50K
Cardiochip
WTCCC1 Case Control 4992 MI rs10801555 Affymetrix 500K
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Table 3.1 continued, Studies included in meta-analysis
Studies from Literature based Search
Physicians Health
Study
Nested Case
Control (RCT) 670 MI rs1061170
Taqman (Applied
Biosystems)
Rotterdam
Nested Case
Control
(Cohort)
5529 MI rs1061170 Taqman (AppliedBiosystems)
Southampton Case Control 448 AngiographicallyConfirmed CHD rs1061170
Taqman (Applied
Biosystems)
Atherogene Case Control 1292 MI rs1061170 Taqman (AppliedBiosystems)
ECTIM Case Control 2073 MI rs1061170 Taqman (AppliedBiosystems)
Health
Professionals Study
Nested Case
Control
(Cohort)
2359 Any CHD rs1061170 Taqman (AppliedBiosystems)
Nurses Health Study
Nested Case
Control
(Cohort)
712 Non fatal MI orfatal CHD rs1061170
Taqman (Applied
Biosystems)
Mayo Clinic Case Control 384 AngiographicallyConfirmed CHD rs1061170 RFLP
ARIC
Nested Case
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Figure 3.3 Linkage Disequlibrium plot of SNPs used for meta-analysis of rs1061170 and
CHD. The analysis was based and plotted using HapMap data (NCBI Build 36). The LD values
in the squares are the pairwise r2 values between rs1061170 and other SNPs typed as a proxy
for this SNP is shown.
The odds ratio for CHD in individuals homozygous for the C allele at rs1061170 encoding the
402H variant compared to those homozygous for the common T allele was 1.02 (95% CI 0.91,
1.15) and for heterozygous individuals the odds ratio was 1.05 (95% CI 0.99, 1.11), with little
evidence of heterogeneity (I2 37.3% for homozygous comparison and 0% for heterozygote
comparison) (Figure 3.4 a and b). The summary point estimates were similar for previously
published studies, previously unpublished studies and the newly-genotyped studies with no
evidence for publication bias (Figure 3.5)
96
Figure 3.4 Meta-analysis of the association of the rs1061170 SNP encoding Y402H and
CHD: (a) and individuals homozygous for the C allele for the C allele; (b) and heterozygous for
the C allele, both with reference to TT homozygous subjects.
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Figure 3.4 (b)
Heterogeneity between groups: p =0.200
Overall (I-squared = 0.0%, p = 0.703)
Ealing Diabetics
Rotterdam
PHS
Subtotal (I-squared = 17.6%, p =0.303)
BWHHS
Atherogene
ARIC
Whitehall II
Southampton
HIFMECH
Subtotal (I-squared = 0.0%, p = 0.462)
Newly genotyped
ELSA
UDACS
Study Name
NPHS
Mayo Clinic
Subtotal (I-squared = 0.0%, p = 0.925)
ECTIM
Independently approached
HPS
WTCCC
NHS
Published
rs1061170
rs1061170
rs1061170
rs1061170
rs1061170
rs1061170
rs7529589
rs1061170
rs1061170
rs2300430
rs1061170
SNP
rs1061170
rs1061170
rs1061170
rs1061170
rs10801555
rs1061170
46
180
272
104
174
1003
103
142
453
119
130
TC + TT
cases
230
220
884
678
1704
219
307
5529
670
3437
1292
9424
5039
448
1074
5475
571
Total No. of
individuals
2699
384
2073
2359
4992
712
1.05 (0.99, 1.11)
0.82 (0.44, 1.55)
1.11 (0.82, 1.49)
0.91 (0.65, 1.27)
1.04 (0.86, 1.25)
1.27 (0.85, 1.90)
0.84 (0.61, 1.16)
1.05 (0.92, 1.20)
1.52 (0.91, 2.54)
1.18 (0.71, 1.94)
1.17 (0.90, 1.52)
1.14 (1.02, 1.27)
0.94 (0.65, 1.35)
1.25 (0.83, 1.87)
OR (95% CI)
0.87 (0.67, 1.15)
1.07 (0.67, 1.70)
1.01 (0.93, 1.09)
1.00 (0.83, 1.21)
0.95 (0.79, 1.14)
1.13 (1.00, 1.28)
1.03 (0.74, 1.43)
1.5 2 4
OR
Figure 3.5 Begg’s Funnel plot with pseudo 95% confidence intervals for the studies
included in Figure 3.4
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In a comparative cumulative meta-analysis of the published association studies of rs1061170
in CHD and AMD, the summary effect estimate exhibited only a minor attenuation over time
for AMD while the summary effect estimate in the field of CHD attenuated to the null. (Figure
3.6 a and b)
Figure 3.6 (a) Cumulative meta-analysis of the association between rs1061170 encoding
rs1061170 in CFH and CHD; and (b) cumulative meta-analysis of association between
rs1061170 and late AMD. Both plots show comparisons for CC homozygous individuals
compared to the TT reference group
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3.5 Discussion
Using 7,909 cases and 38,576 controls, the largest accumulated data set on this question to
have been studied to date, I identified a null association of the rs1061170 SNP in CFH with
CHD events. The meta-analysis had >99% power to detect a per-allele odds ratio 1.2, at a
0.05 level of significance.
With the exception of a possible association of the minor (C) allele of rs10611760 SNP with
higher circulating triglyceride concentration (which should be regarded as hypothesis
generating but not definitive) this variant was not associated with any of the other risk factors
or biomarkers evaluated. However, confirmation of the triglyceride association will be
important and is of potential interest because a physical interaction of fH with triglyceride-rich
proteins has been reported, which may have bearing on the mechanism of the fH regulation of
complement function in health and disease [35]. Of the inflammatory markers studied there
has previously been particular interest in the association of CFH genotype with CRP, given fH
is thought to bind CRP. However recent evidence suggests that binding of CRP to fH does not
occur under physiological conditions [177] and, that moreover, the association of CRP with
CHD events is non-causal [56-58, 199].
Previous studies, reported an interaction of BMI and the rs1061170 SNP in CFH on the risk of
AMD [152]. However there was no evidence for such an interaction in relation to CHD, nor
was there any evidence that the effect of the SNP on CHD risk was different in those with
hypertension which had also been suggested previously [198] (Table 3.4). The reliable
demonstration of interactions in genetic studies requires very much larger sample sizes than
those studied in prior reports or even this large meta-analysis. However, the null association
of with CHD events identified here indicates that investigation of any possible interaction is
unlikely to be a high priority for future research.
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Table 3.5 Association of rs1061170 in CFH with CHD limited to individuals with a blood
pressure recording of >140/90, irrespective of blood pressure lowering medication.
Study OR (95% CI) for association with CHD in individuals withHypertension only
TC vs TT CC vs TT
NPHS 0.76 (0.53, 1.10) 0.79 (0.38, 1.55)
Ealing
Diabetes 0.81 (0.49, 1.34) 0.41 (0.15, 1.13)
UCL
Diabetics 1.85 (1.07, 3.18) 1.71 (0.75, 3.93)
HIFMECH 0.93 (0.59, 1.47) 0.77 (0.38, 1.55)
The rs1061170 SNP was first highlighted in a genome wide analysis for its association with
AMD rather than CHD. AMD shares many risk factors with CHD, and inflammation has been
implicated in both. Although the association of this SNP with AMD has proved robust in
numerous subsequent studies, the initially positive association with CHD (which was smaller in
effect size than that for AMD) has progressively declined to the null as more data on this
association have accrued added. By contrast, the association with AMD has been reinforced
and the confidence limits around the effect estimate have narrowed. (Figure 3.6 a and b).
Inflammation has been implicated in a number of common diseases of ageing, of which CHD
is perhaps the most studied and complement activation is one (but not the only) way in which
the inflammatory response can be elicited. However, much of the evidence for the link
between inflammation and CHD is observational and may therefore be prone to confounding
since many inflammation markers are also associated with established risk factors for CHD.
SNPs in genes involved with inflammatory pathways have been associated recently in several
common late onset disorders including diabetes, Alzheimer’s and certain forms of cancer,
providing strong evidence of the importance of inflammation in the pathogenesis of these
disorders. However, none of the genetic variants associated with CHD to date relates directly
to inflammation although it is likely that only a very small proportion of SNPs contributing to
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CHD risk has been uncovered so far. More loci have recently been identified by meta-analysis
of genome wide and association studies of CHD [200], which implicate loci associated with
lipids and lipid handling, primary protein structure, tissue specific gene expression as well as
established risk factors for CHD. Some of the loci were notable in that they associate with
other diseases and disease traits, supporting the view of common pathologies existing
between diseases.
Although CFH does not appear to provide a point of overlap in the pathogenesis of AMD and
CHD, recent evidence suggests that overlaps do exist in other pathways. A recent genome
wide-association study in AMD found several new susceptibility loci known for their
association with circulating HDL-C and triglycerides [36], pointing to possible common
mechanisms and perhaps common preventative treatments for both AMD and CHD. More
broadly, it may prove informative to continue to study SNPs identified for an index association
with AMD for their effect on CHD risk and vice versa.
There are however some limitations to the findings that have been described here. Although
the rs1061170 variant in CFH is a non-synonymous coding SNP, it remains uncertain whether
the encoded variant is itself functional and therefore whether its association with AMD is
explained by LD with another causal allele. The null association of this variant with CHD
therefore does not complete exclude the possibility of association of other SNPs in this gene
with CHD, and more fine mapping approaches may be helpful in answering this question.
These findings however do not completely rule out a potential role for complement activation
in the development of CHD either, because variants encoding other components of the
complement cascade, which have been associated with AMD, were not studied here.
Moreover, this analysis does not exclude a potential causal role of inflammation mediated by
pathways other than complement activation in the pathogenesis of CHD.
3.6 Conclusion
In summary, despite a large sample size and high degree of power to identify modest effects,
these findings were unable to confirm the previously reported association of the AMD-
associated SNP rs1061170 with CHD risk. With the possible exception of triglycerides, this
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SNP was also not associated with any of a wide range of risk factors and biomarkers of CHD
studied. However, bearing in mind the possibility of partially overlapping pathogenesis, studies
of AMD-associated SNPs in CHD and CHD-associated SNPs in AMD may prove mutually
informative for the detection and prevention of both disorders.
103
4 Development and validation of a high-throughput assay for
circulating complement factor H.
If alterations in fH concentration contribute to AMD risk, its measurement could aid risk
stratification and lead to development of interventions that modify fH concentration or function
which may help prevent or treat AMD. At the time this work started, no studies
comprehensively examined the association of genetic variation in the CFH and CFHR region
with fH concentration, or fH concentration with AMD risk. Studies reporting measurement of fH
in patients with AMD and controls after the commencement of this work used different assays
and have studied relatively few individuals (for a summary see Table 4.7).
A key limitation of research in this area to date has been the lack of a high-throughput assay
for fH that can be used to measure fH in stored samples on a large scale. In order to
overcome this major limitation, I helped develop and validate a new high throughout assay for
circulating fH, using an existing commercially available anti-fH antibody used in the Human
Factor H ‘NL’ BINDARID™ radial immune diffusion assay (RID) marketed by The Binding Site
(referred to as BS from here on). The RID is a low-throughput method of assaying fH,
measuring 14 samples per plate, requiring up to 72 hours for completion of the reaction, which
is based on the formation of antigen-antibody precipitin rings. I helped adapt reagents sold as
part of this commercial assay (antibody and calibrator) for a high throughput nephelometric
assay on the Siemens BNII nephelometer. This is a standard assay methodology used for the
quantification of a variety of circulating antigens. In this assay, antigen-antibody complexes in
the sample solution scatter a beam of light with the degree of scatter being used to quantify
antigen concentration. The same method is widely used to measure CRP, Lp (a) and SAP, on
automated clinical chemistry analysers and thus the method could readily be adopted in
hospital clinical practice, given that the instrument used for these measurements is standard
piece of equipment in most hospital clinical biochemistry laboratories.
In this chapter I aim to describe, in detail, the adaptation of the commercially available
reagents for use on the BN II nephelometer. In brief, I re-quantified the fH protein supplied as
a ‘calibrator’ in the commercial BS assay with reference to a gold-standard purified fH
preparation from Professor Paul Morgan’s laboratory (Cardiff). Second, using the recalibrated
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BS fH, I measured fH concentration in a large volume of pooled post-cryoprecipitate material
(supplied as a gift from the National Blood Transfusion Service), which was used as a control
sample for all the subsequent assay work. To confirm the validity and appraise the
performance of the newly developed assay, I assessed agreement between the existing RID
assay and the new nephelometric assay, compared the observed and predicted concentration
of fH in test samples prepared by mixing varying proportions of a plasma sample of known fH
concentration and a plasma sample completely depleted of fH, and assessed the
reproducibility of measurement of fH by determining the intra- and inter-assay coefficient of
variation. In the second part of this series of experiments I evaluated the properties of fH as an
analyte. This was done by determining stability of fH to repeated freeze thaw cycles and to
extremes of temperature. Finally the new nephelometric assay was used to assess the
distribution of fH concentration in a small population of healthy individuals, to assess its
distribution and range of measurement as a pilot study prior to the determination of these
properties in a larger population based sample, the MRC-Fenland study (Chapter 5).
4.1 Materials and Methods
4.1.1 Adaptation of The Binding Site reagents for use on the Siemens BNII
nephelometer, and assessment of validity of the nephelometric method
Immunonephelometry is one of the most frequently used methods to determine protein
concentration in serum, urine and other body fluids. It is based on the property of antigen-
antibody complexes to scatter a light beam. The amount of light scattered by the antigen-
antibody complex is proportional to the amount of antigen in solution, with increased protein
concentrations resulting in more light scatter. Operationally the BNII places the test sample
into a cuvette robotically, into which is added the antibody specific to the analyte whose
measurement is sought. Light emitted from a light emitting diode (LED) at a wavelength of 840
nm is transmitted through the cuvette, and light scattered thereafter is focussed onto a
photodiode (i.e. a photodetector that is capable of converting light to either current or voltage)
through a number of lenses and mirrors (Figure 4.1), which allows the system to be placed
and function in a relatively small space. Once detected at the photodiode the signal is
converted into a concentration of protein by measurement against a calibration curve
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constructed against a standard protein of known concentration. Measurements are taken at
two time points, the first when antibody has been added to the test sample when no immune
complexes have formed, and second when all immune complexes have formed. The final
concentration of protein is calculated by subtracting the initial measure from the final measure.
Each assay therefore requires the following reagents:
1. A specific antibody.
2. A standard preparation of the antigen of interest, necessary for generation of a
calibration curve, against which subsequent measures can be read.
3. Control samples of known antigen concentration to check stability of measurement
over the long term use of the assay.
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Figure 4.1 Operation of the BNII nephelometer, the primary light beam is emitted from the
LED, which is deflected through a mirror and transmitted through the cuvette containing a
sample with unknown concentration of analyte and antibody. The light scattered through the
cuvette is directly proportional to the concentration of the protein under measurement. Light
scatter is detected by a photo detector able to convert this information into a concentration of
protein. Schematic taken from the BNII Operator’s Manual
Reagents from the commercial RID assay were identified that could be adapted for use with
this method. The polyclonal sheep anti-human fH antibody used sold as part of the
commercial assay was purchased in bulk (Human Factor H NL calibrator code RP030, Batch
247673), and stored in 10 ml aliquots at -80°C, and used as the primary antibody. The BS fH
calibrator, assigned with a nominal value by the company of 700 mg/ L, when re-suspended in
655 uL of distilled water was used as the fH standard for nephelometric assay, following re-
calculation of its true concentration with reference to a highly purified fH preparation of known
quantity. The concentration of this highly purified fH was determined by measurement of its
extinction coefficient, as described below. Finally pooled post-cryoprecipitate plasma (that is
plasma material that remains after production of cryoprecipitate, rich in clotting factors VIII,
XIII, von Willebrand factor and fibrinogen used for clinical treatment of clotting disorders has
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been removed) was used as a control. We received 2L of pooled post-cryoprecipitate material
as a gift from the National Blood Service, and this was stored in 5 ml aliquots at -80°C.
The operational parameters for the nephelometric assay of fH on the BNII analyser were
established by The Binding Site (Appendix 1), and then field tested by Ruth Gallimore
(Professor Mark Pepys’s laboratory, Centre for Amyloid and Acute Phase Proteins, UCL), to
determine an initial operating range on the BNII.
4.1.1.1 Preparation of a highly purified preparation of factor H from human plasma
Complement factor H was purified from plasma of individuals homozygous for either the H402
or Y402 variants by a sequential three-step FPLC method at 4°C on ÄKTAprime (GE
Healthcare) in Professor Paul Morgan’s laboratory, Cardiff, by Dr Svetlana Hakobyan. One
hundred mL of filtered (EDTA) plasma was applied to a 5 ml HiTrap column (GE Healthcare)
to which 10mg of mouse anti-human fH monoclonal antibody 35H9 (generated in the Morgan
laboratory) was coupled. Bound protein was eluted at low pH and fractions containing fH
(identified by ELISA) were pooled, dialysed against phosphate buffered saline (PBS: 137 mM
NaCl, 10 mM Phosphate, 2.7 mM KCl, pH 7.4) and applied to a HiTrap-Heparin column (GE
Healthcare) equilibrated with PBS. Bound proteins were eluted with 1M NaCl in PBS.
Fractions containing fH were pooled and polished by gel filtration on Superdex-200
preparative grade matrix in a XK16/70 column (GE Healthcare). Purity was confirmed by
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using plasma from
identified homozygous donors.
4.1.1.2 Preparation of fH depleted plasma
Plasma depleted of fH during the experiments described above, was also used in subsequent
validation experiments. In order to ensure that these samples were completely depleted of fH,
they were run twice over the column. Plasma samples, taken before and after each run were
analysed by dot blotting and Western blotting. For dot-blots, serial dilutions of plasma samples
deplete of fH were spotted on nitrocellulose using a Bio-Dot SF microfiltration apparatus (Bio-
Rad, UK). Blocked membranes were incubated with mouse monoclonal anti-fH antibody MRC
OX-24 for detection of fH [201]. This antibody is specific for the C3b binding domain in the N-
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terminal SCR 5 domain of fH. Bound monoclonal antibody was detected using horseradish
peroxidise (HRP) conjugated rabbit anti-mouse immunoglobulin (Dako, UK) and visualised by
ECL chemiluminescence (GE Healthcare). For Western blotting, purified fH, normal plasma
and depleted plasma were blotted onto a nitrocellulose membrane which was subsequently
blocked and probed with MRC OX-24 as for dot blots, with bound monoclonal antibody being
detected using HRP-conjugated rabbit anti-mouse immunoglobulin as above.
4.1.1.3 Determination of extinction coefficient of purified factor H
The extinction coefficient is a method of determining the concentration of a purified protein
based on the ability of the protein to absorb light at a given wave length, measured at a given
distance of path length. The extinction coefficient of fH was determined directly by the dried
weight analysis of the protein, carried out by Dr Patrizia Mangione in Professor Mark Pepys
laboratory. A 20 ml solution of the purified fH in PBS was extensively dialysed against MilliQ
water for 72 h at 4ºC. Before dialysis, absorbance at 280 nm, corrected for light scattering at
320 nm of 1/10 diluted samples of fH in PBS, was measured in a standard 1 cm light path cell
using a DU650 UV-vis scanning spectrophotometer (Beckman-Coulter UK Ltd.) A final value
of 0.108225 ± 0.0014 (mean ± SD, n= 4) was obtained.
After dialysis the solution was lyophilised, dissolved in MilliQ water (~1.4-1.5 ml) and placed in
a 20 ml straight wall nickel crucible (Sigma) previously cleaned with ethyl acetate and dried at
high temperature before its weight could be determined. The sample was lyophilized for 18 hr
and then cryogenically dried over activated charcoal at -196º C (5 x 10-6 bar) for 48 hr.
4.1.1.4 Quantification of the concentration of Factor H of The Binding Site Calibrator
The fH calibrator supplied by The Binding Site (Human Factor H NL calibrator code RP030
Batch 247673, expiry date: 2010/07) had been assigned a nominal value of 700 mg/mL but
this had not been previously calibrated against a purified fH preparation. Therefore
experiments were conducted to recalibrate The Binding Site calibrator fH with reference to the
purified fH protein obtained from the experiments described in the previous section.
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In order to determine the concentration of the BS calibrator, purified fH (prepared according to
procedure above) was diluted to concentrations of 500, 400, 200 and 100 mg/ L and loaded
onto the RID plate in keeping with manufacturer’s instructions (5 µl loaded per well). After
loading, the plate lid was closed tightly, and placed flat in a moist box incubated at room
temperature until precipitin rings developed to completeness. Samples were loaded in
duplicate, and measures taken from these were used to establish the standard curve for fH.
The BS calibrator was loaded on the same plate, having been reconstituted with 655 µl
distilled water as recommended by the manufacturer, with further samples diluted at 1:2
dilution and run alongside the newly purified fH. On reaching completion, the diameter of the
precipitin rings was measured by capturing an image of the RID plate using BIO-RAD GS-800
densitometer and measuring ring diameters using Adobe Photoshop software. A standard
curve for fH was constructed by plotting the square of the diameters of fH precipitin rings
against their specific protein concentrations, generating a line of best linear fit, using measures
from newly purified fH plated at 4 different concentrations. The concentration of the BS
calibrator could therefore be measured against this standard curve as determined by newly
purified fH, and assigned a new value for use on the BNII nephelometer. In addition, plasma
deplete of fH was loaded onto RID plates in order to ensure these samples generated no
precipitin rings.
The newly assigned value for the Binding Site Calibrator was used as the standard for all
subsequent analyses using the BNII nephelometer. Further calibrations on the BNII were
carried out every month, or earlier if blank values of the cuvettes were high.
4.1.2 Validation of assay on BNII Nephelometer
4.1.2.1 Agreement between radial immune-diffusion assay and immune-nephelometric
assay
Fifty plasma (EDTA) samples taken from healthy volunteers (kindly provided by Professor Tim
Goodship, University of Newcastle) were used to measure fH in both the commercially
available RID (The Binding Site) assay, and the newly developed nephelometric assay. For
the assay 5 ul of sample was applied to wells in duplicate and allowed to diffuse to completion.
Each plate was scanned using standard scanning software, images saved at original
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dimensions as PNG files and ring diameter was measured using Image J software. Factor H
concentration was determined by measuring ring diameter and calculating the concentration
relative to the ring diameter produced by the BS Calibrator (Batch 247673), using its newly
assigned concentration. Agreement between measurements was evaluated using methods
described by Bland and Altman for agreement between two tests [202].
4.1.2.2 Recovery of known concentrations of fH from plasma deplete of fH
To determine the ability of the newly developed assay to detect fH, a recovery experiment was
carried out. Venous blood was drawn into EDTA plasma from one healthy volunteer and the
mean concentration of fH measured using the BNII from 4 replicates. This value was
designated 100%. A fH depleted EDTA plasma sample (from the Morgan laboratory, as
described above) was designated 0%. The two samples were mixed in varying proportions to
generate samples with expected concentrations of 10, 20, 30, 40, 50, 60, 70, 80, or 90% of the
value of the healthy donor. Each dilution was assayed using nephelometry on the BNII in
quadruplicate. Expected concentrations were compared to observed concentrations in order to
determine the degree of recovery.
4.1.2.3 Reproducibility of the nephelometric assay of fH
Non-fasting venous whole blood was drawn from the ante-cubital vein from 5 healthy
volunteers, into EDTA, citrate, heparin and no anti-coagulant. The plasma samples were
separated immediately after centrifugation for 15 minutes at 3000g, and frozen at -80 C.
Serum samples were allowed to clot at room temperature for 30 minutes, the clots rimmed and
left for a further 90 minutes after which serum was separated and stored in aliquots -80 C. All
subjects gave informed consent and collection procedures and approval for the assay as a
service development was given by the Chair of the local ethics committee.
Five replicate measurements of fH were assayed by nephelometry using fresh plasma and
serum from five different individuals to determine average levels of fresh fH. Subsequently 5
measurements were taken over 5 days on the same 5 individuals to determine the inter- and
intra- assay coefficient of variation (CV). Intra-assay CV was calculated for each sample on
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each day (using freshly thawed material on the day of analysis), with inter-assay CV being
calculated on measurements made on separate days.
4.1.3 Evaluation of analyte properties
4.1.3.1 Stability to freeze thaw.
Samples from the same 5 individuals, described above, were subjected to 5 repeated freeze-
thaw cycles, by freezing at -80 C, and thawing at 37 C, with re-measurement of fH using
nephelometry at each thaw, to determine the stability of fH to repeated freeze-thaw.
4.1.3.2 Stability to temperature extremes
The stability of fH at extreme temperatures was tested by selecting samples from 2 of the
above 5 to storage at -80C; -20C; 4C; 24C; 37C; and 45C over a period of 4.
Measurements of fH were made using nephelometry at a weekly interval.
4.1.3.3 Measurement of fH in one hundred healthy individuals
Factor H was measured in plasma (EDTA) from 100 healthy individuals (samples courtesy of
Professor Tim Goodship, Newcastle University), to establish an initial operating range for the
assay and dilutions required to measure fH in a population based sample.
4.2 Results
4.2.1 Adaption of reagents from Binding Site RID Factor H for use on Siemens BNII
Nephelometer
4.2.1.1 Isolation of plasma deplete of Factor H
Preparations of fH-H402 and fH-Y402 were obtained without any detectable contaminants or
aggregates by this three-step method. The proteins were also free of fH-like-1 (FHL-1) and fH-
related proteins. Yield was 25-50% and was similar for the two variants [203].
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Dot blots confirmed plasma from donors was deplete of fH (Figure 4.2), and Western blotting
(Figure 4.3) using the same antibodies confirmed the presence of the appropriately sized
protein in normal plasma, with a higher signal from purified fH, and its complete absence from
fH depleted plasma.
Figure 4.2 Dot blot of fH depleted and normal plasma. Samples of fH-depleted or normal
plasma underwent serial dilution before blotting onto a nitrocellulose membrane, incubation
with MRC OX-24 and then detection with a secondary HRP-conjugated rabbit anti-mouse
antibody.
fH-Depletedplasma
Normal plasma
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Figure 4.3 Western Blot of normal, fh-deplete plasma and purified fH. Using the MRC OX-
24 anti-fH antibody, detection was with a HRP conjugated mouse anti-human monoclonal
antibody (see Methods).
148 kDa
4.2.1.2 Determination of extinction coefficient of purified Factor H
The extinction coefficient of factor H was determined directly by the dried weight analysis of
the protein. The weight of cryogenic dried protein was 0.01g (Table 4.1). This combined with
the volume and absorbance measured where a value of 0.108225 ± 0.0014 (mean ± SD, n= 4)
was obtained, allowed us to establish the concentration of the original solution of factor H in
PBS which was 550 mg/L. Given the linear relationship between absorbance and
concentration of the absorbent species (according to the Beer-Lambert law) we could derive
the value of factor H extinction coefficient at 1mg/ml which was 1.9677.
Table 4.1 Weight of purified fH protein at various stages of drying. Tare value indicates
the vessel with no material in situ.
Weight (g)
Tare 37.49
After 18 hr lyophilization 37.50
After cryogenic drying 37.50
Cryogenic dried protein 0.01
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4.2.1.3 Quantification of the concentration of Factor H of The Binding Site Calibrator
Using the BS RID assay, a standard curve was constructed using the concentration of the
newly purified fH, previously determined as 550 mg/L. This is shown in Figure 4.4. The
concentration of the BS calibrator was then determined using this standard curve, and found
to be 389 mg/ L, and much lower than the nominal value of 700 mg/L reported by the
company. The same batch of BS calibrator was used for all subsequent assays described in
this thesis.
Figure 4.4 Standard curve and re-calibration of the Binding Site fH control with
reference to purified fH using the commercial RID assay.
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Figure 4.5 RID re-calibration plate. An image of the RID plate that was used to re-calibrate
the BS calibrator using pure fH and plasma deplete fH. Neat BS calibrator is shown in wells 7
and 8, plasma depleted fH spiked with BS calibrator is shown in wells 6 and 9, and pure fH
loaded at concentrations of 500 mg/L (wells 1 and 14), 400 mg/ L (wells 2 and 13), 300 mg/L
(wells 3 and 12), 200 mg/L (wells 4 and 11) and 100 mg/ L (wells 5 and 10) are shown.
4.2.1.4 Quantification of factor H concentration in post cryo-precipitate material
Factor H concentration was measured in 10 replicates of pooled post cryo-precipitate material
using the BS calibrator at the newly assigned concentration. A mean value of 288 mg/L was
obtained, which was used as the control value on the BNII nephelometer.
4.2.1.5 Agreement between radial immune-diffusion assay and immune-nephelometric
assay
Complement factor H was measured in plasma from 50 healthy individuals using both the
commercial RID kit and the newly established BNII assay (Table 4.2), to test for agreement
between the two methods using methods described by Bland and Altman [202]. Initial
analyses, plotting the average (of BNII and RID measures) against the difference (BNII minus
RID measures) demonstrated a larger difference in values between the two assays in samples
either at both the higher and lower end of the range of fH concentrations, giving non uniform
limits of agreement. It would be expected that the nephelometric assay would be more precise
than the RID assay.
Given this is not an unusual situation in the evaluation for the measurement of biological
analytes, Bland and Altman have, in addition to the classical Bland-Altman test, developed an
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approach to assess agreement between two methods for the same marker, where the
differences in assay values vary as a function of the absolute measure of the marker [204].
The approach uses a two step regression method. For the first step, the difference between
the marker values obtained from the two assays is regressed on the average of the marker
values as measured by the two assays, and in the second step, the limits of agreement are
calculated and the residuals from the first regression are modelled on the average measure of
the two tests.
Using this method, the nephelometric measures were more sensitive than the RID method
(Figure 4.5). For example, at the higher than average reading of 493.2 mg/L the
nephelometric assay reads 71.2 mg/L higher than the RID assay, with 95% limits of
agreement at 15.4 mg/ L and 181.4 mg/L, and similarly at the lower average reading of 256.4
mg/L the nephelometric assay reads 96.9 mg/L lower that the RID assay with 95% limits of
agreement at -197.8 mg/l and -31.8 mg/l.
Table 4.2 Comparison of the distribution of fH measured by the commercial RID assay
and the newly developed nephelometric assay.
Summary statistics
fH Nephelometric
measurement
fh RID measurement
Number of individuals 50 50
Mean 348.49 370.36
Standard deviation 92.93 40.28
25th Centile 291.50 341.04
Median 328.50 367.68
75th Centile 375.50 394.40
Range 443.00 169.58
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Figure 4.6 Regression based Bland-Altman comparison of fH concentration in 50 samples
analysed using the RID assay and the newly developed nephelometric assay. The difference
refers to the value of fH estimated using nephelometry minus the value using RID.
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4.2.1.6 Recovery
The mean fH concentration calculated from 4 repeated measures of EDTA plasma taken from
one healthy volunteer was 365 mg/L. Samples of varying fH concentration were then prepared
by mixing this sample with fH depleted EDTA plasma to generate samples at concentrations
that varied between 0-100% of the volunteer sample. After measurement on the BNII
nephelometer, the percentage recovery was calculated by comparison of observed to
expected values, and these are shown in Table 4.3 and Figure 4.6. Recovery was close to
100% at all plasma concentrations. For the sample depleted of fH the observed fH
concentration was 7.69 mg/L (SD 0.24 mg/L).
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Table 4.3 Percentage recovery of fH from solutions of plasma containing a range of
known fH concentrations
Concentration of fH in
mixed sample, expressed
as percentage of the
undiluted control
Expected fH
concentrations
(mg/L)
Observed fH
concentration (SD)
(mg/L)
% Recovery (observed-
expected/observed x100)
0% 0.00 7.69 (0.24) .
10% 36.50 48.20 (13.79) 132%
20% 73.00 85.725 (15.80) 117%
30% 109.50 111.75 (6.50) 102%
40% 146.00 147.25 (5.44) 101%
50% 182.50 199.25 (4.57) 109%
60% 219.00 231.00 (5.60) 105%
70% 255.50 259.25 (6.99) 101%
80% 292.00 298.75 (7.54) 102%
90% 328.50 322.75 (9.54) 98%
100% 365.00 364.50 (3.32) 100%
Figure 4.7 Observed and expected concentration of fH in samples containing 0-100% of
the fH concentration of an individual control plasma sample. Each point represents the mean ±
standard deviation of the 4 replicate findings
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4.2.1.7 Stability of Factor H using newly developed assay on BNII
4.2.1.8 Reproducibility and difference of fH measures in plasma and serum
To determine the influence of anti-coagulant, I assayed venous blood collected from 5 healthy
volunteers in plasma, using anticoagulants EDTA, citrate and lithium heparin, as well as no
anticoagulant (serum) (Table 4.4). Measures were broadly consistent between sample types.
Table 4.4 Mean (SEM) of 5 measurements of fH from each of 5 healthy individuals
Fresh
sample EDTA Citrate
Lithium-
Heparin Serum
Individual 1 313.00 (7.12) 306.30 (6.04) 328.20 (7.28) 319.40 (15.8)
Individual 2 267.00 (4.93) 272.00 (4.49) 287.40 (8.38) 287.20 (7.94)
Individual 3 271.00 (6.12) 270.50 (5.50) 286.00 (6.38) 288.40 (6.79)
Individual 4 241.60 (5.80) 236.30 (3.88) 253.80 (4.66) 267.00 (5.50)
Individual 5 229.80 (5.04) 227.00 (3.94) 235.00 (9.10) 247.00 (4.44)
Mean values of fH in serum and plasma were in the range 227 to 328 mg/L (Table 4.4), with
intra-assay CV’s ranging from 4 to 11% (Table 4.5), and inter-assay CV’s ranging from 5-15%
(Table 4.6). The assay has an overall intra-assay and inter-assay precision and accuracy
within 7% and 10% respectively.
Table 4.5 Intra-assay coefficient of variation, calculated separately for plasma and
serum using 5 replicate freshly thawed samples each day from 5 separate individuals.
Intra-assay coefficient of variation
EDTA Citrate Lithium-Heparin Serum
Individual 1 5% 4% 5% 11%
Individual 2 4% 4% 7% 6%
Individual 3 5% 5% 5% 5%
Individual 4 5% 4% 4% 5%
Individual 5 5% 4% 9% 4%
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Table 4.6 Inter-assay coefficient of variation, calculated separately for plasma and
serum using 5 replicate freshly thawed samples each day from 5 separate individuals.
Inter-assay coefficient of variation
EDTA Citrate Lithium Heparin Serum
Individual 1 10% 8% 7% 13%
Individual 2 10% 6% 5% 13%
Individual 3 10% 7% 7% 14%
Individual 4 10% 7% 8% 15%
Individual 5 14% 9% 13% 15%
4.2.2 Stability of factor H using newly developed assay on BNII
4.2.2.1 Stability to freeze thaw and extreme temperatures of measured factor H on the
Siemens BNII
Complement factor H was stable to at least 4 freeze thaw cycles, after which some decrease
in concentration was observed (Figure 4.7) On subjecting samples from two healthy
volunteers to a range of temperatures, fH was found to be is stable at all temperatures up to
37C. However no fH was detectable after incubation at 45C for one week (Figure 4.8).
Figure 4.8 Stability of fH to 5 freeze thaw cycles. Triplicate samples from 5 healthy
volunteers and the post-cryoprecipitate control were subjected to 5 freeze thaw cycles from -
80C to 37C. with the exception of cycle 5 (where only duplicate assays were possible
because of technical difficulties with the nephelometer). Cycle 0-fresh samples; cycle 1 - 7
days after blood draw, cycle 2 and 3 – 10days after blood draw; cycles 4 and 5 – 15 days after
blood draw. (NB unable to complete all cycles with individual 3 lithium heparin plasma due to
lack of sample)
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Figure 4.9 Stability of fH to temperatures. Samples from 2 individuals from around the 25th and 75th centiles of the distribution, and the post-cryo
material were stored at -80C, -20C, 4C, 24C, 37C and 45C. Aliquots were assayed fresh and at weekly intervals for 4 weeks.
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4.2.2.2 Variation and distribution of fH in healthy volunteers
Circulating fH followed a skewed distribution in 100 healthy volunteer samples, with a median of
348 mg/L and a range of 440 mg/L. Summary statistics of fH measures as carried out by
immune-nephelometry are shown in Table 4.3. A similar distribution is seen for fH measured
using RID (median 370.36 mg/ L) although the range measured is narrower (169.58 mg/L).
4.3 Discussion
By using reagents from a pre-existing commercial low throughput assay I have described the
development of a newer high throughput assay for fH which is robust, reliable and simple to
perform, and which uses standard equipment present in any healthcare associated biochemistry
laboratory.
The new assay is more sensitive than the current RID assay, for values across the whole range
of fH found in populations and, in particular, at the extremes of the distribution of fH values.
Although degraded quickly at temperatures > 37°C, fH is remarkably stable over a number of
weeks to ambient and low temperatures, and is resistant to multiple freeze-thaw cycles.
Importantly there are no major differences in measurement of fH across the range of plasma
(EDTA, citrate and lithium heparin) and serum. Collectively these properties of the analyte
render it suitable for measurement in stored samples from population based and control studies
in AMD and CHD. Moreover these properties mean that a test for blood fH could be transferred
quickly to a clinical setting should this marker be found to be useful in predicting risk of AMD or
CHD or the response to treatment.
Samples of fH depleted plasma were found to have a nominal concentration of fH, ~7 mg/L.
This may be because the polyclonal sheep anti-fH antibody used in the assay may have some
cross reactivity with other homologous circulating proteins such as FLH1 or one or more of the
CFHRs. An alternative explanation is that the sample of fH depleted plasma still contains a
small concentration of fH that was detected by the BNII assay. However, given the
concentration range of fH in serum and plasma even if there were some cross reactivity this is
likely to be small and constant, as determined by these experiments.
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Other methods for measuring fH have been reported since this work was initiated (Table 4.7).
However none have been shown to be as robust as the assay described here given the validity
of the assays have not been as comprehensively determined, and stability of fH not been shown
with other assays, as has been demonstrated here. In addition the assay described here is high
throughput, compared to the ELISA based methods of other assays, and given the platform on
which it has been established it can be rapidly moved to a clinical setting. Moreover the current
assay offers an advantage to more traditional assays of fH using an erythrocyte lysis assay,
which would be unable to detect subtle differences in fH concentration on a population scale.
However one advantage that the latter does offer that it tests function of fH which is lacking in
the current assay. Nevertheless, the previously described QTL mapping to the CFH gene has
been associated with concentrations rather than activity. Another possible disadvantage maybe
that the current assay is not able to distinguish between Y402 and 402H forms of the fH protein,
although this information could be obtained by correlation of genetic and phenotypic data,
should the polymorphism underlying this protein change be shown to be functional.
This method therefore allows fH concentration to be measured on a population scale, thereby
allowing description of its molecular epidemiology, the genetic and non genetic determinants to
test the association with both CHD and AMD, and to delineate wither the association of genetic
variation in the CFH gene with AMD is mediated in whole or in part by differences in blood fH
concentration.
Table 4.7 Tabular summary of the results of fH assay in previously reported studies Blank
cells indicate where values have not been reported.
Source Total numberof individuals
Mean
fH
Standard
deviation Median Maximum Minimum Range
Esparza-Gordillo J et al.,
[134]
385 (21
pedigrees)
319.9 71.4 562 116 446
Scholl HP et al.,
AMD CONTROLS [205]
67 515
Hakobyan S et al.,
AMD CONTROLS
(Cardiff) [203]
63 233.24 56.65 349.27 135.54 213.73
Hakobyan S et al.,
AMD CONTROLS
(Spanish) [203]
75 268.69 55.52 398.38 83.05 315.33
125
5 Molecular Epidemiology of circulating complement factor H
Given common variants in CFH are associated with AMD, and that a QTL was previously
mapped to chromosome 1 in the RCA cluster, there is strong biological plausibility that fH
concentrations may mediate the link between SNPs in this region and AMD risk. If so fH might
be a potentially useful biomarker with utility for disease prediction and as a potential drug target.
However very little is known about non-genetic correlates of circulating fH at a population level.
Having established a high-throughput method for measuring fH applicable at a population level,
I aim to describe in this Chapter, measurement of fH in a population based study which has a
wide range of demographic, lifestyle, anthropometric measures and blood biomarkers already
measured. This has allowed for the first time, the determination of the distribution of circulating
fH in an adult white European population, and the cross-sectional correlations and associations
of fH.
5.1 Materials and Methods
5.1.1 Population
The Fenland study is a MRC funded prospective, population based study, which recruited
individuals born between 1950 and 1975 registered at general practices in the east
Cambridgeshire area. It is an ongoing study which aims to recruit 10,000 individuals. A wide
range of blood, metabolic, anthropometric and lifestyle data have been collected in individuals
recruited thus far. I studied a subset of 1514 subjects where fasting serum was available to
measure fH. The samples used for estimation of fH were stored at -80°C, and had not been
through a previous freeze-thaw cycle. All participants of this study gave informed consent and
protocols and collection procedures were approved by the relevant ethics committees.
5.1.2 fH measurement
Factor H was measured once in each sample using the newly developed nephelometric assay
described in Chapter 4. Samples were thawed at room temperature, and centrifuged at 3000g
for 5 minutes prior to loading on the BNII. A volume of 40 uL was used by the analyser to
perform a measurement and concentration was estimated as described in Chapter 4 and
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Appendix 1. A subset of 200 samples, chosen at random were re-measured to ensure
repeatability of the assay within the sample set.
5.1.3 Statistical analysis
For normally distributed continuous variables, means and standard deviations were calculated.
For non-normally distributed variables natural logarithms (loge) were used to transform the
variables where appropriate, and geometric means and approximate standard deviations were
reported. If no normalising transformation was possible, medians and inter-quartile ranges were
calculated. For categorical variables, proportions were calculated. Results were reported
overall and stratified by gender.
The shape of the fH distribution was determined, and any appropriate transformations were
carried out. The central tendency for both untransformed and transformed fH was determined,
as well as appropriate metrics for degree of variability and dispersion. Univariate associations
for cross-sectional associations were performed using Pearson correlation coefficient, correcting
reported p values for multiple testing using the Bonferroni method. In order to further delineate,
and visualise the shape of associations of fH with individual measures, the geometric mean of
loge fH, and its 95% confidence intervals, for each decile of the related marker were calculated
and plotted, for males and females separately. All data-analysis described in this chapter was
carried out using the statistical package Stata (Version 11, StataCorp LP College Station, TX,
USA)
5.2 Results
Baseline characteristics overall and by gender are shown in Table 5.1
5.2.1 Distribution of fH
The distribution of fH concentration in the MRC Fenland study was found to be right skewed,
and normalised by a natural logarithm transformation (loge) (Figure 5.1). The median and the
inter-quartile range for the untransformed distribution were 226.6 mg/L (111.3 mg/L), and the
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transformed means and approximate standard deviation were 232.66 mg/L (74.52). These
measures are summarised in Table 5.2.
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Table 5.1 Baseline characteristics of the MRC Fenland study participants. Means or proportions are given for each variable, for the overall group as well as
gender specific values. *Log transformed, ** 1/SQRT transformation
Male Female Total sample
N Mean SD N Mean SD N Mean SD
Age (at study
entry) 882 44.85 7.27 1092 45.34 7.08 1974 45.12 7.17
Lifestyle measures
% % %
Never smoked 49.94 52.89 51.57
Ex-Smokers 29.51 30.30 29.95
Current Smokers 12.37 10.84 11.52
Never consumed
alcohol 5.57 7.07 6.40
Ex-drinkers 0.11 1.10 0.66
Ever drinkers 0.57 0.73 0.66
Current 81.93 75.94 78.62
Alcohol units/
week 709 11.98 13.79 886 5.05 6.20 1595 8.13 10.85
Anthropometric
measures
Dexa-Total Bone
Mass 660 3254.83 457.57 848 2550.85 362.76 1508 2837.98 528.17
Dexa-Total fat
Mass 660 23056.57 9013.40 848 25531.06 9842.40 1508
24416.9
5 9548.13
Dexa-Total lean
mass 660 58227.59 6829.63 848 40827.52 5187.0
Body fat Percent
(impedance
measure)
Waist hip ratio* 878 0.94 0.06 1090 0.83 0.06 1968 0.88 0.08
BMI* 881 27.48 3.89 1091 26.30 5.13 1972 26.82
4.68
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Male Female Total sample
N Mean SD N Mean SD N Mean SD
Cardiovascular
Measures
Mean SBP 874 128.58 14.11 1076 118.56 15.48 1950 123.05 15.69
Mean DBP 877 78.35 10.40 1082 73.87 9.86 1959 75.88 10.34
Resting heart rate 878 66.78 8.744 1087 63.83 8.49 1965 63.83 8.49
Indices of
Glycaemic Control
Fasting Glucose* 882 5.04 0.59 1078 4.73 0.51 1960 4.87 0.57
Glucose 120mins* 870 5.14 1.51 1061 5.04 1.42 1931 5.08 1.46
HbA1c* 880 5.45 0.44 1085 5.36 0.37 1965 5.40 0.41
NEFA* 666 286.71 131.81 848 340.18 160.03 1514 315.53 149.33
Leptin* 667 5.32 4.74 848 16.91 14.62 1515 10.16 10.64
Adiponectin* 667 3.89 1.68 848 6.80 3.18 1515 5.32 2.82
Insulin (pmol/L)* 666 44.08 25.71 848 35.46 20.79 1514 39.02 23.20
Major lipids and
apolipoproteins
Total Cholesterol* 881 5.38 1.04 1087 5.24 0.99 1968 5.30 1.01
Triglyceride* 881 1.28 0.74 1087 0.89 0.47 1968 1.05 0.61
HDL-C* 881 1.23 0.30 1087 1.56 0.40 1968 1.40 0.38
LDL-C 867 3.56 0.91 1082 3.30 0.88 1949 3.41 0.90
ApoE* 667 0.03 0.01 846 0.03 0.01 1513 0.03 0.01
Indices of renal
function
Urea* 881 5.21 1.21 1085 4.62 1.13 1966 4.87 1.20
Creatinine 879 84.68 13.63 1086 66.05 11.87 1965 74.38 15.71
Indices of liver
function and bone
metabolism
Serum albumin 881 43.31 2.61 1086 41.53 2.77 1967 42.33 2.84
Bilirubin* 881 11.14 4.61 1085 8.84 3.76 1966 9.80 4.27
Alkaline
Phosphatase* 880 76.34 20.04 1085 69.06 20.92 1965 72.24 20.93
Alanine
Transaminase* 881 35.44 15.65 1085 22.06 8.99 1966 27.28
13.22
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Table 5.1 continued
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Male Female Total sample
N Mean SD N Mean SD N Mean SD
Gamma GT** 881 0.17 0.04 1085 0.21 0.04 1966 0.19 0.05
Calcium 880 2.29 0.08 1085 2.26 0.09 1965 2.27 0.09
Corrected Calcium 880 2.20 0.08 1085 2.20 0.08 1965 2.20 0.08
Markers of
inflammation
hs CRP* 660 1.40 1.67 842 1.46 1.87 1502 1.43 1.78
fH* 668 258.44 80.65 846 214.13 64.68 1514 232.66 74.52
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Table 5.1 continued
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Figure 5.1 Distribution of circulating fH in the MRC Fenland study and the effect of a
number of transformations
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Table 5.2 Distribution of circulating fH in the MRC Fenland study
Total
Number
Minimun Maximum
25th
centile
50th
centile
75th
centile
Interquartile
range
Mean SD
fh 1514 63.48 847.55 184.77 226.56 296.06 111.29 245.15 83.25
Log fH 1514 63.48 847.55 184.77 226.56 296.06 111.29 232.66 74.52
Univariate associations of log transformed fH were observed with a number of the demographic,
anthropometric measures, all of which are shown in Table 5.3. No clear trend was observed
with age (correlation coefficient 0.01) or smoking (correlation coefficients=0.11) as has been
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previously reported in a smaller (n~300) family based linkage study [134]. However there were a
number of significant positive correlations with major blood lipids, including triglycerides
(correlation coefficient=0.67) total cholesterol (correlation coefficient=0.33) and LDL-C
(correlation coefficient=0.29). fH was inversely correlated with HDL-C (correlation coefficient=-
0.4). Circulating fH was also correlated with indices of adiposity including BMI, (correlation
coefficient=0.43), waist hip ratio (correlation coefficient=0.4). Significant associations were also
observed with liver markers (including ALT, ALP and gamma GT), although no association of fH
with indices of renal function. Log fH was in addition also significantly associated with the
sensitive inflammation marker and acute phase reactant CRP (correlation coefficient =0.4).
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Table 5.3 Unadjusted correlation coefficients of log transformed fH with a range of
anthropometric measures and other biological measures in the MRC Fenland study. P
values reports are adjusted for multiple testing using the Bonferroni method
Variable Correlation Coefficient p value
Lifestyle measures
Age 0.01 <0.001
Alcohol (units per day) 0.09 0.37
Smoking (cigarettes per day) 0.11 1
Anthropometric measures
Log Dexa: total bone mass 0.24 <0.001
Log Dexa: total fat mass 0.4 <0.001
Dexa: total lean mass 0.31 <0.001
Body Fat Percent (Impedance) 0.13 0
Log Waist Hip Ratio 0.4 <0.001
Log BMI 0.43 <0.001
Cardiovascular Measures
Mean SBP 0.27 <0.001
Mean DBP 0.32 <0.001
Resting Heart Rate 0.13 0
Indices of Glycaemic Control
LogFasting Glucose 0.25 <0.001
Glucose 120 minutes 0.3 <0.001
HbA1C 0.3 <0.001
Log NEFA 0 1
Log Leptin 0.21 <0.001
Log Adiponectin -0.41 <0.001
Insulin 0.51 <0.001
Major lipids and apolipoproteins
Total cholesterol 0.33 <0.001
LDL cholesterol 0.29 <0.001
Log HDL Cholesterol -0.4 <0.001
Log Triglycerides 0.67 <0.001
Log ApoE 0.53 <0.001
Indices of renal function
Log Urea 0.09 0.06
Creatinine 0.23 <0.001
Indices of liver function and bone metabolism
Albumin 0.01 1
Log Bilirubin -0.05 1
Log Alkaline Phophatase 0.31 <0.001
Log Alananine Transaminase 0.34 <0.001
SQRT Gamma GT -0.42 <0.001
Calcium 0.14 <0.001
Corrected Calcium 0.15 <0.001
Markers of inflammation
Log hsCRP 0.4 <0.001
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5.2.2 Cross-sectional associations of circulating fH with other variables measured in
the MRC Fenland Study
To further explore the relationship between fH and indices measured broadly in the MRC
Fenland study, the geometric mean of log transformed fH (95%CI) was plotted against the
mean value of each decile of the associated co-variate (Figure 5.2). Associations of fH with
anthropometric measures reflecting fat mass (including Dexa total fat mass, impedance based
measures of body fat percent and log BMI), lipid biomarkers including total cholesterol,
triglyceride and apo-lipoprotein E were positive and approximately linear, while associations
with adiponectin log HDL-C were negative and approximately linear. These were the strongest
associations. Circulating fH was also associated with liver markers of ALT, ALP (positively) and
bilirbun and albumin (negatively), although there was interestingly no association with renal
markers of urea and creatinine. The difference in fH concentration between opposite deciles
was greatest for triglycerides, BMI and HDL-C being as high as 150 mg/L which is
approximately equal to 2 standard deviations of the fH distribution.
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Figure 5.2 Cross-sectional associations of circulating fH in 1500 individuals from the
MRC Fenland study. Mean log fH and its 95% CI was calculated for each decile of the
associated variable and plotted to visualise the shape of the association. Plots are divided into
panels with respect to which system they best reflect.
Panel A: demographic and lifestyle measures. For the alcohol variable 0= never drinkers,1= not
current, 2=ex-drinker, 3=ever drinker 4=current drinker
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Panel C: Cardiovascular Measures
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Figure 5.2 continued
Panel D: Indices of glycaemic control
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Panel E: Major lipids and lipoproteins
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Panel F: Indices of renal function
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Figure 5.2 continued
Panel G: Indices of liver and bone metabolism
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5.3 Discussion
In this Chapter I have described the first use of a newly developed high-throughput
nephelometric assay for circulating fH on a population scale. I have also described, for the first
time, the correlates and associations of circulating fH with age, gender, and a wide range of
lifestyle, anthropometric markers and blood biomarkers related to the risk of late-onset
disorders. Although a smaller scale family based study has been carried out as part of a linkage
scan to identify the QTL for fH [134], which estimated that 60% of variation in circulating plasma
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fH is determined genetically, but also suggested that there were important environmental
determinants of fH such as age and smoking. However the small size of that study (n=358) and
the number of covariates, limit conclusions about the associations of fH. More recently a further
small study (n=398) evaluated adipose CFH gene expression in a subset of individuals as well
as measuring both circulating fH and fB by in-house ELISA methods [206]. They demonstrated
a positive association with BMI, waist circumference, triglycerides and inflammatory markers,
and a negative association with insulin sensitivity and HDL-C, in keeping with our observations
on a larger scale. Isolated adipocytes were demonstrated to have a low basal production of fH,
and concentrations were higher in individuals with altered glucose tolerance and insulin
resistance, with a demonstrable reduction of fH and fB levels with weight loss and treatment
with the anti-diabetic drug rosiglitazone (a member of the thiazolidinediones class of drugs).
However given the larger scale of the data described in this chapter and the number of co-
variates that have been measured, the current description of the molecular epidemiology of fH
the largest and most comprehensive to date.
The association of fH with measured blood lipid fractions is of particular interest given that
recent proteomic analyses have demonstrated that circulating complement components
complex with HDL-C [35]. However, fH was found to be inversely associated with HDL-C in the
MRC Fenland study, which cannot simply be explained by binding complexes between HDL-C
and fH which would be expected to produce a positive association. These associations may
have implications for disease mechanism. There is observational evidence linking HDL-C and
triglyceride to CHD risk, however the effect of these markers is less clear in AMD. However
more direct evidence of a link between HDL-C with AMD in particular has emerged from denser
coverage GWAS where variants in genes that underlie variation in circulating HDL-C are also
associated with AMD [36, 37]. Further support for a relationship between lipid and lipid related
markers with fH is described in Chapter 3, where 402H homozygote individuals were observed
to have a significant association with circulating triglyceride.
Beyond the association of fH with particular subsets of markers, the results of measurement of
fH on this scale are important in terms of relating what is known about the biology and
pathological function of fH to its measurement in a healthy population based sample. fH is made
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in the liver [133] and in MRC-Fenland, there is a correlation with other measures of synthetic
function of the liver (albumin) and liver function in general (measures of ALP, ALT and bilirubin).
The initial observation that fH was produced by the liver [133], also indicated that fH mRNA
expression was independent of the acute phase marker serum amyloid A (SAA), indicating that
fH is not an acute phase reactant, but rather produced at a steady state. Complete absence of
the protein is associated with uncontrolled activation of the complement system, supporting its
constant production. Half life measurements of factor H have come from studies where fH is
infused into an individual deficient of fH secondary to a premature stop codon preventing
adequate section of the protein. Infusion of purified fH into this individual thus allowed an
estimation of a half life of about 6 days [207].
In addition to production by the liver, as already discussed, there is evidence of production of fH
at local sites outside of the liver which may contribute to the overall plasma concentration or
may represent local concentrations particular if fH at these sites in surface bound, which serves
to inhibit complement activation in specific micro-environments. This may be one explanation of
the lack of evidence of an association with renal function (creatinine and urea) in this study,
despite the well known associations of fH deficiency in certain rare forms of renal disease.
There are some limitations to this analysis which are worthy of discussion. The analyses
presented here are restricted largely to white Europeans and therefore may not be reflective of
fH distributions in samples of other ethnicities. I have already demonstrated in Chapter 2, that
there is a difference in the frequency of the rs1061170 SNP encoding Y402H, the putative
functional SNP in AMD, between white Europeans and east Asian populations. As I have
hypothesised that variation in the gene underlies differences in circulating fH, it would be
important to determine distributions of fH in ethnically diverse populations where dense
genotyping is also available, to allow for a comparison of how genotype and fH levels are
related. Moreover, it is also important to replicate these findings in other European samples in
order to confirm the distributions and cross-sectional observations. Other aspects that would be
of interest are (i) the biological variability in fH concentration measured in serial samples from
the same individual and (ii) to confirm or refute earlier findings that fH is not an acute phase
reactant given its central role in regulation of complement activation.
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The importance of the new assay for fH will now be in investigating differences in levels of fH in
individuals with and without AMD (the finding of no effect of the genetic variants in CFH and
CHD makes this association less likely), and to assess if it is indeed a putative biomarker for
one of both of these diseases. This knowledge could impact not only on prediction of both
disorders and early targeting of expensive therapies for AMD but may also inform on whether
targeting fH or its downstream actions will be useful therapeutically.
141
6 Genetic determinants of circulating complement factor H using a
genome wide association scan
In this chapter I aim to describe the experiments used to identify the genetic loci influencing the
concentration of circulating fH using a genome wide association scan. Genome wide scans by
their design provide a hypothesis free approach to identify possible genetic loci associated with
a disease or trait. They are therefore a useful tool in determining genetic contributions of
seemingly unrelated loci to a trait or disease, and thus have a clear advantage over previous
candidate gene studies.
A previous genome wide, family-based linkage study has mapped a number of regions as being
associated with circulating fH [134], although none of these reached the pre-specified threshold
for linkage (LOD >3). However a biologically plausible QTL was mapped to the RCA cluster of
chromosome 1 for fH (LOD score 2.03), which not only includes the CFH gene, but also the
CFHR genes and other genes with complement regulatory activities (see introduction for details
of genes in this region). Importantly the linkage peak also extended to other complement
associated genes outside the CFH/CFHR gene family, including CR1 (complement receptor 1)
which has most recently been associated with Alzheimer’s disease using a genome wide
approach [11]. Other regions of the genome putatively involved with fH regulation were
additionally identified including a locus on chromosome 2p21-24.1 (LOD score 2.15) and
chromosome 15q22.1-24.1 (LOD score 2.00). In comparison to the standards of current
genome wide scans, this was a relatively small study of 358 individuals belonging to 21 three- to
five-generation extended pedigrees. Further evidence for the role of the RCA cluster in
influencing circulating fH comes from a study in which variants in the CFH promoter have been
associated with alteration of fH levels in a cohort of paediatric cases of meningitis [12]. Using
newer technologies, with higher density coverage of variants across the genome, and with the
added advantage of being able to infer non-genotyped variants against a densely genotyped
reference panels (HapMap 3 (www. hapmap.ncbi.nlm.nih.gov) and the 1000 genomes project
(www.1000genomes.org)), allowing for an even higher resolution of signal, allows confirmation
and extension of these findings to further pin-point genetic regulation of circulating fH. Finding
loci for fH in this way may provide an additional route for locating regions of the genome in other
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diseases in which we know complement has been implicated, including AMD, aHUS, MPGNII,
Alzheimer’s disease and meningitis in which complement regulation has been implicated [11,
12, 131].
6.1 Materials and Methods
6.1.1 Population
The MRC Fenland study, which was described in more detail in Chapter 5, was used for this
experiment. The 1514 individuals who had measures for serum fH in whom there was SNP data
available which allowed me to carry out a genome wide scan for circulating fH. Of these
individuals 1500 Caucasian individuals were used for this study in order to eliminate possible
confounding due to population stratification. Identification of individuals of Caucasian decent
were identified using the self-reported ethnicity data in the Fenland study.
6.1.2 Genotyping
Genotyping in MRC Fenland was carried out in the MRC Epidemiology Unit in Cambridge, using
the Affymetrix 500k Human GeneChip. Five hundred thousand single nucleotide
polymorphisms were genotyped in each individual using this commercial chip. Genotyping by
this method is based on the use of single oligonucleotide primers for amplification coupled to
allelic discrimination on the DNA mirco-arrays. Markers on this chip have been chosen using a
tagging SNP approach from the reference HapMap panel, in order to capture variation across
the whole genome for SNPs with a minor allele frequency of greater than 1%. Genotyping was
carried out in all individuals using one chip per person, with an automated genotyping algorithm
used for calling BRLMM (Bayesian Robust Linear Model with Mahalanobis distance classifier
http://media.affymetrix.com/support/technical/whitepapers/brlmm_whitepaper.pdf). Where the
algorithm was unable to call the genotype, allelic discrimination plots were examined visually,
and manually called if appropriate. For genotypes that could not be called, SNPs were excluded
from the subsequent analysis.
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6.1.3 Measurement of fH
Measurement of fH was carried out using the nephelometric assay described in chapter 4, and
values attained for the Fenland data set have already been extensively described in chapter 5.
For purposes of analysis, values of fH were log transformed given its skewed distribution.
6.1.4 Statistical analysis
All statistical analyses presented in this chapter were carried out by Daniel Barnes (statistician
at the MRC Epidemiology Unit, Strangeways Research Laboratory, Cambridge), using methods
developed by Jian’an Luan (statistician at the MRC Epidemiology Unit, Institute of Metabolic
Science, Cambridge). Methods are summarised below and are also available in reference [208].
Quality control statistics for genotypes were carried out on genotypes successfully typed or
called. Departure from HWE was calculated using a 2 test, which also serves as a measure of
genotyping quality. A threshold of significance was set at a p value of less than 2x10-8,
assuming a 5% significance level Bonferroni adjusted for ~2.5 million SNPs. Analyses were
limited to self-reported Caucasians in the Fenland dataset, and the resulting quantile-quantile
(QQ) plot was inspected visually to determine if there was evidence of significant population
stratification, and a genomic control calculated at that stage. Missing autosomal genotypes were
imputed that were present in HapMap Phase II/ NCBI build 36, but were not present in the
genome-wide chip or did not pass direct genotyping quality control. For each sample, genotypes
were imputed using data from the GWAS chip and HapMap phased genotype data from the 60
CEU HapMap founders. SNPs that were retained included those with a MAF>1%. Missing
genotypes were imputed using the statistical software IMPUTE version
0.4(mathgen.stats.ox.ac.uk/impute/), which determines the probability distribution of missing
genotypes conditioned on a set of known haplotypes and an estimated fine-scale recombination
map. Imputation was based on 362,000 autosomal SNPs with a MAF of >1% that appear on
HapMap. Imputed SNPs were excluded if they had an imputation information score of 0.4 a
MAF <1% or were not in HWE equilibrium (p value <1x10-6). Both directly typed and imputed
SNPs were then tested for association with log transformed fH using an additive genetic model
adjusting for age and sex. Log transformed fH was used as fH distribution is skewed and
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normalised by log to base e transformation, as described in Chapter 5. Association analyses
were carried out using SNPTEST version 1 [209]. The threshold p value was set at 2x10-8, to
account for multiple testing.
6.2 Results
6.2.1 Quality Control
362,059 directly genotyped SNPs passed initial quality control, with call rates of >95% and that
did not deviate from HWE using a threshold of ≥1x10
-7. These included SNPs that were not
initially called by automated calling algorithm and were called using visual inspection of allelic
discrimination plots. Using information from these SNPs a further 2,080,823 SNPs were
imputed, of which 1,891,264 were included in the final analysis after quality control. Therefore a
total of 2,253,323 SNPs in total were used for the genome wide association analysis. Genomic
control was not applied as was calculated to be 1.0057
6.2.2 Association results
No SNP, directly genotyped or imputed crossed a pre-specified genome wide statistical
significance (p value of 2x10-8). However 40 SNPs achieved a p value of ≤1x10-5., of these, 19
were located in a 1 MB region including the CFH-CFHR gene region on chromosome 1 (Figure
6.1, Figure 6.2, Table 6.1). The strongest signal for log fH was rs644598, an inter-genic SNP
whose closest reference gene is CFHR3, although SNPs in CFH, CFHR1 and CFHR3 share p
values at the 10-6 level (Table 6.1). Of the other loci with a p value of ≤1x10-5 , 15 SNPs were in
or close to the ELAVL2 gene, 2 in the CRB1 gene, and 1 each in the WNT5A, DCL1 GRB14
and PHACTR1 genes. The Q-Q plot (Figure 6.2), confirms the likelihood of these associations
and confirms that these are unlikely to be due to population sub-structure, with the genomic
inflation factor being calculated as 1.0057.
145
Figure 6.1 Graphical representation (Manhattan plot) for genome wide scan of circulating
log fH concentration in the MRC Fenland study. In this scan no markers reached genome
wide significance although there are a number of peaks which are worthy of replication.
Figure 6.2 Quantile-quanitle plot of genome wide association scan of circulating log fH
concentration in the MRC Fenland study. Genomic inflation factor λ=1.0057 
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Table 6.1 Top association signals from a GWAS for circulating fH in the MRC Fenland population. Hits are organised from the smallest p value to largest, and
the table has been restricted to just show signals below a p value of <0.000001) SNPs may occur within genes themselves or within intergenic regions which are not
covered by the Affymetrix chip used or typed in the HapMap reference panel, and thus the closest and second closest reference genes are also given, as markers
may highlight areas of association in genes which are in LD with these markers.
SNP Chromosome
In
reference
gene
Reference gene 60
kb away from SNP
Closest
reference
gene
Distance from
closest reference
gene (kb)
Second
closest
reference
gene
Distance from
second reference
gene (kb)
Beta
coefficient
(log fH)
Standard
error
P value
rs644598 1 CFH;CFHR3;CFHR1 CFHR3 3705 CFHR1 22283
0.08 0.02
1.92x10-06
rs446713 1 CFHR3;CFHR1 CFHR1 6984 CFHR3 19004 0.08 0.02 2.18x10-06
rs6445740 3 WNT5A WNT5A 37573 ERC2 80165
0.06 0.01
2.26x10-06
rs377298 1 CFHR3 CFH;CFHR3;CFHR1 CFHR3 4331 CFHR1 30319 -0.07 0.02 2.49x10-06
rs449847 1 CFH;CFHR3;CFHR1 CFHR3 12781 CFH 14517
-0.08 0.02
2.60x10-06
rs11985642 8 DLC1 DLC1 DLC1 132255 C8orf79 352856 0.07 0.02 2.79x10-06
rs4131556 9 ELAVL2 253702 TUSC1 1596628
-0.06 0.01
3.65x10-06
rs10966201 9 ELAVL2 253125 TUSC1 1597205 -0.06 0.01 3.67x10-06
rs1223552 6 PHACTR1 PHACTR1 PHACTR1 113688 TBC1D7 131345
0.06 0.01
3.77x10-06
rs12379069 9 ELAVL2 249305 TUSC1 1601025 0.06 0.01 3.84x10-06
rs371075 1 CFHR3;CFHR1 CFHR1 12024 CFHR3 13964
0.07 0.02
4.28x10-06
rs426736 1 CFHR3 CFH;CFHR3;CFHR1 CFHR3 2455 CFHR1 28443 -0.07 0.02 4.46x10-06
rs385390
1 CFH;CFHR3;CFHR1 CFHR3 2 CFH 27296
-0.07 0.02 4.66x10-06
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SNP Chromosome
In
reference
gene
Reference gene 60
kb away from SNP
Closest
reference
gene
Distance from
closest reference
gene (kb)
Second
closest
reference
gene
Distance from
second reference
gene (kb)
Beta
coefficient
(log fH)
Standard
error
P value
rs1065489 1 CFH CFH;CFHR3 CFH 6857 CFHR3 34155
-0.07 0.02
4.71x10-06
s11582939
1 CFH CFH;CFHR3 CFH 6474 CFHR3 33772
-0.07 0.02
4.71x10-06
s11799380 1 CFH CFH;CFHR3 CFH 8176 CFHR3 35474
-0.07 0.02
5.00x10-06
rs3828022 1 CRB1 CRB1 CRB1 70674 ZBTB41 138409 -0.12 0.03 5.02x10-06
s10966195 9 ELAVL2 249019 TUSC1 1601311
-0.06 0.01
5.04x10-06
s13027837 2 GRB14 GRB14 GRB14 40638 COBLL1 103537 0.08 0.02 5.57x10-06
rs4487866 9 ELAVL2 261273 TUSC1 1589057
-0.06 0.01
5.57x10-06
s10511739 9 ELAVL2 265279 TUSC1 1585051 0.06 0.01 5.60x10-06
rs7033446 9 ELAVL2 283688 TUSC1 1566642
0.06 0.01
5.60x10-06
s10489456 1 CFH CFH;CFHR3 CFH 16822 CFHR3 56414 0.07 0.02 5.62x10-06
rs7032051 9 ELAVL2 279432 TUSC1 1570898
-0.06 0.01
5.62x10-06
rs3753396 1 CFH CFH;CFHR3 CFH 20889 CFHR3 48187 -0.07 0.02 5.63x10-06
s10645026 9 ELAVL2 272629 TUSC1 1577701
-0.06 0.01
5.63x10-06
s10966216 9 ELAVL2 279907 TUSC1 1570423 -0.06 0.01 5.64x10-06
rs4445308 9 ELAVL2 269299 TUSC1 1581031
-0.06 0.01
5.67x10-06
rs4072605 9 ELAVL2 261787 TUSC1 1588543 0.06 0.01 5.82x10-06
rs70620
1 CFH CFH;CFHR3 CFH 11634 CFHR3 38932
0.07 0.02 6.42x10-06
Table 6.1 continued
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SNP Chromosome
In
reference
gene
Reference gene 60
kb away from SNP
Closest
reference
gene
Distance from
closest reference
gene (kb)
Second
closest
reference
gene
Distance from
second reference
gene (kb)
Beta
coefficient
(log fH)
Standard
error
P value
rs378283
1 CFHR3 CFH;CFHR3;CFHR1 CFHR3 4586 CFHR1 30574
0.07 0.02
6.47x10-06
rs11801630 1 CFH CFH;CFHR3 CFH 21455 CFHR3 51781 -0.07 0.02 6.48x10-06
rs389897 1 CFHR3 CFH;CFHR3;CFHR1 CFHR3 4442 CFHR1 30430
-0.07 0.02
6.50x10-06
rs643781 1 CFHR3 CFH;CFHR3;CFHR1 CFHR3 2692 CFHR1 28680 -0.07 0.02 6.72x10-06
rs370789 1 CFHR3 CFH;CFHR3;CFHR1 CFHR3 6632 CFHR1 32620
-0.07 0.02
6.73x10-06
rs445207 1 CFHR3 CFH;CFHR3;CFHR1 CFHR3 5816 CFH 33114 0.07 0.02 7.03x10-06
rs4246854 9 ELAVL2 256335 TUSC1 1593995
0.06 0.01
7.05x10-06
rs4977910 9 ELAVL2 256513 TUSC1 1593817 0.06 0.01 7.05x10-06
rs12380144 9 ELAVL2 257376 TUSC1 1592954
-0.06 0.01
7.18x10-06
rs1009187 1 CRB1 CRB1 CRB1 19512 ZBTB41 87247 -0.13 0.03 9.98x10-06
Table 6.1 continued
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6.2.2.1 Chromosome 1
Most SNPs identified in CFH/CFHR region cluster around CFH, CFHR1 and CFHR3, rather than
extending to any of the downstream CFHR related genes (Table 6.1). This represents the locus
that incorporates the deletion that has been shown to be protective for AMD [114], and it is
feasible that a deletion may alter circulating levels of fH. Although centred around these 3 genes,
there is an additional signal 1 Mb further downstream where 2 SNPs (rs3828022 and rs1009187;
(p= 5.02 X 10-06 and 9.98 x 10-06 respectively) in the CRB1 (Crumbs homologue 1) gene (Figure
6.3). CRB1 encodes a homologue of a gene first identified in Drosophila encoding the crumbs
protein which is one part of the molecular scaffold that controls the development of the eye,
particularly in determination of polarity of photoreceptor cells in the fruit fly. In humans the
homolog protein localises to the inner segment of photoreceptor cells. Mutations in this gene are
associated with a number of inherited retinal dystrophies, although the most severe being Leber’s
congenital amaurosis, which represents a clinically severe form of retinitis pigmentosa. This
region is not in LD with the CFH/ CFHR region, and has not been identified, as yet, as being
associated with AMD, even using the more recently published denser genome wide platforms [36,
37]. However unlike these GWAS which do identify other complement related genes (namely CFI,
CFB and C3) as being associated with AMD, no other complement related genes outside of the
CFH/ CFHR locus were identified by the recent GWAS as being associated with circulating fH
levels. Moreover no other inflammatory pathway genes were associated with fH levels.
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Figure 6.3 Regional association plot for SNPs in the CFH gene cluster for circulating fH
concentration. Most significant association is shown in purple and the colour of the remaining
SNP associations is based on the LD between these SNPs and the most associated SNP. The
number of SNPs typed in HapMap are shown in the topmost track, with the number of SNPs
directly genotyped/ imputed displayed in the track labelled plotted SNPs.
6.2.2.2 Chromosome 3
Of the loci that are outside of the CFH/ CFHR family and chromosome 1, the top signals of
association in order, included WNT5A (wingless-type MMTV integration site family, member 5A,
Figure 6.4), which belongs to the WNT gene family of structurally related genes, encoding
secreted signalling proteins. WNT5A has been identified in Xenopus to bind to the human
frizzled-5(hFz5) receptor, which mediates induction of cell polarity and migration, which may also
be the mechanism that mediates its role in tumour-genesis, although this is less well understood
(reviewed in [210]). The second closest gene to this marker is ERC2 (ELKS/RAB6
interacting/CAST family member) which is thought to be involved in the organisation of the
cellular cyto-matrix at active zones of nerve terminals which are involved in the regulation of
neurotransmitter release [211]. It has most recently been found to be associated with behaviour
associated with smoking cessation, in genome wide studies [212].
151
Figure 6.4 Regional association plot of signal in and surrounding WNT5a for circulating fH
concentration.
6.2.2.3 Chromosome 8
The next most significant marker was in the gene DLC1 (deleted in liver cancer) on chromosome
8, (Figure 6.5), encoding a GTPase-activating protein, and a member of the rho-GAP family,
which is important in regulation of small GTP binding proteins, essential in cellular signalling
pathways and regulating in particular processes which are involved in cytoskeletal changes[213].
In humans the most common disease association for DLC1 is cancer, having been identified as a
tumour suppressor gene, and is implicated in a number of common cancers (reviewed in [214]
being thought to mediate cancer growth by alteration in cytoskeletal function in cell migration.
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Figure 6.5 Regional association plot for DLC1 and circulating fH concentration.
Although both signals- WNT5A and DLC1 were single SNPs at this p value (10-6), they are
unlikely to be false positive findings given the signal of association extends to other SNPs with
higher p values (Figure 6.1).
6.2.2.4 Chromosome 9
Similarly markers in an intergenic region on chromosome 9p were not only well represented at
the p<0.00001 level but also extend to higher p values. (Figure 6.1). Chromosome 9p has, like
DLC1, been implicated in the development of a number of tumours, housing a number of putative
tumour suppressor genes. The region identified in this genome scan is downstream of the inter-
genic region on chromosome 9p that has previously been associated with CHD [215, 216] and
T2DM [217, 218], the signals for which themselves are in inter-genic regions, although closest to
cell cycle regulator genes CDKN2A and CDKN2B . In the current genome scan, the closest gene
to the most significant markers in the inter-genic region was ELAVL2 ((embryonic lethal,
abnormal vision, Drosophila)-like 2), (Figure 6.6). The encoded protein is essential to regulation
of transcription through RNA binding, playing a pivotal role in development of the fruit fly nervous
system. The human homolog Hel-N1 [219] is a member of family of proteins with similar functions
ascribed to it as in the fruit fly, that is mainly in post-transcriptional processing. Increased levels
ELAVL2 mRNA has been found in individuals with small cell lung cancer [220], although it has
been also implicated in other cancer types. The next closest gene to this region is TUSC 1
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(tumour suppressor candidate 1) which has also been implicated in lung tumourogenesis [221]
(Figure 6.6), although from the regional association plot, Figure 6.6, it is clear that the signal is
largely due to SNPs closest to ELAVL2, with TUSC1 being further downstream.
Figure 6.6 Regional association plot for locus on Chromosome 9 and circulating fH
concentration. Closest reference genes being ELAVL2 and further downstream TUSC1.
6.2.2.5 Chromosome 6
Of the other signals that only contain one SNP at this level of significance, although other SNPs
at higher p values follow, is PHACTR1 (phosphate and actin regulator 1), on chromosome 6,
which belongs to a family of 4 structurally related proteins thought to function as protein
phosphate 1 and actin regulators [222] with functionally diverse roles within the brain. Of note
markers in this locus have also been identified in a GWAS of early onset MI [223]. The closest
next gene to PHACTR1 as well as markers in intergenic regions with p values of <0.0001/
<0.0001, is TBC1D7 (TBC domain family member 7) (Figure 6.7). This gene belongs to family of
proteins that are thought to have a role in regulating cell growth and differentiation, and although
have not come up as hits in GWAS, proteins encoded by this gene are found to be expressed in
lung cancers using cDNA microarray experiments, where they are thought to confer growth
promoting activity of the tumour [224].
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Figure 6.7 Regional association scan for PHACTR1 and signal on chromosome 6 and
circulating fH concentration.
6.2.2.6 Chromosome 2
The final signal at this p-value comes from Grb14 (growth factor receptor-bound protein 14), on
chromosome 2 (Figure 6.8). This protein is a member of a family of structurally related multi
domain adapter proteins, which, as a family, have been shown to have diverse cellular functions,
and Grb14, in particular has been implicated in regulation of insulin receptor signalling [225]. The
next closest gene to Grb14, is COBLL1, which is a protein encoding gene thus far implicated in
cancer and thought to be of use in predicting survival of patients undergoing surgery for the
tumour of the pleural lining: mesothelioma [226].
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Figure 6.8 Regional association plot for signal in chromosome 2 and circulating fH
concentration.
6.3 Discussion
The findings described in this chapter are consistent with the hypotheses described at the outset
in that SNPs in the vicinity of CFH gene and extending the RCA cluster on chromosome 1q
encompassing CFHR1-5 acting in cis contribute to the variation in circulating fH. The associations
also provide further confirmation of the validity of the newly developed nephelometric assay for fH
described in chapter 4 whose development has allowed the conduct of a GWAS of the requisite
scale.
An important question which arises is whether the SNPs in this region associated with fH overlap
with those associated with the risk of AMD. An overlap of this type would provide strong evidence
that the associations of SNPs in this region with AMD risk are explained in whole or part by
alterations in circulating fH. This question is discussed in greater detail in the next chapter.
SNPs at a number other loci also showed associations with fH in this GWAS. These are also of
interest as they may provide insight into pathways involved in the determination of fH
concentration in the steady state. The association signals are all in regions which appear to play
some role in the regulation of cellular cytoskeletal structures and signalling. In general, proteins
encoded by the genes in which these signals are from, or the gene closest to these signals
appear to play a role in human cancers. The exception to this is the CRB1 locus, which is known
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to be associated with an inherited eye disease, although this signal has not been reported in
either the first generation of GWAS for AMD, or indeed the more recent GWAS which have
employed denser platforms with additional imputation to further refine signals. In these recent
AMD studies the notable successes were other regions of the complement cascade, including the
previously identified SNP in C3, SNPs in CFI and CFB. Apart from these, these two reports
largely focussed on SNPs in CETP, which contributes to the determination of circulating HDL-C
and LIPC which is associated with circulating triglycerides. In Chapter 5, determination of the
molecular epidemiology, and non-genetic correlates of fH highlighted numerous lipid markers as
being associated with circulating fH levels, moreover in Chapter 3, the rs1061170 genotype was
also associated with circulating triglyceride levels. Findings from this scan however do not provide
evidence of an association with any of the 90 or so loci known to be associated with the major
circulating lipids [227], which we may take to interpret that although fH is correlated with
circulating lipid associated particles, which may themselves be a risk for AMD, none of the lipid
associated genes contribute to determination of circulating concentrations of fH. The mechanism
of their association is therefore more likely to be at the protein level, which has already been
suggested by recent shot-gun proteomic studies, discussed previously [35].
The genome scan approach is useful in elucidating how circulating fH may be controlled.
However, it does not tell us what the mechanisms that govern the action of fH, which could be
important for disease mechanisms, not only in AMD but for other diseases with which fH protein
function and or concentration is thought to be altered. These pathways must still be elucidated by
mechanistic studies, using GWAS as a guiding tool. In this scan, the genetic determinants of
circulating fH were from genes that would not obviously be associated with inflammation, and
perhaps the interpretation is more challenging. This is in contrast to the recent finding of variants
in CFH being associated in a genome scan with the risk of meningitis [12]. This observation is
explained with greater ease as bacteria are known to use binding to fH as a way of avoiding
detection by the immune system, and thereby causing disease.
Other limitations of the genome wide approach are the absence of rare variants, which are not
well represented by whole genome arrays. Most variation will be common, and therefore
expected to be associated with a modest effect size (the exception of course being GWAS in
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AMD). However the contribution of rare variation has not really been elucidated to common traits
and disease, and may be worthy to capture as it is these variants which may offer potential
therapeutic targets, which will not only be useful for individuals with a given trait/ disease, but may
be useful in more general terms. The obvious example of this strategy is the use of lipid lowering
drugs which were targeted at those with familial hypercholesterolaemia or those at high absolute
CVD risk, but now that they are off patent, thus cheaper, and the benefits of lowering cholesterol
in the general population are known, statins are used more widely. The detection of rare variants
determining traits and disease will begin to emerge with sequencing projects, both small and
large scale- the 1000 genomes project being an example of such a resource. With sequence
information becoming available across a wide range of ethnic groups worldwide will give the area
more of a sense of the genetic regulation of traits and disease, the value of rare variants and the
contribution of private mutations.
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7 High resolution association analysis of the SNPs in the RCA cluster, fH
concentration and AMD risk
SNPs in the RCA cluster are associated with AMD risk. Although much of the focus has been on
rs1061170 encoding Y402H, many other SNPs in this region are associated with AMD. The
region of association encompasses SNPs spanning ~1Mb between KCNT2 and ZBTB41 (position
194844122 to 195389437) including complement factor H and 5 other complement factor H
related genes [36, 37]. In chapters 6, I identified SNPs within the same region as being
associated with circulating fH. A recent GWAS also identified SNPs in the vicinity of CFH that
were associated with risk of invasive meningococcal disease [12]. However there are several
unanswered questions regarding these associations which are addressed by work in this chapter:
1. Which SNPs in the RCA gene cluster are associated with a higher risk of AMD, and is the
association explained by rs1061170 encoding Y402H alone?
2. To what extent do SNPs associated with fH concentration (identified by GWAS in chapter
6) overlap with the SNPs associated with AMD risk
3. Is fH concentration itself associated with risk of AMD
Work in this chapter had the aim of 1) applying tagging SNPs as an efficient means of capturing
genetic variation in the CFH/ CFHR gene cluster; 2) imputing unobserved genotypes across the
whole 1Mb region in order to provide a more high resolution map of genotypes in this region
using a fine scale recombination map and densely genotyped references panels. Using these two
strategies I was able to identify if variants other than rs1061170 were associated with AMD risk
and circulating fH levels. A third and separate aim of this chapter was to establish the relationship
between circulating fH levels and AMD risk.
7.1 Methods
7.1.1 Studies
The analyses for single SNP associations were based on two studies of AMD (in which
measurement of fH concentration had also been made). The first was the EUREYE study which
was described previously in Chapter 2. Briefly this was a cross-sectional study investigating the
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prevalence and risk factors for AMD in 7 European countries. AMD was diagnosed based on
fundal photographs which were graded centrally using standardised protocols based on the
ICARMS grading scheme [94]. The second study was the Cambridge Eye Study, a case-control
study of unrelated individuals, over the age of 50, ascertained through hospital based ophthalmic
clinics, general practices, optometrists and charitable societies for people with visual impairments
in the East Anglian region. Where willing, spouses of identified cases were examined, and if
unaffected were used as controls and, if affected included as cases. Cases and controls were
examined by an ophthalmologist and all individuals completed a health and lifestyle questionnaire
modified from that used for the European Prospective Investigation of Cancer (EPIC). All
individuals had colour stereoscopic fundus photography of the macular region with grading
according to the ICARMS classification [94]. Grading took place at Moorfields Eye Hospital by two
independent ophthalmologists, with any discrepancy in grading being referred to a third
ophthalmologist for arbitration using additional information from medical records and any previous
fundal photographs and flourescin angiography where available. Individuals were included as
cases if they were confirmed to have GA or CNV in one or both eyes. Individuals with early AMD
were not included in the Cambridge study. Controls were similarly examined and included if they
had a normal macula or non-extensive small or intermediate drusen and minimal hypo- or hyper-
pigmentation. Individuals with inflammatory or other retino-vasuclar diseases were excluded.
7.1.2 SNP selection
For the EUREYE study SNPs were identified in the region encompassing CFH to CFHR5 that
maximised the variation across this region in European individuals, also known as a tagging SNP
approach (carried out by Dr Tina Shah, UCL). The approach utilises prior knowledge of the
linkage disequilibrium between SNPs catalogued by the Human HapMap. Two statistics can be
used to determine the association between SNPs, the first is D’ and the second is r2, the latter of
which is a correlation co-efficient, and calculated using D’, and is the more stringent of the two,
and therefore used in preference. Thresholds used in the selection of tagging SNPs were an r2 of
0.8 and a minor allele frequency (MAF) of >5%. Where possible the directly typed SNP panel was
enriched for non-synonymous SNPs as these may encode functional variation in the protein.
Tagging SNPs were further supplemented by SNPs that had been reported in the literature as
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being associated with AMD, where it was felt that these SNPs should be typed directly in order to
preserve consistency with previously reported findings. These included the rs1061170 variant as
well as the variant identified to tag the CNV in this region [228]. Tagging SNPs identified using
this approach were typed in the EUREYE case-control subset.
The Cambridge AMD study had previously genotyped a number of SNPs in this region, which had
been chosen and typed a priori by Professor Alan Wright (University of Edinburgh). SNPs were
chosen based on evidence in Professor Wright’s lab of a potential association with fH level. The
rs1061170 SNP in the Cambridge AMD study was typed and reported independently [154].
7.1.3 Measurement of fH
Circulating fH was measured in plasma samples from EUREYE (drawn in EDTA) and the
Cambridge study (drawn in Lithium Heparin) using the newly established nephelometric method
as described in Chapter 4. Previous analysis has indicated that the values of fH are equivalent in
plasma samples obtained with different anti-coagulants (Chapter 4).
7.1.4 Genotyping
Genotyping in the EUREYE study was carried out as described in Chapter 2, using KASPar
technology by KBiosciences. The rs1061170 SNP in the Cambridge AMD study was typed by Dr
Tiina Sepp using the ABI PRISM SNaPshot ddNTP Primer Extension Kit. Genotypes were called
using an automated allelic discrimination method using a 3100 Genetic Analyses (Applied
Biosystems). The remainder of the SNPs in the Cambridge AMD study were typed in Professor
Wright’s laboratory Taqman.
7.1.5 Imputation of untyped SNPs
Missing genotypes were imputed in the EUREYE study alone where there was a wider range of
typed SNPs across which imputation could be performed. Missing genotypes were imputed
against a European reference panel taken from the pilot release of the 1000 Genomes Project
and the HapMap project phase 3. Both reference panels which contain two different sets of SNPs
were incorporated into one imputation analysis using IMPUTE2 [229]. The 1000 Genome
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reference panel provides a wide coverage of SNPs, in that it contains many more SNPs than
available on the HapMap catalogue, although the latter provides deeper coverage of typed SNPs
as it contains a greater sampling of chromosomes from each represented population on the
catalogue. Combining these panels in a single imputation analysis therefore results in an
extensive coverage of the genome (using 1000 Genomes) and increased accuracy at a subset of
SNPs (using HapMap 3). Reference panels from chromosome 1 from HapMap and 1000
genomes were used, together with the recombination map from HapMap as provided on the
IMPUTE2 website (www.mathgen.stats.ox.ac.uk/impute/impute_v2). Genotypes were imputed for
a 1Mb region extending from CFH to CRB1, which encompassed signals from both the fH GWAS
described in Chapter 6 and the recently published AMD GWAS (Figure 7.1).
Quality control filters were applied at the stage of association testing of the imputed genotypes,
as software used for this stage (SNPTest version 2) takes into account genotype uncertainty.
Filters that are commonly applied are first exclusion of SNPs with MAF <1% and second filtering
is done on the basis of a metric which measures the degree of uncertainty around the imputed
genotype. In IMPUTE2 and SNPTEST v2 this metric is commonly referred to as “info”, which
usually takes a value from 0 to 1, and is a ratio of the observed to the complete information
available. There is no consensus on what value of a cut off should be used [230], although a
commonly used cut-off that is applied is 0.3, and this was used here. No cut off for MAF was
used, given imputing against 1000 Genomes may reveal some important hits which are rare (rare
variants are often thought to account for some of the dark matter of the genome [231]), although
an important caveat to this is that identification of any rare variants by such a method would need
to be replicated in another data set so as to ensure any finding is true rather than a false positive
association.
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Figure 7.1 Imputation of SNPs in the CFH gene cluster. SNPs across the CFH/ CFHR locus
extending down to the CRB locus were imputed, based on the genome wide findings described in
Chapter 5, where the signal for fH extends to CRB, the LD plot (based on r2 values) is also
shown, and were taken from HapMap.
7.1.6 Statistical analysis
7.1.6.1 Single SNP analysis
For both studies, genotyping call rates were calculated, and a threshold of 90% was set for
inclusion of SNPs to be analysed. Departure from HWE was tested in controls only using a 2
test. SNPs that did not meet these quality control criteria in either study were excluded from
further analyses. Association analyses were carried out in two stages: the first was based on the
genotyped SNPs in both studies, and the second used imputed genotypes in the EUREYE
dataset alone. For the first stage of analysis, using both data sets, association analyses were
carried out in three stages:
163
(i) Genotype-AMD association
(ii) Genotype-circulating-fH association
(iii) Association of fH with AMD
Analyses were carried out separately for Cambridge and EUREYE, and consistency was checked
across both studies.
7.1.6.1.1 Genotype AMD association
For association analyses each SNP from both EUREYE and Cambridge AMD case-control data
sets that satisfied the QC criteria were tested for association with AMD. Cases in the Cambridge
AMD study were all late AMD, although information on both early and late AMD cases was
available in EUREYE, however results presented in this section are limited to late AMD, given this
is the clinically more significant form of the disease and to ensure comparability of results across
the two studies. SNPs were re-coded as 0, representing homozygote individuals for the common
allele, 1 representing heterozygotes and 2 representing homozygotes for the minor allele. Odds
ratios with 95% CI’s for association of SNPs with late AMD were calculated using logistic
regression on an additive (per allele) scale where the reference is the common rather than the
non-risk allele. Adjustments were made for multiple testing using the Bonferroni method.
7.1.6.1.2 Genotype-fH association
SNPs were then tested for association with circulating fH level on an additive scale, using linear
regression, reporting beta coefficients and 95% CI’s. Coding of SNPs was consistent with that
described above, again correcting for multiple testing using the Bonferroni correction.
For SNPs where an association with AMD has been previously reported the genotype and fH
association was probed in a little more detail. Box plots indicating median, 25th and 75th centile
values of fH levels were plotted for each SNP according to genotype group and association
tested using ANOVA.
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7.1.6.1.3 Association of fH concentration with AMD risk
Association of fH levels and AMD was performed using logistic regression models, using
standardised log fH as a predictor variable, so as to express the odds ratio per one standard
deviation of a change in log fH. Consistent with the analyses described above unadjusted
analyses are presented.
SNPs that were significant in the above analyses were then entered into a forward fitting logistic
(for late AMD as an outcome) or linear (for fH) stepwise model, with a p value of 0.05 set as the
cut off for entry into the model, to test the statistical independence of association signals.
7.1.6.2 Imputation analysis
For the second stage of analysis, EUREYE alone was used to infer missing genotypes across a 1
Mb region (Figure 7.1) using reference panels from HapMap and 1000 Genomes, as described.
Associations for this region were then tested using the SNPTEST Version 2 software
(www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html), using a frequentist, additive model,
where alleles are automatically coded 0 and 1, and thus and additive test estimates the increase
in log-odds that can be attributed to the allele coded 1. Where a model cannot be fitted to the
data the p-value is set to -1.Genotype uncertainty was accounted for by using the “method –
expected” option, using expected genotype counts (also known as genotype dosages). Filtering
for uncertainly around genotypes was carried out using a threshold value of 0.3, and no cut off for
MAF was used.
The EUREYE study has information on both early and late disease and therefore imputation
analyses was carried out with (i) all AMD- encompassing early and late as one outcome (ii) early
AMD only (iii) late AMD only and (iv) log fH. Further conditional analyses on the rs1061170 SNP
were performed for all above outcomes.
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7.2 Results
7.2.1 Baseline Characteristics of studies
Baseline characteristics for the EUREYE study are given in Table 2.2 and for the Cambridge Eye
study are given in the publication pertaining to the study [154] indicating no differences between
characteristics of cases and controls apart from disease status.
7.2.2 Identification of tag SNPs and genotyping quality
SNPs that were identified using the tagging SNP approach which were subsequently directly
typed in both studies are indicated in Figure 7.2 and Figure 7.3 show the LD plot for both the
EUREYE and Cambridge AMD datasets, indicating that there is a low level of LD between the
SNPs typed, which is what would be expected using such an approach to capture haplotype
diversity across the region. Quality control statistics, including call rates, HWE and MAF of SNPs
typed in these studies is given in Table 7.1
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Figure 7.2 SNPs directly typed in EUREYE and Cambridge AMD study
SNPs typed in
Cambridge
AMD study
(Ensemble
annotations)
SNPs typed
in EUREYE
(Ensemble
annotations)
Genes in
Region/
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Figure 7.3 LD (r2) between SNPs typed in Cambridge AMD and EUREYE studies. These
show the success of the tagging approach in that the LD is low between chosen SNPs, which
enables variation across the haplotype to be captured. LD plots were created using Haploview
[232].
SNPs typed in
EUREYE
SNPs typed in
Cambridge
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Table 7.1 Quality Control statistics for SNPs directly typed in EUREYE and the Cambridge
AMD studies
Marker Chromosome1 position EUREYE EUREYE/ controls Cambridge Cambridge/ controls
Call
rate HWE chi
2 HWE
p Call rate
HWE
chi2
HWE
p
rs800292 194908856 88% 4.24 0.40 94% 0.03 0.86
rs1329423 194913010 90% 0.59 0.44
rs1061170 194925860 90% 0.93 0.33 99% 4.55 0.03
rs10922096 194929082 91% 0.93 0.33
rs1048663 194941605 95% 0.03 0.85
rs2274700 194949570 95% 2.29 0.13
rs6677604 194953541 91% 1.55 0.21 95% 0.02 0.89
rs3753396 194962365 90% 0.09 0.76
rs419137 194963498 91% 5.49 0.02
rs1410996 194963556 91% 0.05 0.83
rs2284664 194969148 91% 0.06 0.81
rs1329428 194969433 1.85 0.17
rs412852 194970330 1.51 0.22
rs1065489 194976397 91% 0.00 0.97
rs11582939 194976780 95% 0.09 0.77
rs1066420 194987678 96% 9.02 0.00
rs377298 195025164 87% 71.73 0.00
rs432007 195059087 90% 119.16 0.00
rs6657442 195104683 91% 0.16 0.69
rs7517126 195106895 92% 0.86 0.35 93% 0.33 0.56
rs12240143 195111640 90% 0.01 0.93
rs12404243 195129192 91% 3.43 0.06
rs1409153 195146628 88% 2.10 0.15
rs10494745 195154080 91% 0.01 0.93
rs2986127 195171294 83% 0.71 0.40
rs388338 195171556 22% 58.23 0.00
rs1853881 195182368 91% 0.06 0.81
rs6669207 195206465 91% 0.18 0.67
rs6667243 195208116 91% 0.90 0.34
rs9427940 195209976 91% 0.55 0.46
rs3748557 195213492 91% 1.49 0.22
rs1759016 195219121 100% 51.87 0.00
rs10922152 195229629 91% 0.22 0.64
rs12116643 195239806 90% 0.90 0.34
Blue: SNPs typed in EUREYE and Cambridge; Red: SNPs typed in Cambridge only and Black: SNPs typed in EUREYE only
Based on the statistics presented in Table 7.1, SNPs with a call rate of below 90% and a HWE p
value <0.05 were excluded from subsequent single SNP analyses. These SNPs included
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rs800292, rs377298, rs1409153, rs2986127, rs388338, rs1065489, rs12240143 and rs10494745
in the EUREYE study. All SNPs in the Cambridge AMD study had call rates above 90% although
rs1066420 was excluded on the basis of deviation from HWE. The remaining SNPs were carried
forward to the subsequent analyses.
7.2.3 Analysis using directly typed SNPs
7.2.3.1 Genotype-AMD association
Single marker analyses from EUREYE and Cambridge AMD study re-affirmed the strong
association of late AMD with the rs1061170 SNP encoding Y402H, with an unadjusted OR of
2.30 95% CI (1.94, 2.73) in EUREYE and similarly an odds of 2.55 95% CI (2.44, 2.66) in the
Cambridge data set. In addition a number of other SNPs in this region are significant for their
association with late AMD. In EUREYE these include SNPs in CFH rs10922096; a coding variant,
rs6677604; and rs1410996, rs2284664; all intronic variants, and of note rs1410996 has
previously been shown to confer AMD risk that is independent of rs1061170 [233]; SNPs in
CFHR1 included rs432007, and intergenic SNPs rs6657442, rs7517126, rs6667243, rs9427940
(between CFHR4 and CFHR5) and SNPs in CFHR2 included rs1853881 (Table 7.2). Of these
SNPs, rs6677604 was also present and significant for its association with late AMD in the
Cambridge AMD dataset (OR 0.37 95%CI 0.34, 0.76), although rs7517126 was only marginally
significant in the Cambridge AMD study. An additional SNP rs800292 which was excluded from
the EUREYE analyses because of QC, was significant in Cambridge AMD (OR 0.38 95% CI
(0.37, 0.39)), and has been previously reported for its association with AMD, of note tagging a
protective haplotype [233].
SNPs which were significant at this stage for each study were then taken forward into a
regression model to test the statistical independence of these signals. For EUREYE, out of the 11
significant SNPs only 2 were retained within the model with p values of <0.05. These were
rs1061170 (the Y402H SNP) and rs1410996, an intronic CFH SNP. When adjusting for age,
SNPs rs6677604, rs7517126 and rs1853881 were no longer significantly associated with late
AMD and taking the remaining 7 SNPs forward into an age adjusted stepwise analysis (using
p<0.05 as a cut off), again only rs1061170 and rs1410996 were retained.
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Similarly for the Cambridge AMD data set rs800292, rs1061170, rs1048663, rs1329428,
rs412852 were all significant in the initial analysis, after correcting for multiple comparisons.
Taking these forward into a stepwise regression model, again the rs1061170 SNP was retained
and in addition, the rs1329428 an intronic SNP in CFH was retained, suggesting that the signal
for late AMD is narrowed down to the CFH gene itself.
A further exploratory analysis of early AMD in EUREYE only show that only rs1061170 and
rs1410996 were significant at the first stage of SNP by SNP analyses, prior to proceeding to a
step-wise regression analysis.
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Table 7.2 Association of SNPs in the RCA cluster with late AMD and log fH in the Cambridge AMD and EUREYE case-control datasets. Both corrected and
uncorrected p values are shown.
SNP EUREYE- AMD
AMD
association
P value
Corrected P
value
 Coefficient for
association with
fH (95% CI)
Uncorrected
lfH P value
Corrected
P value
Cambridge
AMD
AMD
association
P value
Corrected P
value
 Coefficient for
association with
lfH (95% CI)
Uncorrected
lfH P value
Corrected P
value
rs800292 Excluded 0.38(0.37,0.39) 8.53×10-17 6.83×10-16 -0.02(-0.05,0.01) 0.19 1.0
rs1329423 0.89(0.7,1.13) 0.34 0.68 -0.01(-0.05,0.03) 0.66 1.0
rs1061170 2.3(1.94,2.73) 3.10×10-21 6.20×10-20 -0.01(-0.06,0.04) 0.64 1.0 2.55(2.44,2.66) 1.17×10-23 9.38×10-23 0.02(0,0.05) 4.80×10-2 0.38
rs10922096 0.58(0.47,0.71) 3.00×10-7 6.00×10-6 -0.03(-0.07,0.02) 0.19 1.0
rs1048663 0.37(0.28,0.49) 8.00×10-12 6.40×10-11 0.01(-0.02,0.04) 0.45 1.0
rs2274700 Excluded
rs6677604 0.62(0.5,0.77) 1.20×10-5 2.40×10-4 0.07(0.03,0.12) 7.50×10-3 0.15 0.51(0.34,0.76) 1.00×10-3 8.00×10-3 0.04(0,0.07) 5.30×10-2 0.42
rs3753396 0.87(0.6,1.26) 4.50×10-1 0.90 -0.04(-0.11,0.02) 0.16 1.0
rs419137 1.32(0.97,1.8) 8.20×10-2 0.16 0.04(-0.01,0.08) 0.09 1.0
rs1410996 0.43(0.33,0.57) 8.60×10-10 1.72×10-8 0.02(-0.03,0.07) 0.33 1.0
rs2284664 0.46(0.34,0.62) 2.80×10-7 5.60×10-6 -0.04(-0.07,0) 0.05 1.0
rs1329428 0.37(0.27,0.5) 8.00×10-11 6.40×10-10 0.01(-0.01,0.04) 0.31 1.0
rs412852 2.47(2.19,2.79) 8.60×10-49 6.88×10-48 0.03(0.01,0.06) 7.50×10-3 6.00×10-2
rs1065489 Excluded
rs11582939 0.91(0.74,1.12) 0.39 1.0 -0.08(-0.11,-0.05) 4.00×10-6 3.20×10-5
rs1066420 Excluded
rs377298 Excluded
rs432007 0.54(0.45,0.65) 7.80×10-10 1.56×10-9 -0.02(-0.06,0.02) 0.31 1.0
rs6657442 0.49(0.38,0.65) 2.60×10-7 5.20E-06 -0.04(-0.07,0) 0.03 0.6
rs7517126 0.56(0.48,0.66) 6.80×10-12 1.36×10-10 0.07(0.01,0.12) 2.10×10-2 0.42 0.61(0.35,1.06) 7.90×10-2 0.63 0.04(0,0.08) 6.10×10-2 0.49
rs12240143 Excluded
rs12404243 0.82(0.64,1.05) 0.01 1.0 0(-0.06,0.05) 0.094 0.19
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SNP EUREYE- AMD
AMD
association
P value
Corrected P
value
 Coefficient for
association with
fH (95% CI)
Uncorrected
lfH P value
Corrected
P value
Cambridge
AMD
AMD
association
P value
Corrected P
value
 Coefficient for
association with
lfH (95% CI)
Uncorrected
lfH P value
Corrected P
value
rs1409153 Excluded
rs10494745 Excluded
rs2986127 Excluded
rs388338 Excluded
rs1853881 1.59(1.3,1.93) 5.40×10-6 1.08×10-4 -0.01(-0.07,0.05) 0.69 1.0
rs6669207 0.79(0.59,1.06) 0.012 1.0 0(-0.05,0.05) 0.91 1.0
rs6667243 0.46(0.39,0.54) 4.40×10-20 8.80×10-19 -0.02(-0.06,0.03) 0.39 1.0
rs9427940 0.59(0.48,0.72) 4.80×10-7 9.60×10-6 0.06(0.02,0.1) 0.011 0.2
rs3748557 0.75(0.52,1.1) 0.014 1.0 -0.01(-0.08,0.05) 0.61 1.0
rs1759016 0.72(0.48,1.07) 0.01 1.0 0.01(-0.02,0.04) 0.57 1.0
rs10922152 0.55(0.46,0.65) 3.30×10-11 6.60×10-10 -0.01(-0.05,0.03) 0.46 1.0
rs12116643 0.44(0.31,0.64) 1.70×10-5 3.40×10-4 -0.04(-0.09,0) 0.062 1.0
Blue: SNPs typed in EUREYE and Cambridge, Red: SNPs typed in Cambridge only and Black: SNPs typed in EUREYE only. SNPs that have been excluded in these analyses because they have not passed QC criteria are indicated
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7.2.3.2 Genotype-fH association
The same SNPs that were tested for association with AMD were then tested for their
association with circulating fH levels which had been measured in both studies. Log
transformed values of fH were used for analyses, given skewed distributions of fH in both
studies which were normalised with this transformation. After adjusting the p values for multiple
testing, none of the SNPs associated with late AMD were significantly associated with fH in the
EUREYE dataset Table 7.2. In the Cambridge AMD case-control study however 2 SNPs were
associated with fH, rs10922096 ( β coefficient of log fH -0.09 95% CI (-0.13, -0.06) p value 
1.04×10-6) and rs11582939 (β coefficient of log fH -0.08 95% CI (-0.11, -0.05) p value 4×10-6),
and one marginally associated with fH levels, rs412852 (β coefficient of log fH 0.03 95% CI 
(0.01, 0.06) p value 7.5×10-3). Of these, only rs412852 was the only SNP also associated with
AMD (OR 2.47, 95% CI (2.19, 2.79) and p value 8.6×10-49). The results for all SNPs analysed
for both EUREYE and Cambridge AMD study are given in Table 7.2. In order to compare the
SNP effects on AMD and fH together, SNPs were re-coded to compare the risk versus non risk
genotype, and OR’s were plotted against  coefficients for effect on log fH (Figure 7.4)
SNPs that had previously been reported as having an association with AMD were probed a little
further in terms of their fH associations per genotype group. Even though the above analyses
show no or marginal associations between SNPs and fH, interrogating individual SNP
associations with fH level may give an indication of a trend in change of levels, which may in
itself be important and borne out by replication of any findings in other studies with both
genotypes and fH measures. SNPs selected, based on previous publications [114, 233, 234]
were rs800292, rs1061170 (Y402H), rs3753396 and rs1410996, which were all genotyped in
EUREYE, although out of these, genotypes for the rs1061170 and rs800292 were only available
in the Cambridge AMD study.
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Figure 7.4 Scatter plot of OR for late AMD and beta coefficient for the SNP effect on log
fH. Analysis indicates per allele estimates, SNPs have been re-coded so to compare the risk
verses the non risk genotypes.
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Figure 7.5 SNPs previously reported for association with AMD and their association with
fH
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7.2.3.3 Circulating fH-AMD association
Circulating levels of fH were not associated with late AMD in either EUREYE or the Cambridge
Eye study. There was no significant difference in fH levels between cases of late AMD and
controls (Table 7.3 and 7.4). Odds ratios were expressed as one standard deviation increase in
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log fH. Unadjusted odds in late AMD in EUREYE were 0.87 95% CI (0.70, 1.08), and in
Cambridge were 1.08 95% CI (0.92, 1.26).
Table 7.3 Association of fH with late AMD in EUREYE
EUREYE Controls N=568 Late AMD Cases N=124 OR* (95% CI) P value
fH** 231.85 (93.06) 218.10 (95.33) 0.87 (0.70, 1.08) 0.20
Table 7.4 Association of fH with late AMD in the Cambridge AMD study
CAMBRIDGE Controls N=264 Late AMD Cases N=378 OR* (95% CI) P value
fH** 284.68 (68.12) 289.65 (65.25) 1.08 (0.92, 1.26) 0.35
*Odds for a 1 SD increase in log fH, ** log transformed data with approximate SD’s.
Exploratory unadjusted analysis in the EUREYE data set showed no association of fH with early
AMD either.
7.2.4 Imputation and association of imputed SNPs with fH and AMD in EUREYE
Imputation was specified for a ~1Mb region from KCNT2 to DENND1B, a region which
incorporates CFH and the CFHRs (Figure 7.1). This region in addition incorporates the CRB1
gene which although not a complement related protein, was found to be associated with fH
levels in Chapter 6. Samples used from EUREYE are given in Table 7.1, which were used to
infer genotypes. SNPs with initial low call rates, <80% were excluded (rs388338). Following
imputation 2764 SNPs were available, from which a further 867 were excluded by QC criteria,
leaving 1897 SNPs across this 1Mb region available to test for association. The imputation
results are summarised in Figure 7.5 and Tables 7.5-7.8. In the tables, the top 25 most
significant SNPs are given, and if the rs1061170 SNP is not in this list it is indicated as an
addition.
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Figure 7.6 Association of typed and imputed SNPs in the CFH region with AMD and fH
concentration. The region of CFH and CFHR’s is indicated. The –log p values for the
association are shown of directly typed SNPs and AMD (closed green circles), and imputed
SNPs with any AMD (open dark blue circles), late AMD (open mid blue circles), early AMD open
light blue circles and log fH (open red circles).
All AMD
Late AMD
Early AMD
Log fH
Genotyped SNPs
0
5
10
15
20
25
194600000 194800000 195000000 195200000 195400000 195600000 195800000
Base pair position on Chromosome 1
M
in
us
Lo
g
P
va
lu
es
CFH/CFHR genes
Although results are shown for any AMD (all, early and late), late AMD encompassing GA and
CNV is thought to represent the most unequivocal AMD phenotype and account for the most
sight threatening forms of disease. Analysis of the association plot shows that signals for late
AMD span the whole CFH/ CFHR cluster, and extend further down to include CRB1 which was
identified in the fH GWAS, and has role in the developing retina. However further extension
beyond this region is not excluded as imputation was limited to this area. However recent
GWAS did not report findings of further extension of this signal extending into other RCA
associated genes in addition to the CFH/ CFHR cluster. Tables 7.5-7.8 outline the 25 top
ranking signals for these associations. For late AMD, these are largely intergenic SNPs
although analysis of signals lower down to this are largely CFH SNPs (Appendix 2).
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Table 7.5 Association of imputed SNPs with any AMD
Rank rs-ID BP Position P value Gene
Predicted
function of SNP
1 rs506317 194983776 1.40x10-08 CFH 3downstream
2 rs10922097 194931105 1.60x10-08 CFH intronic
3 rs1089033 194933416 1.60x10-08 CFH intronic
4 1-194938293 194938293 1.90x10-08
5 rs9970075 194940053 2.50x10-08 CFH intronic
6 rs1061170 194925860 2.50x10-08 CFH coding
7 rs9970784 194940425 2.60x10-08 CFH intronic
8 rs402991 194942726 2.60x10-08 CFH intronic
9 rs6664705 194944465 2.60x10-08 CFH intronic
10 rs1887973 194941802 2.60x10-08 CFH intronic
11 rs203685 194944568 2.60x10-08 CFH intronic
12 rs399469 194942728 2.60x10-08 CFH intronic
13 rs203677 194949989 2.70x10-08 CFH intronic
14 rs203680 194947998 2.70x10-08 CFH intronic
15 rs203683 194945055 2.70x10-08 CFH intronic
16 rs203679 194949141 2.70x10-08 CFH intronic
17 rs7522681 194945228 2.70x10-08 CFH intronic
18 rs203674 194951248 2.70x10-08 CFH intronic
19 rs374896 194959001 2.90x10-08 CFH intronic
20 rs403846 194963360 2.90x10-08 CFH intronic
21 rs381974 194959295 2.90x10-08 CFH intronic
22 rs393955 194959093 2.90x10-08 CFH intronic
23 rs2860102 194934942 2.90x10-08 CFH intronic
24 rs203672 194955685 2.90x10-08 CFH intronic
25 rs456761 195078019 3.00x10-08
Intergenic
(CFH and
CFR3)
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Table 7.6 Association of imputed SNPs with early AMD
Rank rs-ID BP Position P value Gene
Predicted function
of SNP
1 rs203687 194940893 4.70x10-06 CFH intronic
2 rs10922097 194931105 6.60x10-06 CFH intronic
3 rs1089033 194933416 6.80x10-06 CFH intronic
4 rs506317 194983776 7.60x10-06 CFH 3downstream
5 1-194938293 194938293 1.00x10-05 CFH
6 rs10733086 194943558 1.2x10-05 CFH intronic
7 rs1410997 194943786 1.2x10-05 CFH intronic
8 rs2019724 194941540 1.2x10-05 CFH intronic
9 rs6428357 194942194 1.2x10-05 CFH intronic
10 rs9970075 194940053 1.2x10-05 CFH intronic
11 rs1831282 194940616 1.3x10-05 CFH intronic
12 rs1887973 194941802 1.3x10-05 CFH intronic
13 rs203674 194951248 1.3x10-05 CFH intronic
14 rs203677 194949989 1.3x10-05 CFH intronic
15 rs203679 194949141 1.3x10-05 CFH intronic
16 rs203680 194947998 1.3x10-05 CFH intronic
17 rs203683 194945055 1.3x10-05 CFH intronic
18 rs203685 194944568 1.3x10-05 CFH intronic
19 rs379489 194960074 1.3x10-05 CFH intronic
20 rs399469 194942728 1.3x10-05 CFH intronic
21 rs402991 194942726 1.3x10-05 CFH intronic
22 rs6664705 194944465 1.3x10-05 CFH intronic
23 rs7522681 194945228 1.3x10-05 CFH intronic
24 rs9970784 194940425 1.3x10-05 CFH intronic
25 1-195081157 195081157 1.4x10-05
Intergenic
(CFHR1-3)
100 rs1061170 194925860 2.5x10-05 CFH Coding
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Table 7.7 Association of imputed SNPs with late AMD
Rank rs-ID BP Position P value Gene
Predicted function
of SNP
1 rs410895 195039969 6.20x10-11
Intergenic
(CFHR1-3)
2 rs6699120 195173543 6.20x10-11
Intergenic
(CFHR4-2)
3 rs570965 195172614 7.00x10-11
Intergenic
(CFHR4-2)
4 rs2878690 195160176 7.10x10-11
Intergenic
(CFHR4-2)
5 rs4428917 195162983 7.10x10-11
Intergenic
(CFHR4-2)
6 rs1359594 195194051 8.70x10-11 CFHR2 intronic
7 rs2026547 195194414 8.70x10-11 CFHR2 intronic
8 rs1853883 195148223 8.80x10-11 CFHR4 intronic
9 1-195079152 195079152 1.10x10-10
Intergenic
(CFH-CFH3)
10 rs57720283 195076226 1.10x10-10
Intergenic
(CFH-CFH3)
11 rs6695525 195112144 1.20x10-10
LOC100289145
(CFHR1-4)
12 rs1963606 195089476 1.80x10-10
LOC100289145
(CFHR1-4)
13 rs1963607 195089582 1.80x10-10
LOC100289145
(CFHR1-4)
14 rs10754206 195087547 1.90x10-10
LOC100289145
(CFHR1-4)
15 rs10922142 195087731 1.90x10-10
LOC100289145
(CFHR1-4)
16 rs6665824 195086857 1.90x10-10
LOC100289145
(CFHR1-4)
17 1-195081157 195081157 2.00x10-10
LOC100289145
(CFHR1-4)
18 1-195081164 195081164 2.00x10-10
LOC100289145
(CFHR1-4)
19 1-195082766 195082766 2.00x10-10
LOC100289145
(between
CFHR1-4)
20 rs10922140 195085116 2.00x10-10
LOC100289145
(CFHR1-4)
21 rs1738740 195075263 2.00x10-10
Intergenic
(CHFR1-4)
22 rs412967 195080339 2.00x10-10
Intergenic
(CHFR1-4)
23 rs455199 195077757 2.00x10-10
Intergenic
(between CFH
and CFR3)
24 rs456761 195078019 2.00x10-10
Intergenic
(CFH and
CFR3)
25 rs61822193 195081192 2.00x10-10
Intergenic
(CFH and
CFR3)
32 rs1061170 194925860 9.8x10-10 CFH coding
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Table 7.8 Association of imputed SNPs with log fH
Rank rs-ID BP Position P value Gene
Predicted function
of SNP
1 rs6677604 194953541 1.65x10-04 CFH intronic
2 1-194992562 194992562 1.92x10-04 CFH
3 1-194993006 194993006 1.93x10-04 CFH
4 rs12026252 195447943 2.06x10-04
Intergenic
(between
ZBTB41-
CRB1)
5 rs10801598 195450279 2.06x10-04
Intergenic
(between
ZBTB41-
CRB1)
6 rs1577802 195468419 2.07x10-04
Intergenic
(between
ZBTB41-
CRB1)
7 rs4915393 195444410 2.06x10-04
Intergenic
(between
ZBTB41-
CRB1)
8 rs7547972 195442782 2.08x10-04
Intergenic
(between
ZBTB41-
CRB1)
9 rs10801600 195483589 2.79x10-04
Intergenic
(between
ZBTB41-
CRB1)
10 rs2064456 194971066 3.05x10-04 CFH intronic
11 rs4915440 195498434 3.26x10-04
Intergenic
(between
ZBTB41-
CRB1)
12 rs10801597 195441837 3.32x10-04
Intergenic
(between
ZBTB41-
CRB1)
13 1-194995616 194995616 4.01x10-04 CFH
14 rs16840522 194977539 4.49x10-04 CFH intronic
15 rs12022402 195504560 5.28x10-04 CRB1 intronic
16 rs7548481 195514437 5.28x10-04 CRB1 intronic
17 rs1337170 195535116 5.31x10-04 CRB1 intronic
18 rs7418217 195538871 5.33x10-04 CRB1 intronic
19 rs6689009 194965086 5.51x10-04 CFH intronic
20 rs6677460 194951198 5.56x10-04 CFH intronic
21 rs2300429 194941979 5.58x10-04 CFH intronic
22 rs33915960 194943336 5.58x10-04 CFH intronic
23 rs35617250 194946305 5.59x10-04 CFH intronic
24 rs12134598 194947624 5.59x10-04 CFH intronic
25 1-195003848 195003848 5.64x10-04 CFH
1405 rs1061170 194925860 0.58 CFH coding
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Further conditioning analysis on rs1061170 for late AMD data did not change the top ranking
signals, the position of some of these changed in the ranking order although no new signals
were found with conditioning analysis.
7.3 Discussion
In this chapter I have re-affirmed the signal from the most replicated rs1061170 SNP with late
AMD in the EUREYE and Cambridge eye studies. In addition to this SNP, I have shown that the
signal is not confined to rs1061170 but spans CFH and also includes CFHR genes. Imputation
analysis demonstrates that the extension of this signal could be up to 1Mb downstream of the
CFH/ CFHR cluster. Analysis conditioning on rs1061170 in addition did not yield a signal that
was different to the unconditioned analysis. In so doing however I was not able to refine the
signal for AMD in itself, but rather shown that the region of association is broad, and extends 1
Mb downstream of the CFH/ CFHR cluster. The recent AMD GWAS [36] which has greater
power (2157 cases and 1150 controls) which used a denser SNP array in comparison with the
first of the AMD GWAS, and in addition imputed against HapMap resulting in the study of ~2.5
million SNPs, also shows that although the region of association is greatest for the CFH gene,
the signal is broader, extending both upstream and downstream (Figure 7.6).
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Figure 7.7 Regional association plot for the CFH region from recent AMD GWAS, taken
from Chen et al, PNAS, 2010 [36]
The association of other regions of the genome which are related to complement regulation and
in particular the alternative pathway (CFB, CFI, C3) were also demonstrated in this GWAS, a
finding not reported in the initial AMD GWAS (Figure 7.7), supporting the view that AMD is likely
to result from multiple disease associated alleles at more than one locus. Although this may be
the case, the alternative complement pathway is by far the strongest pathway signal arising
from the genome scan which poses the important question of whether variation in these genes
cause alternations in the cognate protein as the mechanism by which risk is increased.
However there was a lack of overlap between the disease-causing SNPs identified in this
chapter and those that were shown to be associated with fH levels in Chapter 6. One reason
for this could be that the AMD signal is dependent on fH function rather than on fH
concentration. Given the complement pathway is an amplification cascade, it may be that small
changes in concentration may have large functional effects which would be missed by just
measuring fH levels. However there are currently no scalable functional activity assays of the
alternative pathway in general and of fH in particular and therefore this remains a hypothesis
that still needs to be tested. Another reason which has already been touched upon in prior
chapters is local synthesis of fH may account for local retinal effects and therefore circulating
levels of fH may be a poor indicator of local activity or function.
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Figure 7.8 Manhattan plot from the updated AMD GWAS. Apart from the SNPs at the
ARMS2 locus, whose function is not completely understood, the loci identified contain genes in
the complement pathway, and also implicated are genes in the regulation of circulating lipids.
This figure is taken from Chen et al, PNAS, 2010 [36]
Data emerging from the area of renal disease however appears to suggest that SNPs in CFH
do contribute to alterations in the circulating pool of fH, in keeping with finding from the original
linkage studies which provided evidence for a QTL at the RCA cluster [134]. By developing
antibodies that specifically detect either the Y402 or the H402 protein product, Hakobyan et al
[203, 235] have shown what the contribution of each allele to the circulating fH pool is by
heterozygotes, which has aided in the identification of novel mutations in aHUS [235]. However
another important finding demonstrated by the latter study which is pertinent to the discussion
here, is that on investigating a pedigree of aHUS, the index case, a rs1061170 heterozygote,
had normal levels of Y402 although low levels of H402, that is they had a low expression allele.
This individual also carried another common mutation associated with aHUS (R1210C) also in a
heterozygote state. However siblings with this mutation did not develop aHUS and others who
were also rs1061170 heterozygote were found to have normal levels of H402. Although a
genetic basis of this difference and the cause of the low expression of H402 in the index case
was not identified, it was shown that this individual had a 5 fold higher than expected level of
FHL-1, suggesting that a mutation which disrupts alternative splicing of fH could be responsible.
This is an important consideration in the interpretation of the results presented here given the
shared epitopes between fH, FHL-1 and the FHR proteins. The commercial antibody used to
develop the assay discussed in Chapter 3 is a polyclonal antibody, and may well recognise
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shared epitopes between fH and FHL-1 as well as the FHR’s. Therefore the association or lack
thereof of fH with AMD in the data presented here could be because the signal is noisy, and
other proteins are being measured. On the other hand if the epitopes which are recognised by
the antibody are limited to fH specific regions, this would indicate that it may be the alternatively
spliced form of the protein, FHL-1 or FHR proteins are linked with AMD rather than fH itself. This
may be an explanation as to why no overlap is seen between SNPs identified in the fH GWAS
(Chapter 6) and the SNPs identified through imputation as well as those directly genotyped for
association with AMD in this Chapter. It may also be an explanation of why the signal for the
genotype- AMD signal in this and other studies is very compelling, and in this situation the
expectation would be that the signal from the encoded protein is just as strong if not stronger,
however this is not the case.
The lack of overlap between fH and AMD SNPs is however in contrast to the overlap that is
seen for the fH GWAS SNPs (Chapter 6) and findings from the recent GWAS in meningococcal
disease [12]. Four of the top ranking SNPs in this study (Figure 7.8) have also been identified
the GWAS presented in Chapter 6 (Table 6.1) with the remaining SNPs also appearing as high
ranking signals in the fH GWAS. This and a previous report by the same group of a CFH
promoter SNP implicated in susceptibility to meningococcal disease [236] and altering levels of
circulating fH lends further support to the initial hypothesis that changes in levels of the protein
are likely to mediate disease, however as already mentioned bearing in mind the amplification
nature of the complement cascade these changes may well be small. It remains to be
investigated as to what the changes in fH levels are in these individuals with meningococcal
disease compared to controls.
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Figure 7.9 Associations of SNPs in the CFH region with meningococcal disease, taken
from Davila S et al [12]. Amongst the top ranking signals in this study SNPs rs426736,
rs385390, rs371075, rs1065489 were associated with fH concentration in the MRC Fenland
study (Table 6.1).
Whether related to fH function or concentration, the genetic association of CFH for AMD
remains compelling, with further evidence of a possible pharmacogenetic effect of the
rs1061170 SNP, with HH402 individuals having a poorer response to intravitreal injections of
the VEGF monoclonal antibody bevacizumab [237].
Other limitations of the methods of analysis used in this chapter are worthy of discussion. In the
imputation process employed to refine the signal for AMD may have excluded by QC filters rarer
SNPs which may have greater uncertainty when imputation is attempted. One way to overcome
this would be to not use any QC filters, which has been advocated before [238], and it is for this
reason that no MAF filters were used, although bearing in mind any finding of a SNP which is
rare would need to be replicated. One other way to attempt to identify rarer mutations would be
used genotyped data and impute against reference panels (HapMap and 1000 Genomes) of
African descent populations who have smaller haplotype blocks and mutations which are found
at a reduced frequency in other populations. These results could then be validated through
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direct genotyping and comparison across populations, and aid in the identification of possible
causal mutations. .
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8 Discussion, and future work
Age-related macular degeneration is a devastating condition and emerging as the most
common cause of blindness in the ageing population. Unlike cardiovascular disease, risk factors
and benefits of risk factor modification in slowing disease progression are only now emerging
from prospective studies of AMD. No clinical tests are available which adequately predict those
who are most susceptible to disease, or that can aid in risk stratification. Moreover no
treatments have been identified that reduce progression of early stages of disease thus
avoiding the more sight threatening form of AMD. These factors together have been the impetus
for identifying biological pathways that may confer susceptibility to AMD and which may be
targetable with therapies at an early stage so as to reduce the public health burden of AMD.
The contribution of genetics in the post-genome era has been central in attempting to address
these questions for AMD. Although the RCA cluster and complement was identified by family
based linkage scans [134] and observational data of analysis of drusen in affected individuals
[105], a GWAS was responsible for refining the signal down to complement factor H [10], and as
such led to candidate gene association studies of variants in complement related genes which
have subsequently been shown to confer AMD risk (see results of meta-analysis Chapter 2).
AMD is thus an exemplar of the integration of different genetic approaches in delineating
genetic contributions to a disease. The efforts have combined to place the alternative
complement pathway firmly on the AMD map. AMD in this respect is also the success story of
GWAS, in that resulting discoveries have the potential to achieve all that is hoped of this
approach (Figure 8.1). Specifically these aims are to identify novel biological pathways which
may result in clinical advances including the identification of biomarkers that may have a role in
prediction and stratification of disease, and within these pathways identifying therapeutic targets
whose manipulation may be of benefit in preventing or slowing disease progression. All these
criteria are satisfied by the example of AMD, identification of the alternative complement
pathway has been a major step forward in identifying disease mechanisms, and also potential
overlapping mechanisms with other diseases given the existing association of CFH mutations in
renal diseases such as MPGN II and aHUS (both reviewed in [127]) as well as newly identified
associations such as meningococcal disease [12] Biological measurement of proteins encoded
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by these genes may offer potential biomarkers which themselves may be open to
pharmacological manipulation, and as such are already on the drug development radar [15].
Cheap and high throughput methods of genotyping in themselves offer the potential of a
predictive test, and this is an attractive approach given the high risk associated with the
rs1061170 SNP. The potential of combining a number of SNP markers has already been
evaluated in one study, albeit small, in order to test the predictive utility of SNPs in complement
genes for AMD [138]. Furthermore the aim of achieving individual level therapeutic optimisation
is also evolving in the AMD field with the finding that the rs1061170 SNP is associated with
differential response to VEGF blockade in individuals with late stage AMD [239]. So in terms of
GWAS AMD certainly ticks, or appears to tick all the boxes.
Figure 8.1 Potential translational applications of findings from GWAS in common disease
Figure taken from McCarthy et al Nature Genetics 2007 [240]
These are however headlines and discussion of the finer print is necessary in understanding
where we are in reality in translating these findings into clinical practice, and putting findings
from AMD into the broader context of GWAS in other diseases to understand that although
apparently successful here, this approach is not a panacea for all common diseases.
AMD is touted as the GWAS success story, the exception to the rule, or rather the hypothesis
being that common diseases are likely to arise from the presence of common variants which are
predicted to have only a modest influence on disease, commonly referred to the “common-
disease, common variant hypothesis” [241]. It was this hypothesis that underpinned the
cataloguing of common variants (HapMap) after completion of the draft sequence of the human
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genome, enabling subsequent genome wide scans. Such scans in common diseases for
example T2DM [242] and Crohn’s Disease [243] have revealed ≥20 different loci which are 
associated with disease. Like AMD these scans have provided novel insights which are already
directing research in these areas, such as the importance of autophagy as a mechanism in
Crohn’s and the importance of insulin secretion over signalling in T2DM. However it is also
evident from these scans that the relative contribution to disease for each SNP across the
different loci is small, and as such GWAS in general have fallen short in explaining the
heritability of common diseases or traits. The best example of this is probably that of human
height where large twin studies have shown that 90% of variation in height is attributable to
inherited factors [244]. GWAS have uncovered 180 loci associated with human height [245]
although these explain less than 10% of the variation. In effect the observation that Ronald
Fisher made almost a century ago that a number of genetic variants, whose individual effect is
small, can explain a quantitative trait [246] is supported by the results of genome wide scans.
How do these findings then translate, if at all into being clinically useful? Either used singly or as
aggregate gene based scores these common variants are poor discriminators of disease both in
models and in real examples (Figure 8.2), taking for example T2DM. Common SNPs with
intermediate risk define individuals where most events are likely to be observed, and could
therefore be compared to biomarkers such as blood pressure or cholesterol in prediction of
CHD risk for example. However it may be that identification of rarer alleles which are
associated with larger effect sizes may be useful as predictive tests. These data will perhaps
emerge with the completion of the 1000 genomes project and expansion of genetic studies
across the globe, so that population frequencies of variants in themselves may provide
important insights into risk and mechanisms of disease, and may importantly lead to the
identification of therapies that are applicable not only to those at greatest risk, although at a
population based level. In this way genetics can contribute to public health in reducing the risk
of populations as opposed to individuals [247].
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Figure 8.2 Performance of a hypothetical genotype based risk score (a) and empirical
evaluation of a genotype risk score (b) for Type 2 Diabetes. In the simulation study in (a),
Janssens et al simulated the effect of 40 SNPs with variable genotype frequencies and a
population disease risk of 10%. With low genotype frequencies (1%) no individual carried more
than 6/40 of the risk genotypes, with an increasing genotype frequency (30%) all individuals
carried at least 6 of the risk genotypes. Because the frequency distribution of common inherited
alleles is normal more cases of those with T2DM would be expected to have “bell” of the curve
that is intermediate risk alleles, and as shown in the simulation study a genotype based score
would not be of clinical utility. Talmud et al (b) found this to be true when using a genotyped
based score in a population based cohort that were genotyped for common T2DM SNPs,
illustrating that thus far a phenotype score currently has more predictive value than a genotyped
based score.
(a) (b)
So even though AMD stands out as a beacon of success of GWAS, like other common
diseases it does also suffer the same problems of clinical utility of its genetic findings as other
GWAS mentioned above, and this is perhaps why there currently is no translation of the findings
from these studies. Some of these issues are discussed in a discursive paper highlighting the
short falls of genetics in AMD prediction [248]. Here it is argued that genetic studies to date in
AMD have largely been case-control studies, and although this is a useful design to maximise
power of uncovering risk variants, when it comes to applying a genetic test at a population level,
it is likely to be over-estimating the effect size, and in reality such tests will be poorly
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discriminative in individuals with intermediate findings. One solution to this is longitudinal data
and the prospective assessment of variants in predicting incident disease, although using this
approach the clinical utility of some of these variants may not be realised for many years to
come. Moreover, although useful to investigate, there is no effective intervention that can be
offered to those even if they are identified to be at greater risk of AMD, although show few signs
of the disease at the point of screening. Although the focus in genetics is moving at a fast pace,
what is described here- that is GWAS and generating an inventory of regional variation followed
by genotyping efforts to fine map regions with the strongest claims, this is now being overtaken
by large scale re-sequencing projects which are not always just tailored to test a hypothesis as
the next step in confirming or refuting an association. Therefore focus on the pathways that are
highlighted from such studies may be a good first step in attempting to change the clinical
course of disease, and that has what has been attempted by this thesis.
8.1 Summary
Evidence emerging from different disciplines in AMD research have converged on the idea that
there may be shared factors that contribute to both AMD and CVD. Findings from GWAS in
AMD show that complement in particular is likely to play a causal role in AMD. Observational
evidence in the cardiovascular arena has previously linked complement with atherosclerosis. In
this thesis I therefore set out to establish if complement and in particular complement factor H,
the most significant signal from AMD GWAS, was a shared risk factor for AMD and CHD, with a
focus first on the most replicated SNP from the AMD studies, and second in establishing if risk
is mediated by the encoded protein, circulating fH. In doing so I have for the first time reported
the most comprehensive analysis of the rs1061170 SNP encoding Y402H in AMD and CHD
showing a consistent link of this putatively functional SNP with AMD, and by collecting a large
number of studies have been able to more precisely define the effect size associated with
rs1061170. A similar approach in CHD showed no association of rs1061170 with CHD or any
conventional risk factors of CHD, supporting the view that CFH may not be a shared risk factor
for CHD and AMD. However given the strong signal associated with AMD I continued on my line
of investigation in trying to establish if the basis of risk in AMD is conferred by alterations in the
concentration of circulating fH, which was supported by findings from previous linkage scan of
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fH identifying a QTL in the RCA cluster of chromosome 1. In order to address this hypothesis I,
with others, developed a high throughput robust assay for measuring circulating fH using an
existing commercial assay and scaling up the throughput on a platform that is rapidly
translatable into a clinical setting. By establishing this assay I have been able to determine the
molecular epidemiology of fH for the first time, taking advantage of a wide number of markers
already measured in a population based study. This demonstrated novel associations with
circulating lipids and lipoproteins as well as anthropometric measures of body fat. Another
advantage in using the Fenland MRC study was the availability of genome wide data (both
directly genotyped and imputed against HapMap), again providing for the first time a
comprehensive investigation of the genetic determinants of circulating fH. This confirmed the
association of SNPs in the CFH/ CFHR region as being associated with fH levels, although no
signals reached genome wide significance. In addition other loci, largely those that appear to be
involved in determination of cell polarity, cyto-skeletal elements and cell growth are also
implicated. There is however a lack of signals from other complement related genes.
Establishment of the assay for circulating fH allowed me to then address the hypothesis that
SNPs associated with AMD may also be associated with alterations of fH and changes in
circulating concentrations may predispose to AMD. However no association between SNPs
associated with AMD and fH was established, and moreover no association of fH with AMD was
found.
8.2 Future work
In order to take the findings forward it would be important to firstly establish the specificity of the
commercial polyclonal antibody that has been used in establishing the high throughput assay,
refining the signal further down to either fH, FHL-1 or indeed fH related proteins. Secondly it
would be important to replicate the findings of the GWAS described in Chapter 6. One approach
could be to measure fH in a dataset with genome wide data, so as to jointly analyse two studies
thus prioritising signals for further replication. This would be important also in terms of defining
the potential overlapping SNPs which regulate fH and are associated with meningococcal
disease, which may lead to important insights into biological mechanisms of subtypes of
meningococcal disease as well as potential therapeutic pathways. Although a convincing
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argument has been presented that fH concentrations are likely to be altered by variation in the
gene and related genes, it may be that this is not the whole story, or as discussed already small
alterations in concentrations could lead to large functional effects. There is currently no good
test to test fH function in population based samples, where one would predict small differences
compared to extreme all-or-nothing mutations. It would therefore be of interest to adapt an
existing assay of either fH or the alternative complement pathway to a scale and sensitivity that
could then be applied to population based cases in order to test this hypothesis. Finally in order
to refine even further the genetic signals that have been identified in GWAS and association
studies of this region, further studies of ethnically diverse populations with differing LD
structures my aid localisation of signals. As a first step however this can be done in silico using
the 1000 genome data and imputing current data against panels from other ethnicities where
the LD structure is different. Together with targeted re-sequencing this approach may help
further refine and identify the causal variants that confer AMD risk.
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10 Appendices
10.1 Appendix 1: Assay protocol for Binding Site RID reagents on BNII
Nephelometer
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10.2 Appendix 2: Top 100 signals from imputation analysis for late AMD
Table shows signals that are not shown in Table 7.7, indicating that the top 100 signals are in
and around the CFH gene.
Rank rs-ID BP Position P value Gene
Predicted
function of SNP
33 rs9427913 195032090 1.00x 10-09 CFHR3 3downstream
34 1-194938293 194938293 1.10x 10-09 Intergenic
35 rs10922092 194924037 1.10x 10-09 CFH intronic
36 rs10922099 194931664 1.10x 10-09 CFH intronic
37 rs10922100 194931831 1.10x 10-09 CFH intronic
38 rs1329422 194921903 1.10x 10-09 CFH intronic
39 rs1329424 194912799 1.10x 10-09 CFH intronic
40 rs3645 194929639 1.10x 10-09 CFH intronic
41 rs528298 194927618 1.10x 10-09 CFH intronic
42 rs528298 194927618 1.10x 10-09 CFH 3downstream
43 rs2860102 194934942 1.20x 10-09 CFH intronic
44 rs10922114 195008412 1.30x 10-09 Intergenic
45 rs10801553 194922366 1.40x 10-09 CFH intronic
46 rs10801554 194924278 1.40x 10-09 CFH intronic
47 rs10801557 194936204 1.40x 10-09 CFH intronic
48 rs10922094 194928128 1.40x 10-09 CFH 3downstream
49 rs10922098 194931274 1.40x 10-09 CFH intronic
50 rs10922101 194932667 1.40x 10-09 CFH intronic
51 rs10922102 194934910 1.40x 10-09 CFH intronic
52 rs10922103 194937741 1.40x 10-09 CFH 3downstream
53 rs12029785 194925528 1.40x 10-09 CFH intronic
54 rs12033127 194930878 1.40x 10-09 CFH intronic
55 rs12038333 194939077 1.40x 10-09 CFH 3downstream
56 rs12038674 194932274 1.40x 10-09 CFH intronic
57 rs12045503 194939096 1.40x 10-09 CFH 3downstream
58 rs1329421 194922828 1.40x 10-09 CFH intronic
59 rs203688 194939008 1.40x 10-09 CFH intronic
60 rs2300430 194922336 1.40x 10-09 CFH intronic
61 rs28664709 194937840 1.40x 10-09 CFH 3downstream
62 rs28853072 194933711 1.40x 10-09 CFH intronic
63 rs36137052 194933636 1.40x 10-09 CFH intronic
64 rs368465 194938604 1.40x 10-09 CFH 3downstream
65 rs402056 194938609 1.40x 10-09 CFH intronic
66 rs485632 194931416 1.40x 10-09 CFH intronic
67 rs488380 194931128 1.40x 10-09 CFH intronic
68 rs529899 194934051 1.40x 10-09 CFH intronic
69 rs570618 194923687 1.40x 10-09 CFH intronic
70 rs579745 194931199 1.40x 10-09 CFH intronic
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Rank rs-ID BP Position P value Gene
Predicted
function of SNP
71 rs7546015 194930705 1.40x 10-09 CFH intronic
72 rs10922094 194928128 1.40x 10-09 CFH intronic
73 rs10922103 194937741 1.40x 10-09 CFH intronic
74 rs12038333 194939077 1.40x 10-09 CFH intronic
75 rs12045503 194939096 1.40x 10-09 CFH intronic
76 rs203688 194939008 1.40x 10-09 CFH 3downstream
77 rs28664709 194937840 1.40x 10-09 CFH intronic
78 rs368465 194938604 1.40x 10-09 CFH intronic
79 rs402056 194938609 1.40x 10-09 CFH 3downstream
80 rs10922111 195083436 1.50x 10-09 Intergenic
81 rs10922112 194998766 1.50x 10-09 Intergenic
82 rs4658046 194937380 1.50x 10-09 CFH 3downstream
83 rs4658046 194937380 1.50x 10-09 CFH intronic
84 rs10754199 194937462 1.60x 10-09 CFH 3downstream
85 rs1887973 194941802 1.60x 10-09 CFH intronic
86 rs203674 194951248 1.60x 10-09 CFH intronic
87 rs203677 194949989 1.60x 10-09 CFH intronic
88 rs203679 194949141 1.60x 10-09 CFH intronic
89 rs203680 194947998 1.60x 10-09 CFH intronic
90 rs203683 194945055 1.60x 10-09 CFH intronic
91 rs203685 194944568 1.60x 10-09 CFH intronic
92 rs399469 194942728 1.60x 10-09 CFH intronic
93 rs402991 194942726 1.60x 10-09 CFH intronic
94 rs6664705 194944465 1.60x 10-09 CFH intronic
95 rs7522681 194945228 1.60x 10-09 CFH intronic
96 rs9970075 194940053 1.60x 10-09 CFH intronic
97 rs9970784 194940425 1.60x 10-09 CFH intronic
98 rs10754199 194937462 1.60x 10-09 CFH intronic
99 rs1061147 194920947 1.70x 10-09 CFH coding
100 rs10801555 194926884 1.70x 10-09 CFH intronic
